microRNA Regulation of Endotoxin Tolerance by Seeley, John
 
 
microRNA Regulation of Endotoxin Tolerance 
 
John J. Seeley 
 
 
 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy 
in the Graduate School of Arts and Sciences 
 
COLUMBIA UNIVERSITY 
2014  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2014 
John J. Seeley 
All rights reserved 
ABSTRACT 
microRNA Regulation of Endotoxin Tolerance 
John J. Seeley 
 
Sepsis affects hundreds of thousands each year in the United States alone, with an estimated 20-30% 
mortality rate in spite of current treatment regimens1.  Sepsis mortality was originally understood to be 
the caused by overproduction of inflammatory cytokines in response to pathogen detection by the host.  
However, recent studies suggest that with modern treatments, secondary infection, rather than 
inflammatory shock, may be of greater concern.  In either case, the failure of a large number of anti-
inflammatory agents to produce beneficial outcomes in sepsis treatment during clinical trial2 suggests 
that the development of a new class of immunomodulatory agents may be required for effective 
treatment. 
In experimental models, pre-treatment with sub-lethal doses of lipopolysaccharide (LPS, previously 
referred to as endotoxin) induces a state of “LPS tolerance” that reduces septic shock lethality.  
Paradoxically, LPS tolerance also results in increased antimicrobial gene expression and resistance to 
secondary infection in some models.  Further exploration of this process may provide drug targets 
capable of limiting inflammation without dampening antimicrobial immunity, which could be of great 
benefit in the treatment of sepsis and chronic inflammatory disease. 
Many groups have studied signaling changes that occur during LPS tolerance.  However, mediators of 
tolerance that can account for the changes in LPS-induced gene expression that result in increased 
microbial resistance are not well described.  This has prevented proper testing of the physiological 
effects of tolerance on disease, and it remains unclear if this process could be artificially induced or is of 
any benefit to sepsis patients. 
Recent in vitro work suggests that tolerant gene expression patterns are the result of large scale changes 
in chromatin organization that occur in macrophages after prolonged LPS stimulation.  Because 
microRNAs (miRNAs), a new class of gene regulator, have been found to regulate chromatin modifying 
complexes in other systems, LPS-induced miRNAs were screened to identify potential mediators of 
tolerance that could cause changes in gene expression patterns without necessarily impacting LPS 
signaling itself. 
Several tolerance-associated miRNAs were identified.  One miRNA in particular, miR-222, was found to 
repress tumor necrosis factor (Tnf) and Brahma-related gene one (Brg1) expression.  This attenuates 
expression of genes dependent on nucleosome remodeling, primarily affecting inflammatory genes.  
Consequently, miR-222 expression effectively limits septic shock lethality.  However, low-level 
responses, as well as NF-κB signaling and the expression of a subset of antimicrobial and antiviral genes, 
are left intact.  Thus, although miR-222 does not entirely recapitulate the tolerance response, by 
directing the LPS response into a less damaging expression profile, miR-222 may accelerate the onset of 
tolerance and be a promising target for therapeutics aiming to treat inflammatory disease without 
compromising host immunity.  
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Chapter 1:  General introduction to LPS tolerance 
Proper regulation of the inflammatory response is vital for organismal homeostasis. Failure to initiate 
innate immune responses leads to pathogen invasion, but systemic production of inflammatory 
cytokines in response to infection (sepsis) can result in lethal septic shock3. It is estimated that 751,000 
cases of sepsis occurred in the United States in 1995, with a mortality rate of 28.6%; deaths related to 
sepsis accounted for 9.3% of all deaths in the country that year4. The hospitalization rate for septicemia 
or sepsis has doubled between 2000 and 2008, and costs of treatment have been rising5. New 
immunomodulatory treatment options are therefore highly desirable. 
Sterile injection of lipopolysaccharide (LPS, a component of bacterial cell walls) into animals can model 
the febrile responses and lethality of septic shock.  This led to the conclusion that the outcomes of 
sepsis are not dependent on live infection, but rather are the result of the production of pro-
inflammatory cytokines, including TNF-α6,7, IL-1β8, and IL-69, by macrophages10.  However, although a 
large number of treatments were developed based on this concept of sepsis, many have failed to 
produce beneficial results when tested in clinical trial.  Even the use of neutralizing anti-TNF-α 
antibodies, which is protective in many mouse models of septic shock, failed to produce a substantial 
benefit2.  This has led many to question whether production of pro-inflammatory cytokines is, in and of 
itself, the principal cause of mortality in human patients. 
It has been noted that in sepsis patients, pro-inflammatory responses are accompanied by the 
production of anti-inflammatory cytokines.  This has led some to hypothesize that the anti-inflammatory 
cytokines may be the actual source of risk in human sepsis patients, given that medical intervention 
often allows patients to survive the initial burst of pro-inflammatory cytokine production that is 
triggered by infection.  In one such model, the anti-inflammatory cytokines prevent full clearance of the 
invading pathogen when it is first detected.  This allows for pathogen spread, triggering another burst of 
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pro- and anti-inflammatory cytokine production, which continues until the responses prove 
overwhelming.  Alternatively, it is possible that the initial invading pathogen is in fact cleared, but in the 
suppressive, anti-inflammatory environment follows, secondary infections can occur and spread faster 
than they can be contained, ultimately causing death of the host2,11.   
In either case, it would seem that new approaches to treatment are needed.  Based on these 
hypotheses, ideal sepsis treatments might modulate the immune response to limit inflammatory 
damage, but also simultaneously prevent the innate immune response from being completely shut 
down, as it is still needed to contain the spread of any lingering or newly invading organisms.  It seems 
counter-intuitive that a means reach these goals simultaneously exists. 
Interestingly, however, animals challenged with low doses of LPS become “tolerant,” and do not 
succumb to septic shock even when re-challenged with up to ten times a normally lethal LPS dose12. 
Paradoxically, LPS-tolerant animals also show reduced pathogen loads and increased survival after 
subsequent infection with bacteria or fungi13-15.  This may be partially due to a reprogramming of the 
macrophage LPS response, in which production of pro-inflammatory cytokines is exchanged for 
production of less damaging, but effective, anti-microbial peptides in response to stimulation16. Artificial 
induction of such a tolerant state in patients therefore seems an attractive means of treating septic 
infection. 
Unfortunately, a clear molecular explanation for LPS tolerance has remained elusive, making it difficult 
to test whether induction of tolerance could indeed be of benefit to sepsis patients.  Identification of 
tolerogenic regulators could allow for a better understanding of the process, and antagonization of 
these regulators would allow for clear testing as to whether tolerance promotes survival of sepsis and 
other inflammatory disease.  Recent work suggests that chromatin complexes may play a large role in 
shaping the magnitude, duration, and patterns of gene expression in the LPS response.  microRNAs 
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(miRNAs), a relatively new class of regulators of gene expression, have been found to regulate the 
functionality of chromatin complexes in other experimental systems, ultimately causing large-scale 
changes in gene expression patterns17,18.  I therefore hypothesized that specific miRNAs are responsible 
for regulating LPS tolerance in macrophages. 
The results of experiments performed to test this hypothesis are discussed in Chapters 2-5.  Each data 
chapter includes its own introduction, containing a summary of information pertinent to the 
experiments of that chapter, as well as a discussion chapter where the most immediate conclusions 
from the results are presented.  An overall summary of conclusions and future directions is given in 
Chapter 6, and materials and methods are discussed in Chapter 7.  First, however, a general introduction 
to the macrophage LPS response, and the chromatin modifications that regulate LPS-induced gene 
expression, is presented below. 
  
LPS recognition and NF-κB activation 
Toll-like receptor 4 (TLR4) is the cell-surface receptor for LPS, which must be bound with the host 
protein MD2 for recognition. CD14 is also required as a co-receptor for full LPS signaling to occur19.  LPS 
binding induces signaling through MyD88, IRAK, and TRAF family members, which activates the inhibitor 
of κB (IκB) kinase (IKK) complex.  This leads to the phosphorylation, ubiquitination, and proteasomal 
degradation of IκB proteins. This allows dimers of the NF-κB family of transcription factors, which were 
retained in the cytosol through interaction with IκBs, to translocate into the nucleus and bind specific 
recognition sequences in the genome (referred to as κB sites) to modulate transcription. Other 
inflammatory stimuli, such as peptidoglycan, IL-1, and TNF-α, also activate the IKK complex in 
macrophages, although they signal through different receptors and only partially overlapping signaling 
pathways20. 
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Although NF-κB is often discussed as a single molecule, it actually consists of a hetero- or homodimer of 
five possible subunits (p65/RelA, p50/NFKB1, c-Rel, RelB, and p52/NFKB2), each of which contains a Rel 
homology domain responsible for DNA binding. However, only three of the subunits (p65, c-Rel, and 
RelB) contain a C-terminal transactivation domain21 required to initiate transcription, so the dimer 
composition determines the ultimate effect of NF-κB binding to a gene promoter. Typically, activation of 
macrophages leads to binding of dimers containing p65 or c-Rel to NF-κB target genes, and the 
triggering of gene expression. However, p50:p50 homodimers can prevent transcription by competing 
for promoter binding (p50 lacks a TAD), and RelB-containing dimers can either repress or activate gene 
expression22. 
Even though the major signaling intermediates and NF-κB recognition sites have been identified, 
whether a particular NF-κB-dependent gene will be expressed, and at what levels, after LPS stimulation 
remains hard to predict. This is especially true after LPS tolerization. 
 
Nucleosome positioning regulates a subset of LPS response genes 
LPS response genes can be divided into two groups: early response genes and late response genes.  The 
early response genes, which have been referred to as early primary response genes or genes with 
constitutive and immediately accessible promoters, are generally transcribed within an hour of LPS 
stimulation even in the absence of de novo protein synthesis.  Late response genes, which peak in 
expression after an hour or more of stimulation, require promoter remodeling and often synthesis of 
proteins (as a result of the early response) for transcription to occur.  These genes have been referred to 
as late primary response genes (those that do not require protein synthesis), secondary response genes 
(those that do), or genes with regulated and late accessibility23,24. 
 
5 
 
 
Transcriptional regulation of early response genes 
Early response gene promoters are kept in a constitutively open state, and rely on basally associated 
repressors to prevent transcription in the absence of an appropriate stimulus.  These gene promoters 
tend to be enriched for CpG islands, preventing nucleosomes from stably associating and blocking 
promoter access25.  Nearby nucleosomes also have constitutively high levels of histone H3 acetylation26 
and histone H3 lysine 4 (H3K4) trimethylation27, modifications associated with transcription.  Simple 
overexpression of p65 leads to its association with these promoters, further suggesting their immediate 
accessibility24. 
Constitutive expression of early response genes is prevented by basal association of nuclear co-
repressor (NCOR) and REST co-repressor complexes (CoREST) with these promoters.  Furthermore, 
although RNA polymerase II (Pol II) is also constitutively associated with these promoters, it must be 
phosphorylated at serine 5 by positive transcription elongation factor b (p-TEFb) for full elongation and 
splicing to occur.  This is triggered by the NF-κB-dependent acetylation of histone H4K5/8/12 at early 
gene promoters, which allows for Brd4-mediated p-TEFb recruitment28. 
Thus, early response genes can be rapidly induced upon LPS stimulation, as most transcriptional 
machinery is basally present, and neither nucleosome re-positioning nor protein synthesis are required 
(summarized in Figure 1a-d). 
 
Transcriptional regulation of late response genes 
The late response gene promoters have additional regulatory barriers to transcription.  Unlike the early 
response genes, these promoters generally undergo inducible histone H3 lysine acetylation and 
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trimethylation, and require the recruitment of additional transcriptional machinery prior to 
transcription26,27.  These modifications often depend on the synthesis of intermediates transcribed in the 
primary response.  For instance, Il6 and Il12b transcription depends on the expression of the early 
response gene IkBz, which mediates H3K4 trimethylation and recruitment of p65, TATA-binding protein, 
and Pol II27,29.   
Furthermore, unlike the early response genes, the promoters of late response genes often (though do 
not always) have few CpG islands, leading to their stable association with nucleosomes in vitro.  This 
creates a basal block in promoter accessibility, as assayed by the ability of restriction enzymes to cut 
through the promoter sites in isolated nuclei25.  Transcription of these genes therefore requires 
nucleosomes to be re-positioned to allow for accessibility.  This is accomplished by recruitment of the 
switching defective/sucrose non-fermenting (SWI/SNF, also known as BAF) complex.  This complex, 
containing the Brg1 or Brm1 enzymatic proteins, alters nucleosome-DNA contacts in an ATP-dependent 
manner, often shifting nucleosome position.  Brg1 is inducibly recruited to late gene promoters after LPS 
stimulation, and these promoters subsequently become accessible to restriction enzymes 
experimentally, and presumably to transcription factors and other machinery required for gene 
expression in vivo23,26. 
Nucleosome remodeling by the SWI/SNF complex occurs prior to many other histone modifications and 
transcription factor recruitment.  shRNA-mediated Brg1 and Brm depletion results in substantial losses 
of remodeling, histone H3 lysine acetylation, and C/EBP recruitment in response to LPS stimulation26.  
Conversely, remodeling of the Il12b promoter can still occur in macrophages lacking c-Rel, the NF-κB 
subunit that binds is required for Il12b transcription23.  Furthermore, p65 does not associate with many 
late response promoters after overexpression24, implying that p65 cannot bind to these sequences until 
nucleosome repositioning is complete. 
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The nucleosome repositioning that occurs after LPS stimulation appears to be almost immediately reset 
by Mi-2b, the helicase of the Mi-2/Nurd complex.  Mi-2b reduces accessibility and transcription of late 
response genes and is recruited to these promoters in a Brg1-dependent manner26.  Absence of NF-κB 
binding also shortens the duration of Il12b promoter accessibility, suggesting that transcriptional 
complexes help maintain an accessible state30.  Taken together, this suggests that nucleosome 
remodeling is a dynamically regulated process with regards to LPS stimulation and functions as a gene 
expression checkpoint for most late response genes (summarized in Figure 1e-h). 
 
Figure 1.  Differences in regulation of early and late LPS-response genes. 
Most early LPS-response genes have promoters that are constitutively associated with RNA Pol II and 
accessible to transcription factors.  Basally associated repressor complexes help prevent transcription 
(A).  After LPS stimulation, NF-κB-dependent histone H4 acetylation occurs (B).  This leads to Brd4-
mediated p-TEFb recruitment and phosphorylation of the carboxyl terminal domain of Pol II (C).  This 
allows for full elongation and splicing to occur (D).  Most late LPS-response gene promoters are not 
basally accessible to transcription factors due to nucleosome positioning (E).  Upon LPS stimulation, the 
SWI/SNF complex is recruited to these gene promoters (F) and shifts nucleosome position, allowing for 
additional histone modification and transcription factor recruitment to occur (G).  This allows for Pol II to 
be inducibly recruited and for transcription to occur (H). 
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SWI/SNF complex recruitment 
The factors that guide SWI/SNF complexes to appropriate promoter sites are not well understood.  
However, the process seems to be very tightly controlled, as four nucleosomes are located near the 
Il12b promoter, but only one is remodeled in response to LPS stimulation23.  The remodeling process is 
dependent on TLR4 signaling30 through MyD8827 and protein synthesis23, so proteins produced by the 
primary response are likely involved.  Recruitment of the c-Jun transcription factor kinetically precedes 
chromatin remodeling at these promoters, suggesting its possible involvement24.  Histone H4 acetylation 
also precedes chromatin remodeling24, and studies of the Ifnb1 promoter and recombinant nucleosomes 
find that GCN5-mediated H4K8 acetylation is required for Brg1 recruitment after viral infection31.  
Interestingly, TNF-α treatment24 and residual signaling through the TRIF pathway in LPS-stimulated 
MyD88 knockout macrophages27 cannot induce nucleosome repositioning for many late response genes, 
which may partially explain why TNF and other stimuli are able to induce only a subset of the LPS 
response genes. 
Lineage-specific factors may also be involved in the guidance of the SWI/SNF complex, as the 
requirements for remodeling at a given promoter also vary by cell type.  For instance, the Il6 gene is a 
late response gene requiring chromatin remodeling in macrophages, but behaves as an early response 
gene with basally accessible promoter regions in MEFs25.  Nucleosome positioning near the Il12b 
promoter also varies between macrophage and thymocyte or fibroblast cell lines, although the 
functional role of the nucleosome in question is not clear23. 
This provides a model in which constitutively present transcription factors (which differ based on cell 
lineage), activated transcription factors (such as NF-κB), and newly synthesized primary response 
transcription factors coordinate to induce distinct patterns of gene expression upon LPS stimulation.  
This may perhaps reflect the modular nature of many of these gene subsets; although LPS is a potent 
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inducer of many genes, other TLR and inflammatory signaling pathways may induce only particular 
subsets to ensure appropriate downstream innate and adaptive immune responses are initiated (as 
proposed and discussed further in prior reviews32). 
Because additional regulatory mechanisms exist for the late response genes, both in terms of 
nucleosome repositioning and histone modification, they will likely have more complex responses to in 
vivo infection as well as phenomena such as LPS tolerance, which is discussed below. 
 
LPS tolerance alters gene expression patterns downstream of TLR4 signaling 
LPS tolerance in vivo 
It has been noted for over half a century that animals exposed to low doses of endotoxin can tolerate 
subsequent exposure to extremely high doses of LPS. LPS-induced febrile responses33-35 and metabolic 
changes36 are reduced after tolerization. Lethality from septic shock is also reduced12, suggesting 
tolerance may be a protective response. 
Surprisingly, protection from septic shock does not necessarily come at the cost of lowered resistance to 
infection. Tolerized mice show reduced pathogen loads and increased survival after subsequent 
induction of polymicrobial sepsis (by cecal ligation and puncture13) or infection by Cryptococcus 
neoformins14 or Salmonella enterica15. Baboons primed with an exposure to heat-killed bacteria prior to 
Escherichia coli infusion may also have better survival rates at the cost of increased lung damage, 
although this was not conclusively determined21. The benefit of tolerization in humans is less clear11,37. 
The tolerization process is evolutionarily conserved and has been described in mice12, rats38, rabbits33,35, 
guinea pigs39, monkeys40, and humans34. Even amongst PBMCs isolated from different human 
individuals, the tolerization process is very robust despite large variability in initial cytokine production41. 
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Cell transfer experiments show that the tolerization process is dependent on macrophages42. Co-culture 
systems, studies on cells derived from knockout mice, and transfer experiments confirm that IL-10, nitric 
oxide, TNF-α, IFN-α/β, T-, and B-cells are not required43-45. 
Tolerance was originally proposed to be a state of hypo-responsiveness in LPS-induced macrophage 
activation. Evidence for this conclusion will be discussed below. However, the identification of LPS-
inducible genes that become hyper-responsive after tolerization, as well as the phenomenon of cross-
tolerance (discussed below) and studies of the Tnf and Il1b promoters in macrophages, suggest that 
tolerization involves large-scale reprogramming of gene expression, rather than a simple refractory 
period to stimulation. 
 
TLR4 signaling and LPS tolerance 
Macrophages stimulated with LPS in vitro also undergo tolerization, characterized by reduced 
transcription of many pro-inflammatory cytokines including Il6, Il12b, and Il1b, as well as strongly 
reduced secretion of TNF-α after further LPS stimulation16,46. This likely accounts for the decreases in 
LPS-induced fever and lethality observed in tolerized animals. Higher pre-treatment doses (generally in 
the range of 10 ng/ml to 1 ug/ml LPS) and longer periods of initial stimulation time, up to 24 hours, 
reliably lead to a greater degree of tolerization of macrophages in vitro, as measured by the hypo-
responsiveness of the above genes, although extremely low doses of LPS pre-treatment can cause a 
priming effect on gene expression instead16,47-49. 
Several groups have noted LPS signaling defects in tolerized cells (summarized in Figure 2), leading to 
the suggestion that LPS pre-treatment causes a refractory state in TLR4 signaling. Reported changes 
include reductions in LPS-induced MyD88-TLR4 association50; IRAK activity50,51; IκBα degradation52,53; and 
p3850,52,53, ERK52, JNK53,54 and/or NF-κB activation50-54. This was variously hypothesized to be due to a 
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reduction in cell-surface levels of TLR451,55, or an increase in the expression of A2056,57 or IRAK-M (two 
LPS-inducible, negative regulators of TLR4 signaling)58. However, overexpression of TLR4 in CHO cells 
does not restore signaling after tolerization53, and reductions in surface TLR4 levels do not occur in 
human monocytes50. Neither A2059 nor IRAK-M58 knockout cells are entirely incapable of tolerization, 
although sometimes delays in tolerization are observed. 
Figure 2.  Reported changes in the TLR4 signaling pathway that occur during LPS tolerance. 
Simplified illustration of the TLR4 signaling pathway, highlighting changes that have been observed 
during LPS tolerance.  See text for details. 
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Furthermore, several groups have reported unaltered NF-κB activation upon re-stimulation of tolerized 
cells60-63. In a large number of studies, Tnf transcripts are still found to be produced at normal46 or 
reduced, but clearly detectable levels48,50,52,64, leading to the hypothesis that Tnf may be post-
transcriptionally or post-translationally repressed46 (although this does not explain the transcriptional 
changes noted for other cytokines). This would imply that signaling to the nucleus remains at least 
partially intact in tolerized cells, and other critical regulators are involved in cytokine hypo-
responsiveness. 
 
Cross-tolerance 
The phenomenon of cross-tolerance is a further indication of the existence of tolerogenic mediators 
downstream of TLR4. Pre-treatment with TLR2 agonists can also lead to tolerance to LPS, and vice-versa 
(although in some reports, tolerance will only work in one direction). Tested TLR2 agonists include 
MALP-254, lipoarabinomannan53, soluble tuberculosis factor53, lipoteichoic acid43, and zymosan46,65. 
Cross-tolerization between TNF-α and LPS, as well as IL-1 and LPS, also seems to occur in vivo and in 
vitro, although treatment with higher doses of these cytokines are required to induce complete 
tolerance to LPS than to induce tolerance to cytokine re-stimulation38,52,65,66. Tolerance is not a general 
feature of stimulation, as IL-865 or IL-665,66 pre-treatment does not lead to tolerization. Cross-tolerization 
is not necessarily as dramatic in effect as LPS tolerance, as in some cases only a 50% reduction in TNF-α 
production has been reported. Nevertheless, these observations, taken together with studies of the 
TLR4 signaling pathway after tolerization, would suggest that some shared signaling intermediates or 
factors downstream of NF-κB activation are affected by tolerization. 
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Hyper-responsive genes in LPS tolerance 
A complete loss of signaling also fails to explain one of LPS tolerization’s most poorly understood 
features: while expression of damaging pro-inflammatory genes tends to be repressed in tolerized cells, 
anti-inflammatory and anti-microbial genes are expressed at similar or higher levels upon re-stimulation. 
This phenomenon has been most clearly demonstrated in a recent study using microarray and qPCR 
analysis16. The existence of hyper-responsive anti-microbial genes may provide an explanation for the 
increased microbial clearance and survival that is observed when tolerance is induced prior to infection 
in mice13-15. Genes that have been reported to become hyper-responsive to LPS after tolerization include 
Il1rn41, Tnfr-249, and perhaps Csf367, Vcam168, and Il1045,63,68,69 (although, conflictingly, Il10 becomes 
hypo-responsive in some systems41,54,70). Thus, the same LPS input can lead to dramatically different 
gene expression outputs, clearly indicating the existence of tolerogenic mediators downstream of TLR4 
signaling. This led to the suggestion that LPS tolerance actually involves reprogramming of the 
macrophage rather than simple hypo-responsiveness to LPS signaling. 
 
Studies of tolerance and the Tnf and Il1b promoters 
What regulators might allow the same input stimulus and signaling pathways to produce two (or more) 
dramatically different effects on gene expression? Studies of two early response genes, Tnf and Il1b, 
have led to the proposal of several distinct mechanisms of promoter regulation (Figure 3). 
LPS stimulation of naïve THP1 cells leads to the loss of repressive H3K9 dimethylation at the Tnf71 and 
Il1b promoters72,73.  This modification does not occur in tolerized cells, and heightened expression of 
SIRT1, a histone and protein deacetylase, has been proposed to mediate this process by increasing 
expression and recruitment of the NF-κB subunit RelB to these promoter regions. RelB subsequently 
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recruits the histone H3K9 methyltransferase G9a to these promoters, preventing H3K9 de-methylation. 
G9a recruitment also leads to recruitment of heterochromatin protein 1 and the suppression of target-
gene transcription. Silencing RelB expression increases p65 promoter binding and partially restores gene 
expression in tolerized cells, suggesting it is of prime importance in this process71,72,74,75. SIRT1 is also 
capable of de-acetylating histone H4K14 as well as lysine 310 of p65, thus further repressing residual 
p65 activity at targeted promoters after tolerization74. 
Differential expression and utilization of the NF-κB subunit p50 has also been implicated in the hypo-
responsiveness of Tnf transcription. NF-κB binding to the Tnf promoter has been detected after LPS 
stimulation of both naïve and tolerized Mono Mac 6 cells; however, it has been proposed that the 
complexes in tolerized cells are predominantly composed of p50/p50 homo-dimers, which cannot 
induce transcriptional activity60. Increased p50 binding to Tnf and Ifnb1 promoter constructs after 
Figure 3.   Changes in the nucleus after tolerization. 
Hypo-responsiveness of early response genes has been attributed to an exchange of p65:p50 NF-κB 
dimers for p50:p50 homodimers (A), and SIRT1-mediated exchange of p65:p50 dimers for RelB-
containing dimers (B).  Changes in expression of late response genes have been attributed to differential 
recruitment of the SWI/SNF complex, which is required for nucleosome remodeling and subsequent NF-
κB binding to gene promoters.  Hypo-responsive genes lose SWI/SNF complex recruitment after 
tolerization (C).  Conversely, hyper-responsive genes gain SWI/SNF complex recruitment after 
tolerization (not shown). 
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tolerization has been reported, which supports this hypothesis. Furthermore, macrophages from p50 
knockout mice continue to produce TNF-α upon re-stimulation even after 18-20 hours of LPS pre-
treatment, suggesting that the p50 NF-κB subunit plays a critical role in tolerance, in addition to 
RelB63,76. 
However, other findings do not support this conclusion, as in some reports, genes were still found to 
become hypo-responsive after LPS pre-treatment of RelB and p50 knockout macrophages45. This further 
highlights the complexity of the tolerization process and the difficulty in finding a predominant 
tolerogenic mechanism. It is possible that multiple regulatory mechanisms, including some yet to be 
elucidated, are required to regulate the tolerogenic response at different times and conditions of 
stimulation. 
 
Tolerance and late response genes 
Although Tnf and Il1b have been studied in depth, it is important to note that these are both examples 
of early LPS response genes. Chromatin modifications, which include the covalent modification of 
histone tails and/or nucleosome repositioning, are involved in LPS-responsive gene expression. 
However, the exact modifications that are required vary greatly between the early and late response 
genes, as discussed previously. Promoters of early response genes are kept in an open state even in 
naïve macrophages, and are basally associated with repressor complexes to prevent inappropriate 
transcription.  However, other genes rendered hypo-reponsive by LPS tolerance, including Il6, Il12b and 
Nos2 (involved in LPS-induced nitric oxide synthesis), are a part of the late LPS response, and are not 
immediately accessible25.  These genes require a series of histone modifications (summarized in Table 1) 
and nucleosome remodeling by the SWI/SNF complex before transcription factor and polymerase 
recruitment can occur23-26. 
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It is highly likely that tolerization employs similar mechanisms to modify gene expression. That is, hypo-
responsive early genes will be actively repressed to prevent inappropriate gene expression (by p50, 
RelB, or other factors), whereas late response genes will be regulated at the level of initiating factor 
recruitment. Indeed, it has been noted that Brg1, an enzymatic subunit of the SWI/SNF complex, is 
differentially recruited at hypo-responsive and hyper-responsive gene promoters after tolerization. For 
example, at the promoters of Il6 and Lipg, two genes that become hypo-responsive to LPS, high Brg1 
recruitment is noted only after stimulation of naïve, but not tolerized, cells. Conversely, Brg1 is only 
recruited at high levels to the promoter of the hyper-responsive gene Fpr1 after tolerization has 
Modification Change Effects 
H3K Acetylation Constitutive at early response 
genes26 
Gained at late response genes 
around four hours, after 
SWI/SNF complex 
recruitment26,27 
Associated with transcription 
H4K Acetylation Gained at both early and late 
response genes within one hour 
Required for p-TEFb 
recruitment and transcription of 
early response genes28 
Precedes and may be required 
for SWI/SNF complex 
recruitment at late response 
genes24,31 
H3K4 Trimethylation Constitutive at early response 
genes27 
Gained at late response genes 
by action of intermediates such 
as IκBζ26,27,29 
Associated with transcription 
H3K9 Dimethylation Lost at the Tnf promoter in 
acute LPS responses, but not 
during tolerance71 
Associated with transcriptional 
repression 
H3S10 Phosphorylation Gained at the Tnf promoter in 
acute LPS responses, but not 
during tolerance71 
Correlates with p65 binding 
Table 1.  Histone modifications at inducible gene promoters during the LPS response. 
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occurred16. Furthermore, interferon gamma pre-treatment reduces LPS tolerization69 and prevents Il6 
from becoming hypo-responsive after low-dose tolerization of primary human monocytes. Intriguingly, 
this correlates with partially restored Brg1 and p65 recruitment to the Il6 promoter77. This additional 
regulatory layer may explain discrepancies noted in the timing and LPS dosage required to tolerize late 
response genes, including Il677, Il1245 and Nos278, compared to the early response gene Tnf. However, 
the key regulators of SWI/SNF recruitment (and any additional histone modifications required for late 
response gene expression during tolerance) remain to be identified. 
 
An inclusive model 
It is interesting to note that the hyper-responsive genes are not only expressed to a higher degree, but 
are also expressed very rapidly after tolerization16. This may be important given the observation that 
IκBα degradation in response to LPS stimulation is intact in tolerized THP1 cells, but IκBα re-synthesis 
after stimulation occurs faster than in naïve cells47. This may suggest that the observed defects in TLR4 
signaling of tolerized cells are not entirely irrelevant. Rather, it is possible that NF-κB activation is limited 
to transient pulses of activity after tolerization due to these and other changes in the TLR signaling 
cascade. Combined with an alteration in the prevalence of active NF-κB subunits, this may restrict the 
number of genes that can be expressed: only genes that successfully undergo nucleosome repositioning 
and histone modification in the narrow window of p65 translocation will be successfully transcribed. 
Hyper-responsive genes that have already undergone modifications to more rapidly recruit Brg1 may 
then be more likely to be expressed or expressed at higher levels than other genes. Thus, the kinetics of 
NF-κB activation as well as alterations in dimer equilibrium may reinforce changes in the Brg1 
recruitment response, making the process of tolerization dependent on several partially redundant 
mechanisms for full effectiveness. 
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While the past studies summarized here provide this working model of LPS tolerance functionality, many 
aspects of this model remain untested.  More importantly, many of the regulators that are required for 
such a model to function remain unidentified.  Recently, many novel regulators of gene expression, 
including non-coding RNAs, have been discovered.  Integration of these regulators into the tolerance 
model will provide a greater understanding of its induction, its physiological function, and how it could 
be artificially modulated or induced to ameliorate the effects and progression of inflammatory disease.  
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Chapter 2:  Identification and characterization of miRNAs associated with 
LPS tolerance, including miR-222 
Introduction 
miRNAs have emerged as a new class of short non-coding RNA capable of post-transcriptionally 
regulating gene expression. This generally occurs through miRNA binding to mRNA transcripts based on 
sequence similarity, leading either to transcript degradation or the repression of translation79,80. 
Although miRNAs sometimes have subtle effects on gene expression levels, by targeting mRNAs of key 
regulatory or rate-limiting proteins (or multiple components of a signaling cascade), they can have far-
reaching phenotypic effects under appropriate conditions81.  The biogenesis of miRNAs is discussed 
further in Chapter 3, while mechanisms of miRNA effect are discussed in Chapter 4.  Below, known 
miRNA regulators of the LPS response and their potential contributions to LPS tolerance are 
summarized.  miRNA regulators of chromatin organization in other biological systems are also discussed. 
Several miRNAs are regulated by NF-κB and function as classical negative-feedback regulators in 
macrophages. These miRNAs often remain down- or up-regulated for some time, and may thus 
contribute to tolerance. miR-146a, one of the best characterized examples, is upregulated by LPS 
stimulation in macrophages and suppresses IRAK1 and TRAF6 levels, leading to attenuation of the LPS 
response82. This miRNA continues to be highly expressed after tolerization, and may reinforce previously 
discussed tolerogenic mechanisms83,84, although it cannot account for all of its aspects. miR-146a 
knockout mice are hypersensitive to LPS-induced septic shock, confirming the relevance of miR-146a to 
LPS-induced inflammatory responses in vivo85. 
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microRNA Response to LPS Cell types tested Targets/Effects References 
Let-7 family Upregulated BMDM, HPBM Down-regulates TLR4 
expression; targets IL-6 in 
cancer cell lines 
86-89 
miR-9 Upregulated HPBM Targets NFKB1/p105; affects 
inflammatory gene expression 
in other cell types 
86,90,91 
miR-21 Upregulated RAW264.7, BMDM, 
PBMC, THP1 
Targets PDCD4; inhibits NF-κB 
activation, but increases IL-10 
translation 
92 
miR-98 Downregulated RAW264.7 Represses IL-10 production 93 
miR-99b Upregulated HPBM Targets Tnf and Tnfrsf4 mRNA 
in dendritic cells, although 
protein levels are not changed 
86,94 
miR-125a Upregulated HPBM Targets A20 in malignant B 
cells 
86,95 
miR-125b Upregulated in 
tolerance, 
downregulated in 
naïve LPS response 
Tolerized THP1, 
RAW264.7 
Suppresses TNF-α translation; 
targets IRF4 and enhances 
macrophage activation; 
targets A20 in B cells 
95-98 
miR-132 Upregulated THP1, HPBM Inhibits p300 expression 82,86 
miR-146a Upregulated Knockout mice, 
THP1, HPBM 
Inhibits TLR4 signaling by 
targeting IRAK1, TRAF6; 
mediates transcriptional and 
translational repression of Tnf 
82-86 
miR-147 Upregulated Mouse peritoneal 
macrophages 
Inhibits NF-κB activation 99 
miR-155 Upregulated THP1, HPBM Targets SHIP1 and SOCS1 82,86,100-
102 
miR-187 Upregulated HPBM Directly down-regulates TNF-α 
and IκBζ, leading to modestly 
reduced IL-6 and IL-12p40 
production 
86,103 
miR-221 Upregulated Tolerized THP1 Targets Tnf mRNA for 
degradation 
96 
miR-223 Downregulated RAW264.7, BMDM Targets STAT3, with 
downstream effects on IL-6 
and IL-1β 
104 
miR-579 Upregulated  Tolerized THP1 Suppresses TNF-α translation 96 
Table 2.  miRNA feedback regulators of the LPS response. 
Cell types that were tested and any observed targets and effects of the miRNA are listed.  Effects 
observed in other cell types are sometimes listed if they may be relevant to the LPS response.  BMDM:  
mouse bone marrow-derived macrophages.  HPBM:  human peripheral blood monocytes.  PBMC:  
human peripheral blood mononuclear cells. 
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LPS stimulation of human monocytes also leads to the up-regulation of miR-9, which was found to target 
NFKB1/p105 for translational repression, although the exact ramifications of this targeting on LPS 
signaling were not explored86. Let-7 family members are also up-regulated upon NF-κB activation. 
Because they have been found to regulate TLR4 expression87,88, they may contribute to tolerance in a 
manner similar to miR-146a. miR-147 is also up-regulated in response to LPS and inhibits NF-κB 
activation, although its mechanism of action is unclear99. miR-98 has been found to repress IL-10 
production and is down-regulated by LPS stimulation, giving it a role in anti-inflammatory regulation93. 
Finally, miR-221, miR-579, and miR-125b have been found to be regulated by LPS stimulation and are 
involved in Tnf transcript degradation, which may further explain the strong hypo-responsiveness of Tnf 
in particular96.  The regulation and effects of these and other miRNAs are summarized in Table 2. 
Interestingly, some LPS-induced miRNAs seem capable of differentially regulating the expression of large 
numbers of genes downstream of signaling. For example, miR-21 is induced by LPS within 4 hours, and 
expression is sustained at 24 hours of stimulation. By targeting PDCD4, a regulator with roles in both NF-
κB activation and selective inhibition of cap-dependent translation, miR-21 suppresses NF-κB activation 
and transcription of Il6, but simultaneously promotes production of IL-10 protein92. If this capacity 
extends to other proteins, miR-21 could produce a response with both hypo- and hyper-responsive 
protein production. This does not directly account for the differences in LPS-induced gene transcription 
after tolerization, but could nonetheless contribute to the tolerance phenotype. 
miR-132 is also up-regulated by LPS stimulation of human monocytes82,86, and inhibits expression of 
p300, a transcriptional co-activator105. miR-187 is similarly increased, and down-regulates IκBζ. This 
selectively decreases downstream Pol II recruitment to the Il6 and Il12b promoters86,103. miRNAs that 
regulate transcriptional machinery in this manner have broad yet selective anti-inflammatory potential, 
as they would only attenuate genes that are dependent on a particular co-activator. 
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Although none of these miRNAs completely recapitulates the LPS tolerance phenotype, several of the 
examples discussed above demonstrate the potential for selective gene regulation and a shift toward 
anti-inflammatory responses in macrophages, affecting TLR signaling, NF-κB subunit expression, and 
post-transcriptional regulation of Tnf. In other systems, miRNAs also influence two major groups of 
chromatin regulators identified as likely mediators of tolerization: histone modifying enzymes and 
nucleosome repositioning machinery. 
As SWI/SNF complex recruitment has already been implicated in providing selectivity to gene expression 
after NF-κB activation, identification of regulators of this complex may prove fruitful. The SWI/SNF 
complex may be particularly susceptible to regulation by miRNAs, as function and recruitment of this 
complex is quite sensitive to small alterations in subunit expression. Homozygous deletion of Brg1 
results in embryonic lethality, but even mice heterozygous for Brg1 deletion are born at lower ratios 
than expected and have increased incidences of exencephaly and tumors106,107. Proper Brg1 gene dosage 
is also required for normal cardiac development, and allelic balance between Brg1 and interacting 
transcription factors appears to be important for normal expression of some genes108. In an induced 
signaling system, the glucocorticoid and progesterone receptors seem to compete for available Brg1 to 
facilitate chromatin remodeling prior to gene expression, and 2.5-fold overexpression of Brg1 is 
sufficient to prevent cross-inhibition109. Also of note, in neuronal systems, a switch between expression 
of SWI/SNF complex members BAF53a and BAF53b is required for proper development. This switch is 
regulated by miR-9* and miR-12417. Thus, dynamic regulation of this complex by RNAs during endotoxin 
tolerance is an attractive hypothesis. 
Histone modifications, including H3K14, H4K8, and H4K12 acetylation, can be recognized by Brg1110. H4 
lysine acetylation, in particular, seems to be important for Brg1 recruitment during both the naïve and 
tolerized LPS response16,24,31. Other histone modifications may be required for recruitment of 
transcription factors, including NF-κB p6571,73. miRNAs are predicted to regulate the expression of 
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histone modifying enzymes, and may thereby affect multiple steps of transcriptional initiation. miRNA 
targeting of these enzymes has in some cases been validated experimentally. For instance, the miR-29 
family and miR-290 cluster regulate expression of DNA methyltransferases, and expression of this 
miRNA is sufficient to restore expression of silenced genes111. miR-22 has also been shown to regulate 
the histone deacetylases HDAC4 and HDAC6 in some contexts112,113. 
Interestingly, miR-22 has also been found to attenuate NF-κB activity in hepatocytes by down-regulating 
expression of an NF-κB co-activator, NCOA1114, and miR-29 has been found to influence A20 levels in 
sarcoma cells115. This suggests that miRNAs may be capable of coordinating changes in NF-κB activity 
and chromatin structure.  Whether miRNAs regulate changes in gene expression during LPS tolerance 
through such mechanisms remains to be determined. 
It is worth noting, however, that some LPS-inducible miRNAs play opposing roles in the outcome of 
stimulation. For example, miR-155 and miR-223 are up- and down-regulated by LPS stimulation, 
respectively100,104. However, unlike the miRNAs discussed above, the resultant levels of these miRNAs 
leads to increased TNF production and hypersensitivity to LPS shock97,104. Furthermore, many of the 
discussed miRNAs have additional roles in myeloid cell development, and the predominant transcript 
that is targeted by a given miRNA appears to be context-specific85,116-118. Caution may therefore be 
warranted in extrapolating a miRNA’s effect in the tolerization response based on experimental 
modulation of expression in resting macrophages. 
Thus, it appears that more thorough methods of screening and study designed to specifically 
characterize miRNAs involved in endotoxin tolerance have the potential to identify regulators that more 
fully account for this process.  It is with this in mind that experiments to identify novel miRNA regulators 
of tolerance were performed. 
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Results 
Prolonged LPS stimulation results in tolerance, but short pretreatments can actually prime subsequent 
LPS responses16,47-49.  Therefore, I first examined the kinetics of the tolerization response to identify 
treatment conditions that would allow the two effects to be distinguished.  Accordingly, bone marrow-
derived macrophages (BMDMs) were stimulated with LPS for varying lengths of time, washed, and then 
re-stimulated with LPS, after which the effects of the second LPS response were determined (Figure 4a).  
Interestingly, although production of both IL-6 and IL-12p40 is suppressed, as has been described 
previously, there appears to be some difference in the tolerization kinetics of these LPS-induced genes 
(compare Figure 4b and 4c).  This phenomenon has been observed in some prior studies, and may 
indicate that multiple mechanisms contribute to tolerance, with different selectivity for different genes.  
Alternatively, tolerogenic mechanisms that alter chromatin accessibility may have differential effects on 
Figure 4.  Prolonged, but not short, pretreatment with LPS reduces the potential for inflammatory cytokine 
production in BMDMs. 
BMDMs were pre-treated with LPS for varying amounts of time, then treated with 10 ng/ml LPS 
overnight, as described in (A).  IL-6 (B) and IL-12p40 (C) release into cell supernatants was determined by 
ELISA.  n=3.  Error bars represent SEM. 
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LPS-response genes based on their individual transcriptional requirements.  Regardless, pre-treatment 
with LPS for short periods of time (up to 8 hours) does not lead to tolerization of a second response, and 
may in fact potentiate it.  However, by 48 hours of pre-treatment, tolerance is established for both IL-6 
and IL-12p40 (Figure 4), which is consistent with the work of others16. 
Using this information, miRNA expression in BMDMs treated with LPS for 0 hours, 8 hours, or 48 hours 
was compared by microarray to distinguish miRNAs that closely correlate with tolerogenesis from those 
that may be involved in potentially conflicting acute LPS responses (Figure 5a).  Several miRNAs were 
found to be up- or downregulated within 8 hours, including some known to be LPS-responsive, such as 
miR-146, miR-147, miR-155, and miR-223 (Figure 5b).  This suggested that the LPS treatments had the 
expected effect, and that the microarray was capable of detecting miRNAs of interest.  Of greater 
interest for this study, several miRNAs were found to be at least 2-fold upregulated by microarray 
analysis in tolerized, but not acutely challenged, BMDMs (Figure 5b).  To validate the microarray results, 
qPCR analysis of the expression levels of nine miRNAs detected by the microarray was performed, at 
both 8 and 48 hour time points.  The two assays largely agreed on the expression levels of the miRNAs 
tested, as a linear correlation between the results was observed (Figure 5c).  Expression of the nine 
miRNAs was also examined by qPCR after 96 hours of LPS stimulation.  Of the upregulated miRNAs that 
were differentially expressed between 0-8 and 48-96 hours of LPS stimulation, miR-222, miR-22, and 
miR-29a had the highest levels of expression (Figure 5d).  These miRNAs were chosen for study in 
further detail. 
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It has been noted that pre-treatment with interferon gamma can attenuate the ability of macrophages 
to become tolerant to LPS69.  Therefore, to further test the correlation between upreguation of these 
miRNAs and tolerance, miRNA expression in LPS-treated BMDMs was assayed with and without 
interferon gamma pre-treatment.  Interferon gamma strongly repressed upregulation of miR-222 (Figure 
Figure 5.  Several miRNAs are upregulated after prolonged, but not acute, LPS stimulation. 
(A) Rationale for examining miRNA expression after 48 hours of LPS stimulation.  (B) Differentially 
expressed miRNAs, as determined by microarray.  (C) Comparison of miRNA expression levels measured 
by microarray or by qPCR. (D) Expression levels of nine differentially expressed miRNAs, as determined 
by qPCR.  Note that in this experiment, for the 96-hour time point, LPS-containing medium was replaced 
with fresh medium containing LPS after 48 hours.  n=3 for qPCR values.  Error bars represent SEM.  ** 
indicates a p-value < 0.01, * p < 0.05, + p < 0.10, as determined by a two-tailed Student’s t-test for paired 
values. 
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6a), and also reduced expression of miR-22 (Figure 6b) and miR-29a (Figure 6c).  It is somewhat unclear 
whether interferon gamma pretreatment prevents global miRNA processing, or selectively prevents 
transcription or processing of the tested miRNAs.  However, even with interferon gamma pre-treatment, 
miR-155 is still upregulated to some degree in response to LPS, suggesting some selectivity may be 
involved (Figure 6d). 
To determine whether each miRNA could independently affect the LPS response, naïve BMDMs were 
transfected with miRNA oligonucleotide mimics (to effectively overexpress the miRNA).  Cells were 
Figure 6.  Interferon gamma pre-treatment, which attenuates LPS tolerance, also prevents upregulation 
of miR-222, miR-22, and miR-29a. 
miRNA expression in response to prolonged LPS treatment, with or without interferon gamma pre-
treatment.  Note difference in scale for (D).  n=4.  Error bars represent SEM.  ** indicates a p-value < 
0.01, * p < 0.05, + p < 0.10, as determined by a two-tailed Student’s t-test for paired values. 
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allowed to recover for 24 hours, in order to reduce the likelihood that the transfection itself would alter 
the LPS response, and to allow for miRNA target turnover.  Cells were then stimulated with LPS, and the 
expression of several different LPS-inducible genes was examined (Figure 7a).  The LPS-induced genes 
examined by qPCR were chosen for their requirements for transcription, regulation by tolerization, or 
inflammatory characteristics.  Tnf is a pro-inflammatory, primary, and Brg1-independent gene; Il6 and 
Il12b are pro-inflammatory, secondary, and Brg1-dependent genes; Ifnb1 is an antiviral, primary, and 
Brg1-dependent gene; Cnlp is an antimicrobial gene and becomes hyper-responsive after tolerization; 
and Il10 is anti-inflammatory. 
miR-222, miR-22, and miR-29a all appear capable of affecting gene expression in response to LPS, and 
are generally anti-inflammatory, as they all affect some combination of Tnf, Il6, and Il12b expression.  
Interestingly, however, they do not all affect the same subsets of LPS-response genes.  miR-222, for 
instance, seems to broadly suppress most of the LPS-response genes tested.  miR-22 does not seem to 
affect Tnf, Ifnb1, or Il10 expression.  miR-29a, on the other hand, represses Tnf expression, but leaves 
Cnlp, Ifnb1, and Il10 production intact, at least at the mRNA level (Figure 7b).  Each of these patterns is 
generally consistent with some aspect of LPS tolerance.  However, the differential effects suggest each 
miRNA may each contribute to the tolerogenic phenotype though a different mechanism, which will be 
discussed below.  
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Figure 7.  Tolerance-associated miRNAs are anti-inflammatory, but each miRNA suppresses a different 
subset of LPS-inducible genes. 
(A) Rationale for miRNA overexpression experiments.  (B) BMDMs were transfected with given 
oligonucleotide mimic.  After 24 hours, cells were treated with LPS as indicated, and gene expression 
was determined by qPCR.  n=4.  Error bars represent SEM.  ** indicates a p-value < 0.01, * p < 0.05, + p < 
0.10, as determined by a two-tailed Student’s t-test for paired values. 
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Discussion 
On the surface, it may seem unusual that so many mechanisms are utilized to negatively feed back on 
LPS signaling and NF-κB activation.  However, it should be noted that LPS is a particularly potent 
activator of macrophages, and very fine control of NF-κB activation, through a network of positive and 
negative regulators, may be necessary to prevent such a strong inflammatory response from becoming 
self-sustaining.  Indeed, several distinct mechanisms of inducible downregulation of LPS signaling and 
NF-κB activity have previously been described.  For instance, IκBα is itself an LPS-responsive gene, and 
helps terminate NF-κB activity119.  A20 and IRAK-M are also synthesized in response to LPS signaling, and 
attenuate TLR4 signaling to the IKK complex58,59.  miRNAs likely contribute to this process.  miR-146a has 
already been described as an important, LPS-inducible regulator of TLR4 signaling82.  The novel miRNAs 
identified in our microarray, including miR-222, miR-22, and miR-29a, may also reinforce the 
termination of LPS-induced gene expression. 
This is not to say that all of the LPS-induced miRNAs necessarily promote the same gene expression 
outcome, or that they are all consistently regulated in a way that is anti-inflammatory in nature.  For 
instance, it should be noted that miR-155 is very strongly upregulated early in the LPS response, but is 
generally expected to be pro-inflammatory in macrophages, as it targets Socs1120,121 and Ship1102, two 
negative regulators of inflammatory signaling.  In fact, it is possible that relatively mild upregulation of a 
large number of anti-inflammatory miRNAs is required to counterbalance the very potent upregulation 
of miR-155 in response to LPS.  As miR-155 is upregulated earlier in the LPS response compared to many 
other miRNAs, it is possible that the kinetics of expression of each of the LPS-responsive miRNAs is 
designed to support the development of a strong initial inflammatory response, followed by a 
dampening and ending of inflammatory processes in the macrophage. 
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It is also interesting to note that, although the miRNAs I have studied are anti-inflammatory in nature, 
similar to miR-146a, they do not appear to be regulators that simply terminate LPS signaling or NF-κB 
activity.  Each miRNA appears to affect a distinct subset of LPS-response genes.  Distributing anti-
inflammatory processes amongst these miRNA regulators may simply be a form of mechanistic 
redundancy.  However, the different gene expression outcomes suggest another possible reason for 
having multiple anti-inflammatory miRNAs regulate the inflammatory response:  each miRNA may be 
primarily responsible for regulating a particular module of inflammatory gene expression, and different 
combinations of miRNA expression may be utilized to allow for greater flexibility of inflammatory 
responses to external stimuli.  LPS may induce all of these negative feedback loops simultaneously, but 
other, less potent inflammatory agents may upregulate only a specific subset of these miRNAs.  This may 
skew the gene expression outcome of NF-κB activation toward something that is favorable for a 
particular stimulus, or combination of stimuli.  Expression of these miRNAs may therefore be a means to 
integrate inputs from multiple signaling pathways to mediate an appropriately balanced NF-κB-induced 
gene expression response.  Exploration of this possibility would require more information on how these 
miRNAs are regulated, and how they regulate gene expression in response to other inflammatory 
stimuli.  This is performed to some extent for one miRNA, miR-222, in Chapter 3 of this thesis. 
The effects of these miRNAs on LPS-induced gene expression suggest a mechanism of miRNA activity 
that is downstream of TLR signaling and/or NF-κB activation, as the tested LPS response genes are NF-
κB-dependent, and intact transcription of even a subset of the genes implies that NF-κB activity itself is 
not affected by expression of the miRNAs.  I present more evidence that this is the case for miR-222, 
which seems to affect the capacity for nucleosome organization rather than TLR4 signaling in the 
cytosol, in Chapter 4.  Computational predictions and studies in other cell types support the hypothesis 
that miR-22 and miR-29a also affect the LPS response at the level of chromatin organization.  This is 
discussed in detail in Chapter 6.  
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Chapter 3:  Mechanisms regulating miR-222 expression 
Introduction 
Identification of regulators that govern the expression of the tolerance-associated miRNAs identified in 
Chapter 2 could provide insight into broader mechanisms utilized to control the induction of tolerance.  
Therefore, potential means of regulating the maturation of these miRNAs were examined. 
While miRNAs are small (~22 nucleotide) non-coding RNAs in their mature form, they are generated 
from much longer RNA transcripts through a series of processing steps that occur in both the nucleus 
and the cytoplasm of the cell.  Evidence suggests that each processing step can be used as a means to 
regulate miRNA expression, with some forms of regulation affecting the expression of large numbers of 
miRNAs, and others affecting miRNA expression at an individual level.  This indicates that a great 
diversity of mechanisms could be used to regulate miR-222 expression. 
The most obvious layer of miRNA regulation occurs at the level of transcription.  Many miRNAs have 
been mapped to intergenic regions of the genome, and appear to be located within non-coding primary 
transcripts.  These primary miRNA transcripts (pri-miRNAs) can be transcribed by RNA polymerase III, 
but many are transcribed by RNA polymerase II, and are subsequently spliced and polyadenylated.  In 
these cases, pri-miRNA transcription is regulated similarly to primary transcription of protein-coding 
genes; that is, transcription factors bind to promoter and enhancer sites to recruit RNA Pol II and initiate 
transcription122.   
Within the primary transcript, each miRNA is contained in a stem-loop secondary structure.  These 
structures are recognized and excised from the pri-miRNA by Drosha (Rnasen), a ribonuclease III 
enzyme, and its partner protein DGCR8, generating a pre-miRNA hairpin123-126.  The stem sequences of 
the pre-miRNA are most important for Drosha/DGCR8 recognition, and change of a single nucleotide can 
sometimes prevent proper pri-miRNA processing127.  Although Drosha and DGCR8 are necessary and 
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sufficient for processing of most pri-miRNAs, several pri-miRNAs require binding of Ewing’s sarcoma 
gene (EWS)124 or other RNA helicases, such as p68128, p72124,128, hnRNP M4124, or hnRNP A1129, for proper 
Drosha processing.  Drosha processing can also be inhibited by binding proteins, as Lin28 has been 
shown to inhibit Drosha processing of let-7130.  14% of human pre-miRNA loops are conserved between 
species122, suggesting that pri-miRNA processing by Drosha may be an important regulatory point for a 
large number of miRNAs. 
Other miRNAs are intronic to protein-coding genes, and are regulated in much the same way as 
intergenic miRNAs, except that their primary transcription is usually (though not always) regulated by 
the promoter of the protein coding gene in which they reside.  Many intronic mRNAs regulate the same 
biological processes as the host genes with which they are co-regulated131,132, or form negative feedback 
loops to regulate host gene expression133.  Several of the miRNAs identified in Chapter 2 are intronic 
miRNAs, and are listed along with their host genes in Table 3. 
Once intronic miRNAs are transcribed, they are usually processed out of the intron by Drosha.  However, 
in some cases these miRNAs do not require Drosha processing, as they are able to either form an 
appropriate pre-miRNA hairpin structure after splicing or recruit an alternative processing method.  This 
ability to bypass Drosha processing allows some miRNAs to continue to be expressed even when Drosha 
is knocked out or otherwise limited in function134-136. 
After Drosha processing (or splicing), the pre-miRNA is exported to the cytoplasm by an Exportin-5 
(XPO5)-Ran-GTP complex137.  Once in the cytoplasm, the pre-miRNA is processed by a complex 
containing Argonaute-2 (Ago2) and the Dicer RNase, along with Dicer partner proteins TRBP and PACT, 
which enhance but are not required for Dicer activity138-141.  Dicer cleaves the pre-miRNA, generating an 
approximately 22 nucleotide miRNA:miRNA* duplex, with the exact cut site and length of the resultant 
miRNA fine-tuned by TBRP142.   Lin-28 can again inhibit processing of let-7 at this point.  Although this 
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effect appears to be specific to this miRNA122, this suggests that Dicer processing is also a critical and 
regulated processing step.  In general, Dicer processing seems to be required for mature miRNA 
function; however, one miRNA, miR-451, has been found to require only Arognaute2 for processing, 
possibly due to its unusually short pre-miR hairpin143. 
Usually, only one strand of the miRNA duplex, referred to as the guide strand (as opposed to the 
passenger, or miRNA* strand), is loaded into the RNA-induced silencing complex (RISC) and facilitates 
mRNA silencing.  The miRNA strand with a more stable 5’ base pairing appears to be chosen for use as 
the guide strand in most cases144,145.  This miRNA strand in the RISC then binds to target mRNAs to cause 
mRNA degradation or translational silencing, as discussed in Chapter 4. 
miRNA Mouse 
chromo-
some 
miRNA type Overlapping transcript name and details 
mmu-miR-301a 11 Intronic Ska2 (spindle and kinetochore associated complex 
subunit 2).  Interacts with glucocorticoid receptor146. 
miR-301 negatively regulates Ska2 expression (via 
Meox2 targeting/effects on the CREB pathway)133. 
mmu-miR-223 X Possibly overlaps 
transcript 
F630028O10Rik (RIKEN cDNA F630028O10 gene) 
mmu-miR-23a 8 Intergenic  
mmu-miR-805 Maps to mitochondrial genome; sequence removed from mirbase 
mmu-miR-290 7 Intergenic  
mmu-miR-503 X Intergenic  
mmu-miR-184 9 Intergenic  
mmu-miR-296 2 Intergenic  
mmu-miR-294 7 Intergenic  
mmu-miR-381 12 Intergenic  
mmu-miR-763 10 Intronic Hmga2 (High mobility group AT-hook 2).  Regulated 
by CREB pathway, alters cell adhesion147; Targeted 
by let-7, modulates haematopoietic stem cell 
renewal during development148. 
mmu-miR-762 7 Overlaps 
transcript 
Bcl7c (B cell CLL/lymphoma 7C).  Putative subunit of 
SWI/SNF complex149. 
mmu-miR-711 9 Overlaps 
transcript 
Col7a1 (collagen, type VII, alpha 1).  Involved in 
wound healing150. 
mmu-miR-714 No genomic location data available. 
mmu-miR-709 8 Intronic Rfx1 (regulatory factor X, 1 (influences HLA class II 
expression)).  Knockout leads to early embryonic 
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In an additional regulatory mechanism, some pri-miRNAs can be targeted by ADAR enzymes for 
transcript editing.  These enzymes modify adenosine bases into inosine, which has base-pairing 
properties that are similar to guanosine.  Through this mechanism, ADARs can attenuate or potentiate 
pre-miR recognition and processing by Drosha163,164, as well as potentially alter the miRNA targeting 
profile165.  Up to 16% of human miRNAs might be edited in this manner164.  Among other miRNAs, miR-
22166, miR-99a, and miR-223167 have been found to be edited.  miRNAs can also have base pairs added to 
their 3’ ends.  miR-26, for instance, gains uridine bases as a result of ZCCHC11 function, preventing it 
from repressing IL-6 expression168.  In another exception to normal miRNA regulation, miR-29 appears to 
be re-imported into the nucleus after processing169. 
lethality151.  Prevents DNA methylation at MHCII 
promoters152. 
mmu-miR-222 X Intergenic  
mmu-miR-147 2 Possibly overlaps 
transcript 
AA467197 (expressed sequence AA467197) 
mmu-miR-155 16 Possibly overlaps 
transcript 
ENSMUST00000180991 (lincRNA) 
mmu-miR-684 4 and 2 Intronic (684-1), 
Intergenic (684-
2) 
Dusp19 (dual specificity phosphatase 19).  
Suppresses JNK activation in response to TNF153. 
mmu-miR-146a 11 Intergenic  
mmu-miR-146b 19 Intronic LOC102640430 (uncharacterized LOC102640430) 
mmu-miR-22 11 Overlaps 
transcript 
Mir22hg (Mir22 host gene (non-protein coding)) 
mmu-miR-29a 6 Intergenic  
mmu-miR-342 12 Intronic Evl (Ena-vasodilator stimulated phosphoprotein).  
Involved in actin remodeling154, cortical 
development155, and Listeria motility156.  miRNA and 
host gene silenced in colorectal cancer157. 
mmu-miR-125a 17 Intronic Spaca6 (sperm acrosome associated 6). 
Also near miR-99b and let-7e. 
mmu-miR-99b 17 Intergenic  
Genomic location data from mirbase.org158-162; updated on 1/28/2014. 
Table 3.  Genomic locations of LPS-responsive miRNAs. 
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Finally, in addition to regulation at the levels of transcription, Drosha processing, Dicer processing, 
editing, and nuclear import, the function of mature miRNAs can be regulated by the expression of non-
coding “sponge” transcripts that contain multiple miRNA binding sites and can effectively prevent a 
miRNA from binding to its normal mRNA targets.  However, because inhibition by endogenous RNA 
“sponges” is accomplished mostly through miRNA base-pairing, this is discussed in more detail in 
Chapter 4. 
Of the LPS-induced miRNAs identified by microarray, 5 are clearly intronic and 11 are clearly intergenic, 
as shown in Table 3.  Several have been found to overlap a noncoding transcript.  This may simply be the 
primary RNA transcript from which the miRNA is processed, or may be a long noncoding transcript with 
other additional functions.  Because most long noncoding RNAs are not well annotated, it is difficult to 
make this determination in most cases.  No clear pattern of regulation of these miRNAs was apparent.  
Therefore, in order to gain a broader understanding of the regulation of tolerance, I examined possible 
regulators of one tolerance-associated miRNA, miR-222, in particular. 
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Results 
It has previously been reported that miR-221 and miR-222 are intergenic and are processed from the 
same pri-miRNA170.  It therefore seemed unusual that upregulation of mature miR-222, but not miR-221, 
was detected in response to LPS stimulation by microarray.  qPCR was performed to confirm the 
microarray result with regard to miR-221. Mature miR-222, but not miR-221, expression was again 
found to be induced by prolonged LPS stimulation of BMDMs (Figure 8). 
Although miR-221 and miR-222 have similar mature sequences, particularly within the seed region 
(Figure 9a), their overall stem-loop structures and mature miRNA lengths are different (Figure 9a and 
9b).  Small changes in hairpin structure and base pairing have been found to affect processing of miRNAs 
by Dicer and Drosha127.  It is therefore possible that miR-221 is not processed to its mature form 
efficiently in BMDMs.  An analysis of data from a survey of miRNA expression in normal human tissues171 
Figure 8.  Unlike miR-222, miR-221 does not appear to be upregulated in BMDMs in response to LPS 
stimulation. 
Mature miRNA expression was determined by qPCR after stimulation of BMDMs with LPS for the given 
lengths of time.  n=4.  Error bars represent SEM.  ** indicates a p-value < 0.01, * p < 0.05, + p < 0.10, as 
determined by a two-tailed Student’s t-test for paired values. 
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finds that miR-221 is generally expressed at lower copy numbers than miR-222 (Figure 9c), suggesting 
this may be a general phenomenon for this miRNA pair. 
Figure 9.  Although they have similar mature sequences, miR-221 and miR-222 have different pre-miRNA 
hairpin structures and are differentially expressed in various tissues. 
(A) Alignment of mature miR-221 and miR-222 sequences, as annotated in miRBase.  miRNA seed 
regions are shaded in gray.  (B) Hairpin structures of miR-221 and miR-222 precursors, using miRBase-
annotated sequences.  Secondary structure was determined using the RNAfold program172-174.  Color 
scale indicates probability of base-pairing.  (C) miRNA copy number in given healthy human tissues, as 
determined by another group in a prior publication171.  Higher values are shaded in darker blue.  Higher 
221/222 ratios are shaded in red; lower ratios are shaded in green. 
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miR-221 expression therefore does not appear to be regulated by LPS stimulation, and is unlikely to play 
a role in the inflammatory responses that are being tested.  However, to ensure that miR-221 does not 
have effects on the inflammatory response that conflict with those of miR-222, which could confound 
our analysis, the effect of each miRNA on the LPS response was tested. 
Overexpression of either miR-221 or miR-222, by transfection of an oligonucleotide mimic, was able to 
repress LPS-induced production of several pro-inflammatory cytokines, including TNF-α, IL-6, and IL-
12p40.  miR-222 appears to be slightly better at repressing cytokine production, as it repressed 
production to a slightly higher degree than either miR-221 alone or a mix of the two oligonucleotides, 
although the difference between the two is not great (Figure 10a).  Conversely, antagonization of either 
miRNA resulted in increased pro-inflammatory cytokine production, with modulation of miR-222 
Figure 10.  miR-221 and miR-222 suppress pro-inflammatory cytokine production in similar ways. 
BMDMs were transfected with equimolar concentrations of miRNA oligonucleotide mimics (A) or 
antagonists (B).  After 24 hours, BMDMs were stimulated with LPS and cytokine production was 
measured by ELISA.  n=5.   Error bars represent SEM.  ** indicates a p-value < 0.01, * p < 0.05, + p < 0.10, 
as determined by a two-tailed Student’s t-test for paired values. 
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expression again having a greater effect.  The two miRNAs may have an additive effect, as 
antagonization of the two together has a slightly greater effect than antagonization of miR-222 alone 
(Figure 10b).  Regardless, as LPS-induced upregulation of miR-221 was not noted, and the two miRNAs 
seem to have similar effects on LPS stimulation of macrophages, further investigation of miR-222 alone 
was deemed sufficient for these studies. 
A previous report found that miR-222 expression is partially dependent on NF-κB activation170.  This is 
surprising, as NF-κB activation following LPS stimulation of BMDMs is quite rapid, yet miR-222 shows 
delayed upregulation kinetics.  Furthermore, upregulation of miR-222 in response to TNF-α or LPS does 
not seem to be particularly dose-dependent (Figure 11), whereas many NF-κB dependent genes, such as 
IL-6 and IL-12p40, do appear to be regulated in a dose dependent manner (for instance, Figure 25).  
Taken together, this suggested that NF-κB is not the main factor determining miR-222 expression levels. 
Therefore other factors that might regulate miR-222 expression in BMDMs were examined.  The first 
possibility considered was that miR-222 upregulation is not a direct result of LPS stimulation, but is 
rather dependent on autocrine or paracrine signaling by a cytokine that is induced by LPS treatment.  To 
test this, BMDMs were stimulated with a number of pro- and anti-inflammatory agents, including 
Figure 11.  miR-222 upregulation in response to TNF-α or LPS does not appear to be dose-dependent. 
BMDMs were stimulated with increasing doses of recombinant TNF-α (A) or LPS (B) for 24 hours. Mature 
miR-222 levels were determined by qPCR.  n=5 (A), n=4 (B).  Error bars represent SEM.  ** indicates a p-
value < 0.01, * p < 0.05, + p < 0.10, as determined by a two-tailed Student’s t-test for paired values. 
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several that are produced in response to LPS.  Prolonged TNF-α and IL-1β treatment, which can also 
induce a weak form of tolerance 38,175, also upregulated miR-222 expression (Figure 12).  However, short 
periods of stimulation do not cause miR-222 upregulation, suggesting that a requirement for cytokine 
synthesis and autocrine signaling is not responsible for the delayed kinetics of miR-222 expression.  
Rather, a process that is activated in response to prolonged pro-inflammatory conditions, in general, 
may be involved. 
A recent publication found that Fra-1 binds to the miR-222 promoter region176.  Fra-1, also known as 
Fosl1, is in the Fos family of proteins, and together with proteins of the Jun family can form the 
heterodimeric AP-1 transcription factor complex177.  As AP-1 family members, including Fra-1, are also 
upregulated by LPS stimulation and play a role in inflammatory gene expression178, Fra-1 seemed a 
possible mediator of LPS-induced miR-222 upregulation in BMDMs. 
Figure 12.  miR-222 is upregulated by TNF-α and IL-1β treatment, but not with notably faster kinetics 
compared than LPS stimulation. 
BMDMs were stimulated with given agents for 8 or 24 hours, and mature miR-222 expression was 
determined by qPCR.  n=3 (LPS), n=5 (all other stimulations).  Error bars represent SEM.  ** indicates a p-
value < 0.01, * p < 0.05, + p < 0.10, as determined by a two-tailed Student’s t-test for paired values. 
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Figure 13.  Fra-1 represses miR-222 expression, and is downregulated in response to LPS stimulation. 
Deletion of Fra-1 in BMDMs generated from a conditional knockout mouse was confirmed by PCR of 
genomic DNA (A) and qPCR for mRNA of the deleted region of Fra-1 (B).  Mature miR-222 induction in 
response to LPS was analyzed by qPCR in these BMDMs (C).  Fra-1 mRNA levels were measured by qPCR 
in wildtype BMDMs stimulated with LPS (D), with LPS in the presence or absence of interferon gamma 
(E), in the presence or absence of the BAY 11-7082 inhibitor of NF-κB activation (F).  Tnf production was 
measured in BAY-treated cells as a measure of its efficacy (G).   Error bars represent SEM.  ** indicates a 
p-value < 0.01, * p < 0.05, + p < 0.10, as determined by a two-tailed Student’s t-test for paired values. 
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Fra-1 could bind to the miR-222 promoter in BMDMs to either repress or facilitate transcription.  
Therefore, to determine the effect Fra-1 has on miR-222 expression, BMDMs were generated from a 
mouse in which an exon of the Fra1 gene was flanked by loxP sites, and Cre recombinase was expressed 
during embryonic development from a MORE-cre allele.  This causes Fra-1 deletion throughout the 
mouse179.  Fra-1 deletion was confirmed both by PCR of genomic DNA and qPCR for mRNA from the 
deleted region.  Fra-1 was depleted by at least 50% compared to a littermate control mouse (Figures 13a 
and 13b). 
Using these cells, miR-222 induction in response to LPS was examined.  miR-222 levels are significantly 
increased in Fra-1 depleted macrophages (Figure 13c), suggesting that Fra-1 represses miR-222 
expression in BMDMs.  In wildtype BMDMs, Fra-1 mRNA levels are repressed by long periods of LPS 
stimulation (Figure 13d).  Because interferon gamma pre-treatment prevents miR-222 upregulation 
(Figure 6a), I tested whether interferon pre-treatment also prevents LPS-induced repression of Fra-1.  
This is indeed the case (Figure 13e).  This suggests a model in which miR-222 expression is basally 
repressed in BMDMs by Fra-1.  It is only after Fra-1 is itself transcriptionally repressed in response to LPS 
stimulation, and existing Fra-1 protein has turned over, that increased miR-222 transcription can occur.  
This results in the delayed kinetics of miR-222 expression in response to LPS. 
Finally, as it has been suggested that NF-κB contributes to miR-222 regulation170, I wished to determine 
whether inhibition of NF-κB activation could impact miR-222 expression.  Treatment of BMDMs with 
BAY 11-7082, a chemical inhibitor of NF-κB activation, attenuated NF-κB-dependent gene expression 
(Figure 13g).  However, this also led to an increase in Fra-1 levels (Figure 13f).  It is thus possible that NF-
κB directly regulates miR-222 expression, or affects miR-222 levels only by repressing Fra-1 levels in 
BMDMs. 
 
44 
 
Discussion 
The differential expression of mature miR-221 and miR-222 in response to LPS stimulation in BMDMs is 
puzzling, given that they are a part of a single transcriptional unit.  This suggests that expression of miR-
221 and miR-222 may be regulated at the level of pri-miRNA or pre-miRNA precursor processing.  In this 
regard, it is notable that, although miR-221 is generally present at lower levels than miR-222, this is not 
always the case, and the ratio of miR-221/miR-222 expression can vary by tissue type (Figure 9c).  This 
may imply that a Drosha or Dicer helper protein that is required for miR-221 processing is present in 
some cells, but is not expressed in BMDMs. 
It is alternatively possible that miR-222 is basally processed only at low levels in BMDMs, and the LPS-
induced increase in mature miR-222 levels that I observe is a result of an increase in miR-222 processing, 
rather than an upregulation of miR-222 transcription.  It has been noted that the Dicer helper protein 
TRBP is phosphorylated by mitogen-activated protein kinase activation, resulting in increased miRNA 
processing180.  It is therefore possible that LPS stimulation increases the expression or selectivity of 
miRNA processing proteins, which then specifically promote excision of miR-222, but not miR-221, from 
its pri-miRNA or pre-miRNA.  The requirement for synthesis of these proteins could also explain the 
delayed upregulation of mature miR-222 transcripts in response to LPS.  As I did not directly examine 
primary miR-222 transcript levels, I cannot rule out this possibility.  However, the prior finding that the 
AP-1 subunit Fra-1 directly binds to the miR-222 promoter176, taken together with my results indicating 
that mature miR-222 is upregulated in the absence of Fra-1, suggest that a Fra-1-mediated increase in 
transcription of miR-222 is at least partially, if not wholly, responsible for the LPS-induced increase in 
mature miR-222 levels. 
I did not test whether Fra-1 is also involved in the regulation of other miRNAs associated with LPS 
tolerance, such as miR-29a and miR-22.  If Fra-1 also mediated expression of these miRNAs, it is possible 
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that Fra-1 could be an important transcriptional regulator of the overall tolerance phenotype.  However, 
given that array data from various studies indicates that these miRNAs are not always co-expressed171, it 
seems unlikely that these miRNAs would be simply regulated by a single common transcription factor. 
A broader discussion of how Fra-1 regulation could be used by the cell as a “timer” for LPS tolerance is 
presented in Chapter 6.  However, it worth noting here that other studies on Fra-1 suggest that it may 
play a complex role in immune regulation.  Studies of Fra-1 in RAW264.7 macrophages find that Fra-1 
suppresses expression of LPS-response genes178.  While this finding may support a model in which Fra-1 
also represses miR-222 expression, the RAW264.7 study finds an overall effect in which Fra-1 suppresses 
production of pro-inflammatory cytokines.  Why Fra-1 would suppress production of both pro-
inflammatory cytokines and an anti-inflammatory microRNA is unclear.  Furthermore, an in vivo study of 
Fra-1 knockout mice finds that Fra-1 promotes inflammation and mortality in response to LPS-induced 
lung injury181.  These somewhat contradictory findings of both an anti-inflammatory and pro-
inflammatory role for Fra-1 complicate interpretations of its role in regulating inflammation, and may 
indicate that Fra-1 regulates the inflammatory response in ways very specific to cell type and the nature 
of the inflammatory stimulus. 
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Chapter 4:  Characterization of miR-222 targets and mechanism of action 
Introduction 
In mammalian systems, miRNAs primarily function as part of the RNA-induced silencing complex (RISC) 
to target mRNAs in the cytoplasm and suppress gene expression.  Because almost any mRNA can 
potentially be targeted, a wide variety of targets could be responsible for the effects of miR-222 and 
other tolerogenic miRNAs.  In general, however, miRNA targeting follows several patterns.   miRNAs can 
potentially target any portion of a gene transcript, but targeting the 3’ UTR seems to be more common 
and effective.  The most important miRNA sequence for targeting seems to be that of the seed region, 
the ~7 nucleotides at the 5’ end of the miRNA.  This region is often a perfect match to its mRNA target, 
or has a single bulged nucleotide.  Complementarity between the miRNA and mRNA target outside of 
the seed region can occur, but is not required for target suppression, and may rather be used to 
determine the ultimate effect of the miRNA on its target or perhaps be used as a means of allowing for 
preference in transcript targeting182. 
Once the miRNA binds to the target mRNA, there appear to be two primary means with which 
expression of the target is silenced: through translational repression, or through complete degradation 
of the mRNA.  Which of these two means is predominant has been controversial, as evidence has 
supported the utilization of both mechanisms.  Models in which miRNAs accelerate mRNA 
deadenylation and decay of their targets183, or in which miRNAs first repress translation of a target 
before causing mRNA decay184,185, have been proposed.  Regardless, microarray and proteomic studies 
seem to indicate that while translational repression accounts for the effects of some miRNA targeting, 
the majority of miRNA targets are degraded at the mRNA level186, especially when target expression is 
highly suppressed187.  It is possible that the nature of the specific miRNA:mRNA pairing governs whether 
translational suppression or mRNA degradation is the ultimate outcome188. 
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Because the targeting between a miRNA and its mRNA target relies primarily on complementarity of the 
short miRNA seed region, a single miRNA can affect the expression of hundreds of genes.  Expression of 
any one target is often “fine-tuned,” rather than shut off completely; that is, the target is often reduced 
in expression by 50% or less.  Nevertheless, miRNA targeting seems to have profound impacts on many 
processes, either because multiple components of a cellular process are targeted simultaneously, or 
because a target controls a limiting step and is therefore vital to a particular process189. 
A number of algorithms have been developed to predict miRNA targets.  However, because of the wide 
number of potential targets for any single miRNA, and because base-pairing between the miRNA and its 
target need not be perfect, accurate prediction of miRNA targets remains a challenge.  To attempt to 
increase the accuracy of target predictions, some algorithms take into account other probable 
characteristics of a true miRNA binding site.  For example, some algorithms take into account UTR 
conservation amongst animal species, while other algorithms examine the secondary structure of target 
mRNAs to determine whether a predicted binding site is likely to be accessible for miRNA binding190.  
Needless to say, miRNA target prediction algorithms will often fail to agree on whether a particular 
transcript is a genuine miRNA target, and there are many false positive and negative predictions187,188.  
Because of this, it is often useful to compare these computational predictions with experimentally 
obtained microarray data, and any predicted targets will ultimately need to be validated to determine 
miRNA function. 
Interestingly, it has been found that endogenous noncoding transcripts with multiple binding sites for a 
particular miRNA exist, and seem to regulate miRNA function.  It appears that these transcripts serve 
only to compete for available miRNAs, and prevent the miRNA from binding to and repressing normal 
mRNA targets.  Expression of these various decoy transcripts therefore increases expression of the 
mRNA transcripts normally targeted by the miRNA191-195.  Some transcripts that function in this manner 
are circularized as a result of exon-intron splicing, and this structure may make the transcript more 
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effective at antagonizing miRNAs by preventing miRNA-mediated decay of the decoy transcript196. These 
studies illustrate an interesting capacity of the cell to rapidly antagonize miRNA function, but also the 
complexity that exists in miRNA-mRNA targeting choice and downstream effect. 
In order to determine the mechanism of miR-222 activity specifically, target predictions were combined 
with experimental data to identify relevant miR-222 targets in BMDMs.  The results of this process are 
presented below, while the implications of miR-222 targeting with regard to tolerogenesis are discussed 
in the next chapter. 
  
 
49 
 
Results 
miR-222 suppresses the expression of several genes in response to LPS stimulation of macrophages 
(Figure 7 and 10a).  One possibility is that miR-222 causes this effect by targeting each transcript 
directly.  Alternatively, it is possible that miR-222 either inhibits LPS-induced signaling or affects a 
transcriptional component necessary for expression of a subset of (if not all) LPS-response genes. 
To determine whether miR-222 directly targets the LPS response genes that were assayed, I took 
advantage of the fact that miRNAs cause either translational repression, or, more often, mRNA 
degradation of their targets in the cytoplasm.  Thus, when a miRNA is overexpressed, direct targets of 
the miRNA should be affected at the mRNA and/or protein level, but not at the level of primary 
transcription in the nucleus.  On the other hand, indirect effects on gene expression that are due to 
Figure 14.  miR-222 overexpression affects mRNA levels of Tnf, and both mRNA and primary transcript 
levels of other LPS-response genes. 
BMDMs were transfected with control or miR-222 mimic oligonucleotides.  After 24 hours, cells were 
stimulated with LPS and qPCR was performed to determine cytokine mRNA levels (A) or primary 
transcripts levels (B), using primers that span exon-exon or exon-intron junctions, respectively.  n=5.   
Error bars represent SEM.  ** indicates a p-value < 0.01, * p < 0.05, + p < 0.10, as determined by a two-
tailed Student’s t-test for paired values. 
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effects on signal transduction or transcription should cause decreases in primary transcription, mRNA, 
and protein levels simultaneously. 
Interestingly, when miR-222 was overexpressed in BMDMs and the mRNA and primary transcript levels 
of several genes were compared, miR-222 was found to reduce accumulation of Tnf mRNA (Figure 14a) 
in response to LPS stimulation, but not levels of primary Tnf transcripts (Figure 14b).  Results consistent 
with this were observed after miR-222 antagonization (Figure 15).  This suggests that miR-222 may 
directly bind to the UTR of Tnf mRNA and promote its degradation. 
There is a potential miR-222 binding site in the Tnf UTR that is conserved (Figure 16a).  The miR-222:Tnf 
interaction does not appear to be particularly favorable, as evidenced by algorithms finding either no 
predicted binding, or a poor energetic (ΔG) score for binding (compare Figure 16a and Figure 20; a more 
Figure 15.  miR-222 antagonization has modest, but significant, effects on mRNA and primary transcript 
levels of LPS-response genes. 
BMDMs were transfected with control or miR-222 antagonist oligonucleotides, and cytokine mRNA 
levels (A) or primary transcripts levels (B) were determined by qPCR, as in Figure 14.  n=6.   Error bars 
represent SEM.  ** indicates a p-value < 0.01, * p < 0.05, + p < 0.10, as determined by a two-tailed 
Student’s t-test for paired values. 
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negative ΔG indicates a more favorable interaction).  Nevertheless, the potential binding site was tested 
for functionality by inserting the Tnf UTR into the UTR of a luciferase reporter.  The luciferase reporter 
UTR was then mutated to abolish miR-222 binding capacity at that site (as indicated in Figure 16a).  The 
luciferase reporter containing either the intact or mutant Tnf UTR was co-transfected with varying doses 
of a miR-222 mimic into 293FT cells, and luciferase expression was assayed after 12 hours.  A dose-
dependent inhibition of luciferase activity resulted when the reporter contained an intact UTR, but not 
when the UTR was mutated (Figure 16b), suggesting that miR-222 indeed binds to the indicated site to 
prevent translation.  Another group found that miR-221 also directly binds to the Tnf UTR to promote 
mRNA degradation96.  As miR-221 and miR-222 have similar seed sequences (Figure 9), this seems to 
support the assertion that miR-222 directly regulates Tnf levels to reduce inflammation. 
Unlike Tnf, however, Il6, Il12b, and Saa3 are affected at both the level of mRNA accumulation (Figure 
14a) and primary transcription (Figure 14b), suggesting a second mechanism of miR-222 activity exists.  
Because Tnf transcription remains intact after miR-222 overexpression, it seemed unlikely that the loss 
Figure 16.  Tnf is weakly targeted by miR-222 for repression. 
(A) The miR-222 binding site predicted by the PITA algorithm is shown.  (B)  Luciferase activity measured 
12 hours after co-transfection of 293FT cells with increasing concentrations of a miR-222 mimic and a 
reporter containing either the intact Tnf UTR, or the Tnf UTR with a mutation in the miR-222 binding site 
sequence (as shown in A).  n=6.   Error bars represent SEM.  ** indicates a p-value < 0.01, * p < 0.05, + p 
< 0.10, as determined by a two-tailed Student’s t-test for paired values. 
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of transcription of other cytokines is due to an attenuation of TLR4 signaling in these cells.  Indeed, upon 
testing, overexpression of miR-222 did not affect IκBα degradation in response to LPS stimulation when 
measured by flow cytometry (Figure 17a, middle, and 17b), whereas overexpression of miR-146a, which 
has been shown to inhibit TLR4 signaling by reducing IRAK1 and TRAF6 expression levels82, has a clear 
effect (Figure 17a, right, and b).  Thus, miR-222 exerts an effect on genes such as Il6 downstream of IKK 
activation. 
As many signaling pathways converge on this complex, it seemed likely that miR-222 could also inhibit 
cytokine production in response to other inflammatory stimuli.  When tested, both miR-146a and miR-
222 were able to reduce IL-6 mRNA expression in response to LPS (Figure 18b), but only miR-222 
Figure 17.  IκBα degradation is not affected by miR-222 expression. 
IκBα degradation was measured by flow cytometry in immortalized BMDMs transduced with control, 
miR-222, or miR-146a overexpression constructs.  Representative experiment and gating setup is shown 
in (A).  Average percentage of cells with high IκBα in each condition is shown in (B).  To ensure functional 
overexpression was achieved, inhibition of LPS-induced IL-6 production by miRNAs was confirmed (C) 
and overexpression was quantified by qPCR (D).   n=4.   Error bars represent SEM.  ** indicates a p-value 
< 0.01, * p < 0.05, + p < 0.10, as determined by a two-tailed Student’s t-test for paired values. 
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reduced cytokine expression in response to TNF-α stimulation (Fig. 18a).  miR-222 is therefore capable 
of dampening inflammatory responses from initial triggering agents, such as LPS, as well as from 
secondarily produced inflammatory cytokines, including TNF-α, that are released as a result of 
macrophage activation.  This may potentially make it a more powerful suppressor of inflammation than 
other miRNAs, such as miR-146a, that are limited to regulating a single inflammatory pathway (see 
Chapter 6 for further discussion). 
To better understand the mechanism by which miR-222 selectively blocks the transcription of multiple 
LPS-response genes, but not Tnf, it was necessary to identify the direct target of this miRNA.  Although 
several miR-222 targets have been identified in the past, no single target has explained all of the 
phenotypes linked to miR-222 expression176,197-204 (Table 4).  This suggested that the dominant target 
and effect of miR-222 expression may be cell-type specific. 
Figure 18.  Unlike miR-146a, miR-222 blocks inflammatory cytokine transcription in response to both TNF-α 
and LPS stimulation. 
BMDMs were transfected with miRNA mimics.  After 24 hours, cells were stimulated with TNF-α, and 
cytokine production was measured by qPCR (A).  Cytokine production was also measured in response to 
LPS (B) as a positive control for miR-146a mimic function.  n=4.   Error bars represent SEM.  ** indicates 
a p-value < 0.01, * p < 0.05, + p < 0.10, as determined by a two-tailed Student’s t-test for paired values. 
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Along this line, many previously identified miR-222 targets are not expressed highly in resting 
macrophages (Figure 19a), and may be less likely to be miR-222 targets in this context.  Furthermore, 
expression levels of the previously identified miR-222 targets do not decrease dramatically in cells 
stimulated with LPS for 24 hours, when compared to cells stimulated with LPS for 8 hours.  This is the 
time period in which miR-222 increases in expression, and a decrease in expression of miR-222 targets is 
to be expected.  However, the previously defined targets decrease in expression only slightly, or in fact 
increase in expression (Figure 19b).  The effect of miR-222 on Pten, which has been described as a miR-
222 target in human gastric cancer cells204, was also tested directly.  Pten levels are reduced after 
artificial miR-222 overexpression in BMDMs (Figure 19c).  However, Pten levels are not affected by miR-
222 antagonization (Figure 19c), and in wildtype FLDMs, Pten levels are not decreased in response to 
LPS stimulation (Figure 19d).  This suggests that miR-222 can target Pten under artificial, but not 
endogenous, conditions.  It is therefore possible that miR-222 does not preferentially suppress these 
previously identified targets in BMDMs, or that miR-222 does in fact target mRNA of Pten and other 
identified targets, but other means of regulation are dominant. 
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Therefore, to identify the dominant target that is actively regulated by miR-222 in the context of BMDM 
activation, a de novo analysis was performed.  A list of computationally-predicted miR-222 targets was 
filtered using previously generated microarray data to contain only genes that are expressed in 
macrophages, and for which mRNA levels decrease from 8-24 hours of LPS stimulation, the time period 
during which miR-222 is first upregulated.  One of the top candidates identified by this approach was 
Smarca4, hereafter referred to by its more common name, Brg1 (Figure 20c).  As a component of the 
SWI/SNF nucleosome remodeling complex that is required for transcription of some LPS response genes 
Figure 19.  Previously described miR-222 targets do not appear to be regulated by endogenous miR-222 
expression in BMDMs. 
(A) Expression of previously described miR-222 targets in resting BMDMs, as determined by RNA-seq.  
(B) Change in microarray probe fluorescence for previously described miR-222 targets between 8 and 24 
hours of LPS stimulation of fetal liver-derived macrophages (FLDMs).  Note that Smarca4 (Brg1) is not a 
previously predicted target, but is shown in (A) and (B) for comparison, and is discussed below.  (C) Pten 
expression, as determined by qPCR, after oligonucleotide-mediated miR-222 overexpression or 
antagonization in BMDMs.  n=4.   Error bars represent SEM.  (D) Pten expression in LPS-stimulated 
FLDMs, as determined by microarray. 
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(but, notably, is not involved in Tnf transcription)26, targeting of Brg1 by miR-222 also seemed consistent 
with a role for miR-222 in affecting transcription of a subset of pro-inflammatory genes. 
Figure 20.  Brg1 is predicted to be a miR-222 target. 
(A) The miR-222 binding site predicted by the Microcosm and PITA algorithms is shown.  (B) Brg1 levels, 
as determined by microarray analysis of FLDMs.  (C) Top miR-222 targets that are shown to decrease in 
expression by FLDM microarray data, as predicted by the Microcosm algorithm. 
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To validate this analysis, the predicted miR-222 binding site was examined in more detail.  It is 
evolutionarily conserved (Fig. 20a), and predicted to be as accessible and energetically favorable for 
binding as the experimentally validated miR-146a binding sites in the Traf6 and Irak1 UTRs (Figure 21a).  
qPCR was performed, and an inverse correlation between miR-222 and Brg1 expression after prolonged 
LPS stimulation of BMDMs was found (Figure 21b), consistent with the microarray data that was initially 
used (Figure 20b). 
To further test this correlation, Brg1 expression levels were examined after miR-222 overexpression or 
functional depletion.  Upon miR-222 overexpression, Brg1 mRNA levels were reduced to about half the 
level of expression in control cells (Figure 22b), a magnitude of effect that seems generally consistent 
with miRNA targeting189.  Conversely, miR-222 antagonization leads to an increase in Brg1 mRNA levels 
(Figure 22b).  To ensure that the effects on the level of Brg1 transcripts translated into changes in 
protein expression, which would be required for Brg1 to mediate miR-222’s effects, Brg1 protein levels 
were examined by immunoblotting of protein lysates.  Qualitatively similar changes at the mRNA and 
protein levels were observed, with an increase of Brg1 protein detected after miR-222 overexpression, 
and a decrease detected after antagonization (Figure 22c).  Because relatively modest changes in 
protein expression are expected, protein levels were also analyzed by flow cytometry after intracellular 
staining (Figure  22d), which can allow for more accurate quantification of protein levels.  Measuring 
changes in mean fluorescence intensity, I found that experimental modulation of miR-222 expression 
affects Brg1 expression similarly at the protein and mRNA levels (Figure 22b), indicating that miR-222 
can, in fact, actively regulate Brg1 levels.   
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To ensure that the effects seen on Brg1 expression were due to direct targeting, the Brg1 UTR was 
cloned into the UTR of a luciferase reporter, as was discussed previously for Tnf.  Co-transfection of the 
reporter and increasing levels of a miR-222 oligonucleotide mimic led to dose-dependent inhibition of 
Figure 21.  Validation of Brg1 targeting predictions and microarray expression data. 
(A) Comparison of Microcosm and PITA prediction scores for miR-222 targeting of Brg1 (Smarca4) and 
miR-146a targeting of Irak1 and Traf6, which are experimentally validated targets.  (B) miR-222 and Brg1 
transcript levels, as measured by qPCR.  n=3.   Error bars represent SEM.  ** indicates a p-value < 0.01, * 
p < 0.05, + p < 0.10, as determined by a two-tailed Student’s t-test for paired values. 
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luciferase expression (Fig. 22a).  The miR-222 mimic was unable to inhibit luciferase activity when the 
predicted miR-222 site was mutated (sequence in Fig. 20a), validating the miR-222 site as a functional 
regulatory element. 
If the effects of miR-222 are mediated by Brg1 targeting, miR-222 overexpression and Brg1 knockdown 
should have similar effects on LPS-induced gene expression.  To test this hypothesis, expression of genes 
previously identified25 as being Brg1-dependent (<50% LPS-induced expression after Brg1 knockdown, 
compared to control cells) or Brg1-independent (>50% LPS-induced expression after Brg1 knockdown) 
Figure 22.  miR-222 directly affects Brg1 expression levels. 
(A) Luciferase activity measured 12 hours after co-transfection of 293FT cells with increasing 
concentrations of a miR-222 mimic and a reporter containing either the intact Brg1 UTR, or the Brg1 
UTR with a mutation in the miR-222 binding site sequence (as shown in Figure 20A).  (B) Average Brg1 
mRNA levels, as determined by qPCR, or change in protein levels, as measured by flow cytometry, after 
transfection of BMDMs with miR-222 mimic or antagonist oligonucleotides.  (C) Western blot for Brg1 
levels after transduction of immortalized BMDMs with miR-222 overexpression or antagonist constructs.  
(D) Representative flow cytometric analysis of Brg1 levels, measured in immortalized BMDMs after 
intracellular staining and flow cytometry.  Mean fluorescence intensity from 4 experiments was 
averaged and is shown in (B).  n=3 (A), n=4 (B).   Error bars represent SEM.  ** indicates a p-value < 0.01, 
* p < 0.05, + p < 0.10, as determined by a two-tailed Student’s t-test for paired values. 
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was examined in cells transfected with miR-222 mimics.  The Brg1-dependent genes tested were 
generally suppressed by 50% or more (Figure 23b).  The Brg1-independent genes that were tested were 
generally suppressed by 50% or less (Figure 23a).  There was greater variation in the Brg1-independent 
genes; however, it is possible that some “Brg1-independent” genes are in fact partially Brg1-dependent, 
given that a 50% cutoff was used.  Therefore, some noise in this analysis is to be expected.    
Nonetheless, consistent with a model in which miR-222 suppresses LPS-induced gene expression by 
limiting Brg1 levels, miR-222 preferentially suppresses induction of Brg1-dependent genes (Figure 23c). 
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Figure 23.  miR-222 preferentially suppresses Brg1-dependent genes. 
mRNA levels of genes previously classified22,23 as being Brg1-independent (A) or Brg1-dependent (B), as 
measured by qPCR, after transfection of BMDMs with control or miR-222 mimic oligonucleotides.   
Average suppression of peak mRNA levels by miR-222 overexpression is shown in (C) for each category 
of gene.  n=3.   Error bars represent SEM.  ** indicates a p-value < 0.01, * p < 0.05, + p < 0.10, as 
determined by a two-tailed Student’s t-test for paired values. 
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Finally, as miR-222 only reduces, but does not completely abolish, Brg1 expression, Brg1 recruitment to 
gene promoters was examined to ensure the levels of repression that are observed have a functional 
effect.  Consistent with prior findings, Brg1 is recruited to Brg1-independent as well as Brg1-dependent 
genes at late time points (Figure 24, top row).  However, the timing of Brg1 recruitment only correlates 
with actual gene transcription for the genes classified as Brg1-dependent25.  After miR-222 
overexpression, however, LPS-induced Brg1 recruitment to inflammatory gene promoters is reduced 
(Figure 24, top row).  Inducible histone H3 acetylation at the promoters of Brg1-dependent LPS response 
genes does not occur when Brg1 is knocked down26, and is similarly attenuated after miR-222 
overexpression (Figure 24, middle row).  This suggests that miR-222 targeting of Brg1 is sufficient to 
prevent recruitment of Brg1 and the deposition of downstream chromatin changes required for 
transcription.  To ensure that the effect of miR-222 was specific to Brg1, and did not impact upstream 
events that occur prior to Brg1 recruitment, histone H4 acetylation was examined.  At late response 
genes, histone H4 acetylation precedes and is likely required for Brg1 recruitment24,31.  H4K5 acetylation 
is not affected by miR-222 overexpression (Fig. 24, bottom).  These data are consistent with a model in 
which upstream signaling and transcriptional events remain intact, but miR-222-mediated reduction of 
Brg1 levels prevents chromatin modification downstream of Brg1-dependent remodeling, which is 
required for expression of a subset of LPS-response genes.  Other studies of Brg1 suggest that Brg1-
dependent phenotypes are particularly sensitive to changes in Brg1 levels106-109.  Taken together with 
our data, this suggests that the partial suppression of Brg1 by miR-222 is sufficient to affect LPS-induced 
transcription. 
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Figure 24.  Overexpression of miR-222 prevents LPS-induced Brg1 recruitment to inflammatory gene 
promoters. 
Chromatin was immunoprecipitated from immortalized BMDMs transduced with control or miR-222 
overexpression constructs.  Presence of promoters for genes previously found25,26 to be Brg1-
independent, Brg1-dependent, or of housekeeping function was then measured by qPCR.  n=3.   Error 
bars represent SEM.  ** indicates a p-value < 0.01, * p < 0.05, + p < 0.10, as determined by a two-tailed 
Student’s t-test. 
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Discussion 
Prior studies have identified a large number of miR-222 targets in different cell types (Table 4).  
However, no single target seems to explain all of miR-222’s effects.  Why miR-222 has so many potential 
targets that are cell-type dependent is still unclear.  However, it seems that this may be a general 
feature of miRNAs.  Many seem to be capable of affecting hundreds of potential targets, although 
effects on a single dominant target seem sufficient to dramatically change cellular responses.  Which 
target is “dominant” can be very context dependent; upregulation of one transcript with a miRNA 
binding site can relieve miRNA-mediated repression of another191-195.  Thus, it is likely that varying 
conditions in differing cell types will cause some potential miR-222 transcripts to be primarily regulated 
by the miRNA in one cell type, but not in others. 
One of the miR-222 targets identified in this work, TNF-α, is a particularly potent pro-inflammatory 
cytokine, and plays an important role in the proper development and resolution of many inflammatory 
responses.  Mice lacking TNF-α have increased susceptibility to infection, and display dysregulated 
inflammatory responses in response to challenge with infectious agents213.  TNF-α also mediates the 
Target Cell type References 
Estrogen receptor Human tumors and panel of breast cancer cell lines 205 
KIT Human gastrointestinal stromal tumors 206 
P27 (Kip1) Breast cancer cell lines (MCF-7 and  MDA-MB-231), 
prostate cancer lines (PC3, LNCaP, and 22Rv1),  HeLa, 
and U87 cell lines, primary glioblastoma tumors,  BJ 
primary fibroblasts 
203,207-
209 
PTEN Human gastric cancer cell line (SGC7901) 204 
PTP Tumorigenic glioma (LN-18, LN-229 and U87MG) and 
non-tumorigenic (T98G) cells 
 
PUMA A549 lung and MCF-7 breast cancer cell lines 211 
TRPS1 Human tumors and panel of breast cancer cell lines 176,212 
Table 4.  Proposed miR-222 targets. 
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lethality of low-dose LPS-induced septic shock, and TNF-α is linked to the progression of many 
inflammatory diseases6,7.  Fine control of TNF-α production is therefore to be expected. 
This is partly achieved by rapid degradation of Tnf mRNA.  Both constitutive decay214 and AU-rich 
elements (AREs) in the Tnf UTR ensure rapid turnover of the Tnf message and a transient inflammatory 
response.  ARE-dependent decay is mediated by proteins such as TTP, which bind to these regions and 
promote deadenylation and degradation of the Tnf mRNA.  As TTP is itself upregulated in response to 
inflammatory stimuli, this seems to represent an important negative feedback loop215.  This was 
confirmed with TTP knockout mice, which suffer from spontaneous inflammatory conditions that result 
from increased TNF-α levels216.  Mice lacking another ARE-binding protein, AUF1, also show increased 
vulnerability to damage in the context of LPS shock217. 
Several miRNAs have been found to promote ARE-mediated decay of Tnf message96.  It is therefore not 
surprising that an anti-inflammatory miRNA such as miR-222 may also target Tnf directly.  Even if the 
miR-222:Tnf interaction is weak, it could assist in the degradation of Tnf, especially in combination with 
other miRNAs and degradation mechanisms. 
In addition to its effects on Tnf, I find that miR-222 targets Brg1 for suppression, which has a broad but 
selective anti-inflammatory effect.   Because Brg1 is a downstream nuclear component required for 
transcription of several inflammatory genes, miR-222 is able to suppress inflammatory responses to a 
wide variety of stimuli.  However, as miR-222 allows signaling to transcription factors to remain intact, 
the effect of miR-222 is selective, and a subset of genes that do not require Brg1-mediated nucleosome 
remodeling can still be expressed even when miR-222 has been upregulated.  Whether or not a given 
gene will be induced by stimulation when miR-222 levels are high then depends on the gene’s 
requirements for nucleosome repositioning. 
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This has interesting ramifications, as it appears that the requirement for Brg1 remodeling at any given 
gene promoter is not set in stone, and depends on the cell type25.  Furthermore, in macrophages, an 
initial LPS response has been found to alter the chromatin environment of many genes, and this affects 
gene expression in response to later stimuli16.  It is possible that these changes may include alterations 
to nucleosome positioning, or the likelihood of re-positioning in response to activation.  Other 
inflammatory stimuli may cause changes in chromatin organization that are different from those made 
in response to LPS.  Thus it is possible that, depending on the initiating inflammatory response, a given 
gene may have substantially different requirements for chromatin remodeling and expression in 
response to a later stimulus.  If this is the case, depending on the initial form of stimulation, miR-222 
may be able to suppress the expression of very different gene subsets in BMDMs, based on the exact 
stimulus and chromatin modifications that occurred prior to miR-222 upregulation.  This may place miR-
222 in a central role in integrating inflammatory signaling and enforcing a “memory” response, rather 
than being part of a simple negative feedback loop for a single pathway.  The specific effects of miR-222 
on the phenomenon of one such response, LPS tolerance, were therefore examined and are discussed in 
the next chapter, as well as the general discussion in Chapter 6.  
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Chapter 5:  Effects of miR-222 on prolonged inflammatory responses, LPS 
tolerance, and in vivo systemic inflammation 
Introduction 
Studies of macrophages in vitro are useful for analyzing mediators and mechanisms of inflammation and 
tolerance at a cellular level.  However, it is often desirable to know whether a mediator is physiologically 
important in an in vivo model of disease.  This can be particularly important for inflammatory diseases, 
where multiple cell types interact.  A mediator can have differing effects in different cell types, or in 
different inflammatory contexts, which can cause an unexpected phenotype in vivo when compared to 
in vitro cellular models.  Thus, especially when considering potential therapeutics, it is ideal to have a 
way of inducing or repressing a potential mediator of disease in an animal model. 
For miRNAs, the traditional methods of generating knockout and conditional knockout mice can be 
applied.  This has been demonstrated for a variety of miRNAs including miR-155218 and miR-146a116,219, 
as well as intronic miRNAs such as the miR-15a/16-1 cluster220.  Several projects have been initiated to 
delete each murine miRNA (or miRNA cluster) in ES cells in a targeted manner, in order to ultimately 
generate knockout mice for all known murine miRNAs221,222.  Although these projects have not reached 
completion, ES cells and knockout mice have been placed in depositories for easy access as they have 
been generated, facilitating the study of miRNAs in vivo. 
Several means to deliver miRNA mimics and antagonists to cells in vivo have been also designed and 
used successfully, and are of particular use when testing whether a particular miRNA is suitable as a 
drug target.  Although not always ideal, viral vectors containing miRNA-antagonizing constructs have 
been shown to be useful for animal studies.  Viral antagonization of miR-223 in transplanted bone 
marrow was shown to have similar effects on myeloid cell development as a miR-223 knockout 
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mouse223.  Intravenous injection of adeno-associated viral vectors containing miRNA antagonists224 or 
mimics225 led to successful targeting of expression in the liver.  Recently, the use of modified 
oligonucleotides to antagonize miRNA function in vivo seems to have garnered greater attention, both 
for ease of use and potential clinical applications.  Cholesterol-conjugated RNA antagonists 
(“antagomirs”) were shown to be cell-permeable, decrease miRNA levels, and de-repress miRNA targets 
in a variety of tissues (but not the brain) when injected intravenously226.  Unconjugated locked-nucleic-
acid (LNA) oligonucleotides were shown to have similar effects, although the targeted miRNA appeared 
to be kept in a nonfunctional duplex rather than fully degraded with this method227.  Both methods 
produced unexpectedly long-lasting effects. 
Adenoviral131, lentiviral132, antisense oligonucleotide228, and LNA-mediated229 miRNA antagonization 
methods have been used to demonstrate the role of miR-33 in regulating cholesterol homeostasis in 
vivo.  Each method produced similar results.  LNA oligonucleotides have also been used to interrogate 
miR-208a230 and miR-155231 function, while antagomirs have also been used to assay for miR-21232 and 
miR-92a233 effects in vivo.  A variety of other oligonucleotide delivery systems, such as cationic 
lipoplexes234 and polymer nanoparticles235, have also been developed to modulate miRNA expression, 
suggesting knockout mice are not always required to study miRNA function.  Most notably, an LNA anti-
miR targeting miR-122 has been shown to be effective at antagonizing this miRNA in the liver236.  
Because miR-122 is also required for Hepatitis C replication, this anti-miR has been used to successfully 
treat Hepatitis C in animal models237, and has entered clinical trial238. 
In this section, results relating to the effects of miR-222’s effects on tolerance in vitro are presented.  
Results of miR-222 antagonization in vivo, as well as generation of a miR-222 conditional knockout 
mouse, are then discussed. 
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Results 
Antagonization of miR-222 had only a modest effect on acute LPS stimulations (Figure 10b and 15b).  
However, as miR-222 is upregulated relatively late in the LPS response (Figure 6a), it seemed possible 
that antagonization of miR-222 would reveal a stronger effect if prolonged stimulation conditions were 
tested.  I therefore tested the effect of prolonged LPS stimulation on inflammatory cytokine production 
in BMDMs transduced with control or miR-222 antagonization constructs.  As Brg1 was identified as a 
miR-222 target in BMDMs (see Chapter 4), LPS-induced upregulation of two Brg1-dependent cytokines, 
IL-6 and IL-12p40, was specifically examined. 
Stimulation of BMDMs with 10 ng/ml LPS causes a peak of IL-6 production at approximately 12 hours, 
and a peak of IL-12p40 production at 24 hours.  Consistent with the observation that miR-222 is only 
beginning to be upregulated at these time points, only a modest effect on cytokine production is 
Figure 25.  miR-222 limits production of Brg1-dependent pro-inflammatory cytokines in response to 
prolonged LPS stimulation. 
BMDMs were transduced with control or miR-222 antagonization constructs.  After 48 hours, BMDMs 
were stimulated with LPS for the given lengths of time, and cytokine levels in the cell supernatant were 
analyzed by ELISA.  Note that 3 different LPS doses were used.  n=4.   Error bars represent SEM.  ** 
indicates a p-value < 0.01, * p < 0.05, + p < 0.10, as determined by a two-tailed Student’s t-test for paired 
values. 
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observed when these stimulation conditions are used (Figure 25).  However, stimulation with high doses 
of LPS, including 100 ng/ml or 1000 ng/ml, causes cytokine production to peak after 24 to 36 hours of 
stimulation.  Antagonization of miR-222 increases IL-6 and IL-12p40 production significantly during this 
time frame when these doses of LPS are used (Figure 25).  Therefore, consistent with its kinetics of 
upregulation, miR-222 seems to have stronger effects on prolonged inflammatory responses. 
Figure 26.  miR-222 only modestly contributes to LPS tolerance kinetics under weak stimulation conditions. 
BMDMs were transduced with miRNA antagonization constructs, tolerized for varying periods of time, 
and then re-stimulated, as shown (A).  IL-6 (B) and IL-12p40 (C) levels in the cell supernatant were then 
measured by ELISA.  n=2.  Error bars represent SEM. 
 
 
The effect of miR-222 on LPS tolerance was evaluated next.  Studies were again focused on regulation of 
two Brg1-dependent genes, IL-6 and IL-12p40.  These genes become hyporesponsive after LPS 
tolerization; that is, after prolonged stimulation, the two genes are not as highly induced by a 
subsequent stimulation as they would have been if pre-treatment had not been performed.  In order to 
test the effect of miR-222 on this process, BMDMs were transduced with control or miR-222 
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antagonization constructs.  BMDMs were then tolerized by LPS stimulation for varying periods of time, 
washed, and re-stimulated with a relatively low dose of LPS (Figure 26a).  Antagonization of miR-222 
caused a modest delay in tolerance-induced suppression of IL-6 (Figure 26b) and IL-12p40 (Figure 26c) 
production.  Notably, tolerance in general still occurs, suggesting that miR-222 is not the sole mediator 
of this process (see Chapter 6 for a discussion of other possible regulators). 
However, it seemed that there was a still a possible effect on tolerance between 12-18 hours of 
tolerization.  Because miR-222 seemed to be most effective at suppressing cytokine production in 
response to higher doses of LPS stimulation (Figure 25), I therefore tested whether different LPS doses 
could reveal a stronger role for miR-222 in the tolerization process, this time focusing on a single 
tolerization time point (Figure 27a).  Consistent with prior results dealing with prolonged stimulation, 
Figure 27.  miR-222 greatly contributes to the suppression of Brg1-dependent pro-inflammatory cytokines 
during LPS tolerance under strong stimulation conditions. 
BMDMs were transduced with control or miR-222 antagonization constructs, left untreated or tolerized, 
then re-stimulated with the given LPS dose, as shown in (A).  IL-6 (B) and IL-12p40 (C) levels in the cell 
supernatant were then analyzed by ELISA.  n=5.   Error bars represent SEM.  ** indicates a p-value < 
0.01, * p < 0.05, + p < 0.10, as determined by a two-tailed Student’s t-test for paired values. 
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miR-222 contribution to the ability of tolerance to suppress IL-6  (Figure 27b) and IL-12p40 (Figure 27c) 
production was greater when higher doses of LPS were used as a triggering stimulus.  miR-222 may thus 
specifically dampen only strong inflammatory responses.  
The effects on IL-6 and IL-12p40 suggested that miR-222 may contribute to the suppression of some 
genes that become hypo-responsive after LPS tolerance.  However, tolerance affects the expression of a 
very large subset of LPS-response genes.  Some genes become hypo-responsive (such as Il6 and Il12b), 
while others become hyper-responsive to subsequent LPS stimulation.  Therefore, to get a broader 
sense of the effect of miR-222 on the tolerization process, qPCR analysis was performed to assay for 
expression of a wider set of genes after miR-222 antagonization and tolerization. 
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Cells were transduced with control or miR-222 antagonization constructs, then either tolerized or left in 
a naïve state.  Cells were then re-stimulated, and gene expression was analyzed (Figure 28a).  
Antagonization of miR-222 led to the higher expression of several genes that become hypo-responsive 
after tolerization, including Il6 and Il12b (Figure 28b).  Genes that become hyper-responsive after 
tolerization were also affected, however (Figure 28d).  This is perhaps not unexpected, as Brg1 
recruitment to several hyper-responsive gene promoters after tolerization has been noted16.  
Figure 28.  miR-222 represses expression of some, but not all, LPS-inducible genes during LPS tolerance. 
BMDMs were transduced with control or miR-222 antagonization constructs, left untreated or tolerized, 
then re-stimulated as shown in (A).  Expression of genes previously determined16 to become hypo-
responsive after tolerization (B and C) or hyper-responsive after tolerization (D and E) was measured by 
qPCR.  n=5.   Error bars represent SEM.  ** indicates a p-value < 0.01, * p < 0.05, + p < 0.10, as 
determined by a two-tailed Student’s t-test for paired values. 
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Interestingly, however, several antiviral and antimicrobial genes, including Irf1 (a transcription factor 
which is vital for inhibition of some viruses239), Cnlp (which is an antimicrobial peptide240,241), and Gbp2 
(which inhibits viral242 and parasite243 replication), were unaffected by miR-222 antagonization (Figure 
28c and 28e).  These genes are presumably Brg1-independent, although this has yet to be 
experimentally demonstrated during tolerance.  Continued expression of antimicrobial and antiviral 
genes seems to be a signature of tolerance16,244.  Because some antimicrobial genes escape suppression 
by miR-222, miR-222 upregulation may contribute to, but not be wholly responsible for, this tolerogenic 
pattern. 
Overall, the suppression of pro-inflammatory genes, including Il6, Il12b, and Tnf, through a combination 
of direct targeting and Brg1-mediated transcriptional effects, suggests that miR-222 contributes to 
tolerance, and in particular may play a role in limiting inflammatory damage.  Whether suppression of 
Brg1-dependent hyper-responsive genes is incidental or an important part of miR-222 function during 
LPS tolerance is unclear.  Nevertheless, the finding that miR-222 may affect expression of specific gene 
classes may make it a useful therapeutic target for the modulation of inflammatory responses in 
diseases such as sepsis, in which retention of antimicrobial function is desirable, but inflammatory 
responses which result in tissue damage are not.   
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Several experimental models of septic shock exist, and could be used to test this hypothesis.  However, 
to date, a miR-222 knockout mouse has not been generated, making it difficult to specifically test the 
effect miR-222 has in these models.  Therefore, options to modulate miR-222 levels in vivo were 
explored.  It has been reported245 that complexing of oligonucleotides with a chimeric rabies virus 
glycoprotein fragment allows for siRNA delivery to neurons and macrophages in vivo, when 
Figure 29.  A chimeric rabies virus glycoprotein fragment allows for oligonucleotide delivery into 
macrophages in vitro and in vivo. 
(A) BMDMs were treated with miRNA oligonucleotide mimics complexed with rabies virus glycoprotein 
fragment.  After 24 hours, cells were stimulated with LPS and IL-6 production was measured by ELISA.  
(B) BMDMs were treated with miRNA oligonucleotide antagonists complexed with glycoprotein 
fragment and tolerized with 10 ng/ml LPS stimulation for the given time periods.  Cells were washed, 
rested for 2 hours, the re-simulated with LPS overnight.  IL-6 production was measured by ELISA.  (C and 
D) Mice were injected with oligonucleotide complexed with glycoprotein fragment.  Peripheral blood 
samples were assayed for miR-222 levels by qPCR (C) and cytokine levels by ELISA (D).  n=1.  Two 
technical replicates were performed for (D). 
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administered by simple intravenous injection.  Because this method seemed somewhat more cell-type 
specific, and allowed for greater flexibility in terms of synthesis scale, chimeric rabies virus glycoprotein 
complexes were tested for their ability to deliver miRNA mimics and antagonists to macrophages, first in 
vitro, and then in vivo. 
For an initial test, miR-222 and miR-146a mimics were complexed with recombinant chimeric rabies 
virus glycoprotein fragment at molar ratios previously described for in vitro siRNA delivery245.  The 
mimics were tested first as they were more likely to be similar to the siRNA constructs in length and 
structure.  24 hours after delivery of the complexes, BMDMs were stimulated with LPS, and IL-6 
production was measured.  BMDMs treated with miR-222 and 146a mimics produced less IL-6 than 
control cells, suggesting that oligonucleotide delivery was successful (Figure 29a).  Complexes of the 
chimeric virus peptide and miRNA antagonists were also tested in vitro.  BMDMs were treated with 
complexes of the peptide and either a control or miR-222 antagonist oligonucleotide, and after 24 
hours, pre-treated with LPS for the given lengths of time to induce LPS tolerance and miR-222 
expression (to better test whether the miR-222 antagonist was functional).  Cells were then re-
stimulated with LPS, and IL-6 production was measured by ELISA.  Cells treated with the miR-222 
antagonist produced more IL-6 compared to controls, especially at later time points (when miR-222 is 
more highly expressed in control cells), once again suggesting that delivery was successful (Figure 29b).  
Finally, an in vivo test was performed.  A complex of chimeric virus peptide and control or miR-222 
mimic oligonucleotides was prepared as described for in vivo delivery245, and a single dose was delivered 
to mice by retro-orbital injection.  24 hours later, LPS was administered by intraperitoneal injection, and 
cytokine levels in the serum were measured after one hour.  miR-222 levels in blood cells were also 
measured by qPCR.  Delivery of the miRNA mimic slightly increased levels of miR-222, although whether 
this was due to increased delivery to circulating monocytes or simply due to circulating complexes is 
unclear (Figure 29c).  Serum levels of inflammatory cytokines were also reduced (Figure 29d).  Because 
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these tests indicated that the chimeric rabies virus peptide allowed for functional miRNA mimic and 
antagonist delivery, this method was used to determine whether miR-222 plays a role in the host 
response to septic shock. 
The specific anti-inflammatory character of miR-222 implies that miR-222 upregulation may be 
particularly important in protection against lethal inflammatory responses to sepsis.  To test this 
hypothesis, mice were injected with two doses of miR-222 antagonist complexed with the chimeric 
rabies virus glycoprotein.  Mice were then injected with high doses of LPS to initiate septic shock; doses 
were calibrated to be lethal to approximately 50% of control mice after 72 hours, which should be a 
sufficient period of time for miR-222 upregulation and effect to occur in control mice.  Compared to 
mice injected with a control oligonucleotide complex, mice given the miR-222 antagonist were more 
Figure 30.  miR-222 is protective against LPS-induced septic shock. 
Mice were injected with glycoprotein fragment complexes containing control or miR-222 antagonist 
oligonucleotides 24 and 3 hours prior to induction of septic shock.  Survival was then monitored for 72 
hours.  Kaplan-Meier survival curves are shown.  n=11/treatment group.   Significance was determined 
using a logrank test to compare Kaplan-Meier survival curves. 
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likely to succumb to LPS-induced lethality (Figure 30).  Thus, in cases of lethal inflammation, the effects 
of miR-222 on pro-inflammatory cytokine synthesis seem to be predominant. 
Prior in vitro observations indicated that miR-222 may play a role in the suppression of other chronic 
diseases in which inflammatory cytokine production plays a role.  However, many experimental mouse 
models of chronic inflammatory diseases would likely require long-term deletion of miR-222 in order to 
see a phenotype.  Oligonucleotide injection could become cumbersome under these circumstances; 
therefore, work proceeded on the generation of a conditional miR-222 knockout mouse.  This will allow 
for permanent deletion of miR-222 in targeted cells, and a determination of whether this miRNA 
influences chronic disease progression. 
Several large-scale projects have been started with the aim to generate knockout mice of all known 
miRNAs.  Although the technological capacity to complete these projects has been demonstrated, there 
remain many miRNAs for which knockout mice have yet to be created.  miR-222 is in this category.  
Although ES cell targeting and generation of a miR-222 knockout mouse by these projects has yet to be 
performed, one project has created a targeting vector to generate a conditional miR-222 knockout 
allele.  The general design of the targeting vector is shown in Figure 31a; I received this construct as a 
kind gift of Dr. Michael McManus, and utilized it to start the creation of miR-222 conditional knockout 
mice. 
As previously described221, mice resulting from targeting with this vector can be bred with a Cre deleter 
to create a lacZ reporter mouse.  In such an instance, the miRNA is knocked out entirely, and lacZ is 
expressed under the control of the miRNA promoter instead.  Alternatively, the mice resulting from 
targeting with this vector can be bred to mice expressing Frt recombinase to remove the Neomycin 
selection cassette and lacZ reporter.  This leaves miRNA expression intact under the endogenous 
promoter; it is only with expression of the Cre recombinase (as could occur through lentiviral gene 
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transfer, or through breeding with a transgenic mouse designed to artificially express Cre in a specific 
tissue) that miRNA expression is deleted.  This targeting method therefore allows flexibility in use of the 
modified allele. 
Note that with this targeting construct, both miR-221 and miR-222 are flanked by loxP sites, and will be 
inducibly deleted (Figure 31b).  This is somewhat unavoidable for these miRNAs, as they are in very close 
proximity to each other and on the same primary transcript (see Chapter 3).  However, it seems unlikely 
that the deletion of both miR-221 and miR-222 would affect an inflammatory phenotype (see the 
discussion of this chapter for more information), so I proceeded with the use of this targeting vector. 
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The vector was sequenced to ensure that the miR-221 and miR-222 regions were intact, and that the 
homology arms matched genomic sequences 5’ and 3’ of miR-221/222.  Because the 3’ arm was quite 
large (~10 kb), which could make screening for homologous recombination of the vector into ES cell 
clones difficult, the 3’ arm was shortened to ~4.5 kb by digestion with BstEII and religation of two of the 
three resulting fragments.  This created a construct lacking the sequence between the 19085 and 22984 
BstEII cut sites (Figure 31b). 
Figure 31.  Schematic of miR-221/222 conditional knockout targeting vector 
(A) General schematic of targeting vectors generated as part of the miRKO project221.  Note that the 3’ 
homology arm in the miR-221/222 targeting vector was shortened prior to ES cell targeting.  (B) Detailed 
map of the miR-221/222 targeting vector.  BstEII cut sites used to shorten the 3’ arm are also shown. 
 
 
82 
 
The targeting construct was linearized by AsiSI digestion and electroporated into hybrid 129/Bl6 cells.  2 
96-well plates of crude lysate from electroporated ES cell clones were screened by PCR for successful 
insertion of the targeting construct by homologous recombination, using primers that spanned the 5’ 
Figure 32.  Identification of ES cell clones with homologous integration of the 5’ targeting arm. 
(A) Schematic showing locations of primers used to screen for homologous integration of the 5’ arm of 
the targeting vector.  (B)  PCR screening of electroporated ES cell clones for 5’ arm integration. 
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(Figure 32a) and 3’ (Figure 33a) homology arms.  21/192 clones were found to be positive for 5’ arm 
integration (Figure 32b).  Of these, 6 were found to be positive for 3’ arm integration (Figure 33b).  
These clones were expanded, and PCR was again performed on fresh genomic DNA isolates to perform a 
final check for homologous 5’ and 3’ arm integration (Figure 34). 
3 of the 6 positive ES cell clones, 1A4, 2E9, and 2H5, were injected into blastocysts to generate chimeric 
mice.  Injection of 2H5 produced one chimeric male, while injection of 2E9 produced 5 chimeric male 
mice with high degrees of chimerism (Figure 35).  Whether these mice will successfully pass on the 
targeted allele to their offspring remains to be determined at this time. 
Figure 33.  Identification of ES cell clones with homologous integration of the 3’ targeting arm. 
(A) Schematic showing locations of primers used to screen for homologous integration of the 3’ arm of 
the targeting vector.  (B)  PCR screening of ES cell clones for 3’ arm integration. 
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Figure 34.  Confirmation of homology arm recombination. 
PCR to screen for homologous integration of the 5’ (A) and 3’ (B) arms of the targeting vector was 
performed in new DNA preps from ES cell clones previously determined to be positive for integration 
(Figures 32 and 33). 
 
Figure 35.  Chimeric male generated from ES clone 2E9. 
Chimeric mouse (brown) is shown in cage with 2 Bl6 mice.  High degree of chimerism is apparent. 
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Discussion 
Antagonization of miR-222 prolongs production of IL-6 and IL-12p40, two Brg1-dependent genes, in 
response to LPS stimulation of BMDMs.  Increased IL-6 and IL-12p40 production was observed to some 
degree under all conditions tested; however, the increase in magnitude and duration of cytokine 
production was particularly apparent when higher LPS doses (100 ng/ml or 1000 ng/ml) were used as a 
stimulus.   One study found that Brg1 is degraded after LPS stimulation, although a non-canonical means 
of activating NF-κB was used246.  It is therefore possible that Brg1 levels become limiting during strong 
LPS responses, in which IL-6 and IL-12p40 production is sustained for longer periods of time.  
Antagonization of miR-222, which allows for Brg1 re-synthesis, may remove this limitation and allow for 
responses with an even higher magnitude and duration. 
Similar results with IL-6 and IL-12p40 production were observed after induction of LPS tolerance.  When 
inferring a mechanism of miR-222 and Brg1 action from these studies, however, it seems important to 
note a distinction between the two methods used to measure cytokine production.  One method, the 
quantification of mRNA transcript levels by qPCR, examines mRNA levels at a very early time point (4 
hours) after LPS stimulation.  In some ways, this provides a “snapshot” of cytokine production.  
Considering this, it may seem odd that increases in mRNA levels are observed at such an early time 
point.  It seems unlikely that increases in Brg1 levels could cause an increase in transcription of a Brg1-
dependent gene at any given time (as the nucleosome is in a binary state, either open or closed).  
However, the increases in cytokine production observed by qPCR could be due to a population effect.  
Although LPS stimulation should affect all cells, the exact timing of gene expression can vary somewhat.  
Indeed, several studies find that LPS signaling and gene transcription is a somewhat stochastic 
process247.  Increasing Brg1 levels may increase the likelihood and speed at which a given cell will initiate 
transcription of Brg1-dependent genes.  When mRNA from the entire population is measured, this 
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results in the apparent increase in gene expression levels that is observed (see also Chapter 6 and Figure 
36 for a discussion of how this could affect patterns, rather than magnitude, of gene expression). 
On the other hand, measurement of cytokine production by ELISA integrates the effect of signaling and 
transcription over a much longer period of time.  Here, it is possible that the readout captures two 
effects:  that cells lacking miR-222 are more likely to initiate transcription at earlier time points, and also 
that they are maintaining an open chromatin state and continuing to transcribe pro-inflammatory genes 
for longer than would normally occur.  This second possibility is suggested by the fact that the duration, 
and not only the magnitude, of IL-6 and IL-12p40 protein release is increased.  This may be consistent 
with previous studies which have shown that Mi-2b is recruited immediately after Brg1 to inflammatory 
gene promoters and facilitates the resetting of nucleosome positioning at promoters to their basal, 
inaccessible states26.  Brg1 opening of promoters may compete with Mi-2b closing of promoter binding 
sites.  The increased levels of Brg1 which are present after miR-222 antagonization may tip the balance 
to an open promoter state for longer periods of time, allowing for prolonged cytokine production.  
Further ChIP and qPCR measurements would be required to conclusively show this, however. 
Because it is difficult to know how these in vitro stimulation conditions relate to physiological 
inflammatory states, chimeric rabies virus glycoprotein fragment peptides were used to deliver miR-222 
antagonists to mice in vivo.  Antagonization of miR-222 increased lethality to LPS-induced septic shock, 
confirming that miR-222 has an effect on strong, prolonged LPS responses in vivo.  It would also be 
desirable to confirm that miR-222 affects in vivo tolerization processes.  However, several caveats to the 
peptide delivery system make it unsuited to study LPS tolerance, which involves more complex 
phenotypes than simple septic shock experiments.  First, it is important to note that the complexing of 
miRNA antagonist oligonucleotides with a chimeric rabies virus glycoprotein fragment is somewhat, but 
not completely, macrophage specific.  Prior studies of this delivery system find that neuronal cells are 
also targeted for oligonucleotide delivery.  While unlikely to affect septic shock, as LPS-induced septic 
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shock is highly dependent on macrophage function10, it is possible that other cell types that receive the 
miR-222 antagonist could contribute to effects on LPS tolerance.  Furthermore, it is difficult to quantify 
the level of inhibition of miR-222 expression that is achieved in mice treated with the peptide 
complexes, adding technical challenges to long-term studies.  miRNA inhibition can be difficult to detect, 
as antagonists do not always cause degradation of the target miRNA227.  Thus, the miR-222 conditional 
knockout was generated. 
The conditional knockout mouse targets both miR-221 and miR-222 for deletion.  Because the two 
miRNAs are in very close proximity to each other, it is difficult to target one miRNA for conditional 
deletion without potentially altering the hairpin structure of the other.  Thus, as is often the case with 
clustered miRNAs, both miR-221 and miR-222 were targeted for deletion by the miRKO project, which 
was the source of the targeting construct221.  However, given the finding that miR-221 is not upregulated 
by LPS stimulation in BMDMs (Figure 8), this is unlikely to be an issue for this project.  Furthermore, for 
this and other projects, miR-221 and miR-222 have similar mature seed sequences (Figure 9a), and seem 
to have similar gene targeting effects (Figure 10).  Although miR-221 may not be induced by LPS 
stimulation, and may therefore not play much of a role in regulating prolonged inflammatory responses, 
there may be some redundancy between miR-221 and miR-222 in other phenotypes.  Therefore, there 
may actually be a benefit to conditionally deleting both miRNAs in the knockout mouse, as this may aide 
in the discovery of other physiological effects of these two miRNAs. 
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Chapter 6:  Conclusions, perspectives, and future directions 
Role of miRNAs in macrophage development and activation 
Macrophage responses to stimulation seem tailored to the specific immunogenic agents used, and 
phenomenon such as LPS tolerance indicate that there is some “memory” of prior stimulations that 
shapes future macrophage responses.  This has led to the discussion of macrophage activation both as a 
transient process and as something more akin to cell-type differentiation.  Although macrophage 
activation actually seems to lead to a broad spectrum of possible outcomes, classes including M1 (or 
“classically activated”) and M2 (or “alternatively activated”) macrophages have been described248.  The 
ability of miRNAs to regulate developmental processes is well established, as even the first characterized 
miRNAs in animals were found to regulate lineage factors249-251.  It therefore seems plausible that the 
activation and differentiation processes in macrophages may utilize some shared regulatory 
components, including miRNAs.  For instance, several miRNAs, including miR-223, have been found to 
be downregulated after differentiation of human monocytes into macrophages, and regulate the ability 
of the differentiated macrophages to respond to certain stimuli252.   miR-223 is further downregulated 
upon macrophage activation (Figure 5 and prior studies104), suggesting that activation and development 
may share regulators.  Therefore, it is possible that miRNAs may assist not only in the development of 
macrophages, but also in regulating the outcomes of cellular activation upon stimulation (although the 
specific miRNAs involved in each process need not necessarily be the same).  Furthermore, as LPS 
tolerance does not completely shut off inflammatory signaling and can be broken under certain 
conditions, it seems plausible that tolerance may utilize the propensity of miRNAs to fine-tune 
responses, rather than turn them entirely on or off, as well as their dynamic regulation in order to alter 
macrophage activation.  This led to the hypothesis underlying this work: that specific miRNAs contribute 
to LPS tolerance in macrophages.  This will be discussed further below. 
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However, it is important to note that how miRNA processing is regulated on a global scale in response to 
macrophage activation was not thoroughly examined here.  The fact that pre-treatment of cells with 
interferon gamma affects the LPS-induced expression of multiple miRNAs (Figure 6) suggests that 
miRNAs may be globally regulated in some immune response pathways.  However, given the large 
number of miRNA regulatory factors that have been discovered, a very systematic approach to 
examining global miRNA regulation would be necessary to thoroughly examine how LPS signaling 
regulates miRNA processing in general, and this was beyond the scope of these studies. 
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Role of specific miRNAs in LPS tolerance 
Figure 36.  A mechanism by which miR-222 may limit expression of particular gene classes during LPS 
tolerance. 
Most LPS-inducible early response genes have promoters that are openly accessible, and are not 
regulated at the level of nucleosome positioning.  Rather, co-repressors prevent inappropriate 
transcription of these genes in the basal state (A).  NF-κB mediated histone modifications and 
recruitment of elongation factors allows transcription after LPS stimulation (B).  miR-222 does not 
regulate expression of these genes (C-D).  Late response genes often associate with nucleosomes that 
basally block access to promoter sites, preventing transcription prior to LPS stimulation (E).  Recruitment 
of the SWI/SNF complex (including Brg1) after LPS stimulation remodels nucleosome positioning, 
allowing for NF-κB recruitment and transcription of late response genes after LPS stimulation (F).  During 
tolerance, miR-222 limits Brg1 levels.  Competition for remaining SWI/SNF complexes limits transcription 
to “primed” genes with more favorable histone or other promoter modifications.  The pattern and 
kinetics of gene expression now diverge from those of the acute response (G).  Antagonization of miR-
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I identify here one miRNA, miR-222, that may contribute to the selective limitation of gene expression 
during LPS tolerance.  The results presented herein suggest that miR-222 achieves this function primarily 
through regulation of SWI/SNF-mediated nucleosome remodeling.  In the basal state, many 
inflammatory gene promoters in BMDMs are inaccessible to transcription factors because they are 
closely associated with nucleosomes.  This likely acts as a safeguard to prevent inappropriate gene 
transcription (Figure 36e).  However, in an acute LPS response, Brg1, a component of the SWI/SNF 
nucleosome remodeling complex, is recruited to inflammatory gene promoters and shifts nucleosome 
positioning, allowing for promoter access and gene transcription.  Because miR-222 levels are low at this 
point, and Brg1 levels are relatively high, a large number of LPS-response genes can be expressed in 
several waves (Figure 36f).  During LPS tolerance, however, miR-222 is expressed at high levels and 
reduces levels of Brg1, limiting the amount of nucleosome remodeling that can occur.  As there is some 
evidence that promoters compete for available Brg1 and remodeling capacity109, this likely limits gene 
expression only to those genes that are “primed” for recruitment and transcription.  This limits the 
number of LPS response genes that can be expressed, and breaks both the overall pattern and timing of 
LPS-inducible gene expression (Figure 36g).  miR-222’s contribution to this process is evidenced by the 
effects of its antagonization, which allows for increased Brg1 levels and promiscuous expression of a 
large number of genes even after tolerization (Figure 36h).  Genes which do not require Brg1-mediated 
nucleosome remodeling, of course, escape miR-222 regulation, and unless they are directly targeted by 
the miRNA (such as Tnf), are regulated through other means. 
While these and a number of other studies are consistent with this model, the exact histone 
modifications and changes in promoter remodeling that occur during tolerance remain understudied.  
222 increases Brg1 levels, allowing for promiscuous recruitment of the SWI/SNF complex to many LPS 
response genes.  Genes that are normally suppressed are transcribed to higher levels under these 
conditions (H). 
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For instance, while work has been done with some model gene promoters, it is unclear exactly where 
Brg1 is inducibly recruited during acute and tolerized responses on a genome-wide scale.  Generation of 
the miR-222 knockout mouse may assist with the testing of the model we propose, allowing for further 
tests of histone acetylation and other chromatin modifications at hypo- and hyper-responsive genes 
under conditions in which Brg1 levels are not limited.  However, further studies of other regulators are 
clearly warranted. 
Several other miRNAs, including miR-22 and miR-29a, seem to be regulated in a similar manner to miR-
222 (see Chapter 2).  These miRNAs also have predicted targets that, if valid, could also indicate 
important contributions to LPS tolerization.  Although other factors are almost assuredly involved, 
upregulation of these miRNAs may explain part of the “priming” that occurs to affect Brg1 recruitment 
under competitive conditions. 
miR-22, for instance, seems to affect Il6, Il12b, and Cnlp expression, but not Tnf, Ifnb1, or Il10 (Figure 7).  
This suggests that, like miR-222, miR-22 may affect transcriptional responses without altering TLR4 
signaling itself.  miR-22 was found to inihibit NF-κB activity in a reporter cell line by targeting NCOA1114, 
a coactivator that binds to the p50 NF-κB subunit and increases activity of a NF-κB reporter253.  If NCOA1 
is important in expression of only select LPS-response genes in BMDMs, miR-22 may be involved in 
selective tolerogenic suppression (Figure 37b).  However, this coactivator does not appear to be well-
studied in the context of LPS-induced gene expression, making it difficult to draw firm conclusions. 
It is also notable that miR-29a suppresses expression of a set of LPS response genes, including Tnf, Il6, 
and Il12b (Figure 7), that only partially overlaps with the effects of miR-22 or miR-222.  Other studies 
have found that increasing expression of miR-29a may lead to increases in A20 expression (through an 
unusual decoy mechanism)115.  As A20 is a negative regulator of signaling to NF-κB254, reduced TLR4 
signaling in response to LPS stimulation could explain the reduction in Tnf, Il6, and Il12b mRNA levels 
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observed in BMDMs transfected with miR-29a mimics.  Intriguingly, however, several LPS-response 
genes, including Ifnb1, Cnlp and Il10 were found to be expressed at normal levels in these same cells.  
Intact Cnlp and Il10 expression in spite of reduced NF-κB signaling would be especially interesting, as Il10 
and Cnlp have been noted for their resistance to suppression by LPS tolerization. 
Studies of the miR-29 family in other systems suggest a mechanism through which this selective effect 
may be possible.  miR-29 family members have been found to directly target the DNA 
methyltransferases DNMT3a and DNMT3b, and indirectly affect DNMT1 levels via Sp1 targeting18.  In 
certain tumor cells, high DNMT levels decrease expression of tumor suppressor genes; when miR-29 is 
overexpressed, this suppression is alleviated, and tumor suppressor genes are expressed at normal 
levels255.  Similarly, miR-29 was found to be induced by influenza infection, causing decreases in DNMT3 
levels and increases in COX2 expression256.  This suggests that miR-29 may regulate DNA 
methyltransferases to affect expression of specific gene subsets. 
How DNA methyltransferases, and DNMT1 and DNMT3 in particular, are involved in the LPS response is 
unclear.  However, the Tnf and Il1b promoters are H3K9 dimethylated by the G9a methyltransferase; 
this methylation marker is removed during the LPS response68,69.  It is therefore appealing to speculate 
that an array of DNA methyltransferases basally repress LPS-induced gene expression, and that DNMT3 
may selectively target the promoters of genes such as Il10 and Cnlp for methylation.  This may delay 
their expression in the acute LPS response.  However, under the conditions of prolonged LPS stimulation 
that result in LPS tolerance, miR-29a is upregulated and may deplete DNMT3 levels, reducing 
methylation of these particular promoters.  This may allow them to be expressed with faster kinetics 
upon re-stimulation of tolerant cells, and escape the suppression that occurs to other gene classes 
during tolerance (as those genes may be regulated by a different methyltransferase, such as G9a, that is 
not similarly suppressed). 
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 This effect may synergize with miR-29a stabilization of A20.  Because miR-29a simultaneously reduces 
LPS signaling by increasing A20 levels, there may be a narrower window of NF-κB activation during LPS 
tolerance.  This may give the formerly DNMT-targeted genes a selective advantage in expression, as the 
lack of methylation may enable faster recruitment of transcription factors faster compared to promoters 
that may be regulated by other DNA methyltransferases or mechanisms (Figure 37c).  However, this 
model is entirely speculative, whether miR-29 may contribute to inflammatory regulation by affecting 
promoter methylation and macrophage function is an open issue. 
Figure 37.  Possible miRNA contributions to the acute and tolerant LPS responses. 
During the acute LPS response (left), LPS signaling occurs as normal, and may even be augmented by 
strong, but transient upregulation of miR-155 (a).  SWI/SNF and NF-κB coactivator levels permit 
expression of most LPS response genes (b), although the transcription of some genes is delayed 
compared to others.  This delay may be due to the action of DNA methyltransferases at these 
promoters, although this has yet to be examined (c).  During the tolerant LPS response (right), LPS 
signaling to NF-κB still occurs, but is attenuated by miR-146a targeting of IRAK1 and TRAF6, and possibly 
by miR-29a stabilization of A20 (a).  miR-222 limitation of Brg1 and miR-22 limitation of Ncoa1 levels 
may prevent expression of a subset of LPS response genes (b).  Meanwhile, miR-29a limitation of DNA 
methyltransferase levels allows a subset of genes to recruit remaining SWI/SNF and transcriptional 
complexes more rapidly, allowing for transcription even during the tolerant response. 
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Taken together, LPS tolerance involves changes in receptor signaling and chromatin accessibility that 
likely work sequentially to limit gene expression.  This makes it likely that there is a cooperative role for 
several miRNAs, including miR-146a and those I have identified, in the induction of LPS tolerance.  miR-
146a and miR-29a may both limit the activation of the NF-κB transcription factor.  Together with 
limitations imposed on chromatin remodeling by miR-222 and availability of nuclear co-factors for 
transcription mediated by miR-22, there may be dramatic limitations placed on the expression of LPS 
response genes.  Whereas large numbers of genes can be expressed in the acute response, competition 
for these now scarce transcriptional components may limit transcription only to those genes which are 
most "primed" for expression.  Thus, although the effect of these miRNAs in concert remains to be 
examined, a model which combines their effects could help account for the regulation of tolerance at 
the levels of both signaling and chromatin modification that have been observed. 
 
Other unexplored regulatory possibilities  
The model for miR-222 activity presented here provides a mechanism for the suppression of hypo-
responsive genes during tolerance, and may explain how some antimicrobial and antiviral genes that do 
not require nucleosome repositioning escape tolerization.  However, there is a large subset of Brg1-
dependent genes that becomes hyper-responsive to LPS after tolerization.  The model for miR-222 
activity does not clearly address how these hyper-responsive genes escape suppression during LPS 
tolerance.  The effects of Dnmt3 or other histone modifying complexes may perhaps provide an answer, 
but the exact nature of the modifications that prime these gene promoters to recruit the remaining Brg1 
and co-factor complexes during tolerance is largely unknown. 
The role enhancers play in regulating LPS response genes after tolerization is also poorly understood.  It 
is possible that histone modifications occur at these sites, and these contribute to changes in gene 
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expression after tolerization.  Long intergenic non-coding RNAs have also been described recently.  
Although they do not code for a protein (as their name suggests), these RNAs can act as scaffolds for 
regulatory proteins and alter gene expression.  It is possible that differential long non-coding RNA 
expression is responsible for hyper-responsive gene expression during tolerance, but this possibility also 
remains to be examined257. 
 
Fra-1 regulation as a model for tolerogenic signal integration  
In this work, several miRNA mediators of tolerance are identified.  In addition to providing testable 
models of LPS tolerance, as well as potential targets for therapeutic intervention, identification of these 
miRNAs provides targets for further studies to gain insight into a broader, overarching question:  How is 
tolerance triggered?  That is, what controls the miRNA regulators of tolerance? 
The initial studies of the regulation of miR-222 expression presented here suggest that a network of 
transcription factors may interact to determine whether a normal, or a tolerogenic, LPS response is 
produced.  Some transcription factors, such as NF-κB, are regulated with a very rapid time scale.  For 
instance, NF-κB is released from IκB inhibition within minutes of LPS stimulation.  Although required for 
both acute and tolerant LPS responses, NF-κB may by default mediate a typical acute LPS response.  On 
the other hand, other transcription factors that are regulated with delayed kinetics and may be 
responsible for the tolerant LPS response.  For instance, Fra-1, which represses the tolerogenic mediator 
miR-222, is itself repressed after LPS stimulation (Figure 13).  The rate of transcriptional turnover and 
protein degradation of Fra-1 may thus constitute a molecular "timer" for the cell.  Because Fra-1 
repression appears to be dependent on NF-κB activity, Fra-1 may only strongly repressed with prolonged 
LPS stimulation.  Thus, long stimulations promote Fra-1 degradation and the release of tolerogenic 
factors, but short and weak stimulations that do not activate NF-κB to a great extent may be insufficient 
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to cause Fra-1 degradation and relief of tolerogenic suppression.  It is also interesting that interferon 
gamma pre-treatment appears to upregulate Fra-1 levels, and that briefly after LPS stimulation, Fra-1 is 
actually transcriptionally upregulated (possibly by the MAPK pathway258).  This may explain why short 
LPS stimulations prime, rather than tolerize, later responses. 
Similarly, the observation that miR-222 is not affected in a dose-dependent manner (Figure 11) may be 
important.  This could indicate that tolerance can be overcome if a strong enough stimulus is 
encountered, as expression of these tolerogenic mediators will not increase dramatically with increased 
stimulation, whereas inflammatory response genes may have a more dose-dependent response.  miR-
222 and other mediators may thus allow flexibility in the strength of the LPS response, but modulate it 
to keep it within a tolerable range. 
 
Potential uses of a miR-222 conditional knockout mouse 
Generation of the miR-222 conditional knockout mice described in Chapter 5 will enable more thorough 
in vivo studies of the role of miR-222 in the progression or suppression of a number of disease states.  
The first line of study likely to be of interest would be to validate and extend the finding that miR-222 
contributes to survival of LPS-induced septic shock in mice (Figure 30).  Although the high-dose LPS 
septic shock model I used confirms that miR-222 plays a role in regulation of inflammation in vivo, more 
work would be required to determine whether modulation of miR-222 expression could be 
therapeutically useful.  The clinical relevance of LPS-induced shock models have been called into 
question in recent years, as these models cause a relatively early onset of mortality, use only a single 
component of gram-negative bacteria to induce shock (even though many human patients suffer from 
gram positive infections), and do not take into account the complexities of live pathogen infection2,259.  
The miR-222 conditional knockout mouse could facilitate the use of more complex models of sepsis, 
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including cecal ligation and puncture or perotinitis models, to better determine the suitability of miR-
222 as a drug target.  The ability to delete miR-222 either conditionally in macrophages or in the entire 
mouse should also enable studies to determine whether miR-222 contributes to the suppression of 
inflammatory cytokine production in endothelial or other cells that may also contribute to septic shock 
progression and lethality. 
The miR-222 knockout mouse will also allow for the direct testing of the effect of miR-222 on tolerance 
in vivo.  Previous studies have found that tolerance can be induced in vivo by repeated injection of 
sublethal doses of LPS.  However, whether tolerance is truly protective against sepsis in human patients 
remains uncertain.  Having an animal model in which tolerance is even partly abrogated, as is expected 
in the miR-222 knockout, may facilitate studies to gain a greater understanding of this process and 
whether it prevents or contributes to sepsis lethality. 
A previous study of miRNA distribution in healthy human tissues may suggest other areas in which the 
miR-221/222 knockout mouse could have a phenotype.  The highest level of miR-222 expression was 
found in the placenta (Figure 9).  Interestingly, Fra-1 knockout causes death of the fetus due to defects 
in placental vascularization260.  Taken together with studies that find that miR-222 regulates 
vasculogenesis in vitro261, this may suggest that miR-222 is involved in the Fra-1 phenotype. 
The next area of interest indicated by miR-222 distribution may be the heart, where moderate miR-222 
expression and particularly high miR-221 expression was detected; in fact, this is the only tissue in which 
miR-221 levels were found to be higher than miR-222 levels.  Prior studies have also found that Brg1 
plays an important role in heart development108,262.  It is therefore possible miR-221 and/or miR-222 
play a role in Brg1 regulation in heart tissue. 
Moderate miR-222 expression was also noted in the lung and gut.  Whether the miRNA was expressed in 
immune cells resident in these tissues is not clear.  However, a miR-221/222 reporter mouse (generated 
 
99 
 
by breeding mice with the original targeting allele to a Cre deleter mouse) could be used to determine 
whether the higher miRNA levels are in macrophages or surrounding tissues.  If miR-222 is indeed 
elevated in macrophages of these tissues, it could suggest that the miRNA is enforcing tolerance in 
tissues that are exposed to foreign pathogens under normal conditions.  The miR-221/222 knockout 
could then be examined for pathological inflammation in these areas. 
miR-222 was also found to be highly expressed in areas such as the prostate and brain, but its potential 
functions in these areas is unclear.  Studies of these tissues may also benefit from use of the miR-
221/222 reporter mouse, which could help elucidate which cells are expressing the miRNAs in both 
normal and disease states. 
Examination of miR-222 effects in cancer models may also be of particular interest due to the nature of 
the miR-222 targets that have been identified.  Brg1, which I have identified as a target, has been shown 
to have tumor suppressive properties (likely because nucleosome remodeling is required for expression 
of a variety of other tumor suppressor genes)263.  Many other miR-222 targets that have been identified 
in various cell types regulate cellular proliferation, drug resistance, and/or characteristics of malignancy 
(see Table 4), leading many to suggest that miR-221 and miR-222 contribute to the development and 
progression of cancer176,203-212.  This possibility could be more rigorously tested with the miR-221/222 
knockout.  Furthermore, as miR-222 seems to suppress certain inflammatory characteristics of the 
macrophage, it is possible that miR-222 could contribute to cancer progression in two ways:  by 
enhancing growth kinetics of the tumor cells themselves, and also by preventing macrophages from 
recruiting tumoricidal immune cells to the growing tumor.  The miR-221/222 knockout, used with 
conditional Cre expression and/or hematopoietic stem cell transfer methods, could be used to ablate 
miR-221/222 expression specifically in immune or tumor cells of a cancer model, and to determine the 
relative contribution of each to cancer progression. 
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miR-222 may potentially link inflammation and cancer in another way.  miR-222 is upregulated in 
macrophages in response to inflammatory stimulation;  it is possible that inflammatory cytokines may 
also induce miR-222 upregulation in other cell types.  If miR-222 also reduces tumor suppressor levels in 
these cells, this could provide a link between inflammation and cancer, in which inflammatory 
conditions upregulate miR-222, which then suppresses tumor suppressors, ultimately leading to an 
increased probability of tumorigenesis.  This may be similar to what has been observed for some other 
“oncomiRs”.121,264  A link between H. pylori infection, miR-222 upregulation, and gastric cancer has 
already been found197.  The miR-221/222 knockout could be used to experimentally determine the 
strength of this link, and whether miR-222 indeed contributes to inflammation-associated tumorigenesis 
in the manner described. 
Finally, miR-222 has been found to be upregulated in a number of other disease states.  Exosomes 
circulating in the blood of patients with familial hypercholesterolemia265, as well as those released from 
prion-treated neurons266, show elevated miR-222 levels compared to controls.  Macrophages have been 
shown to infiltrate fat and cause inflammatory pathology267, and higher expression of miR-222 was 
observed in the adipose tissue of mice fed with a high fat diet268.  Several of these studies also noted 
upregulation of miR-342-3p or miR-29, which were also detected in our array, suggesting that detection 
of miR-222 was not an anomaly.  However, whether miR-222 expression is merely a symptom of the 
inflammatory nature of these diseases, or could function to slow (or accelerate) disease progression is 
not clear.  Testing of experimental models of these diseases with the miR-221/222 conditional knockout 
mouse could clarify this issue. 
 
Therapeutic modulation of tolerogenic responses 
One of the primary challenges in the treatment of both sepsis and chronic inflammatory disease lies 
with the need to sufficiently dampen immune responses to prevent inflammatory damage without 
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simultaneously allowing for the development of secondary infections.  This may be particularly true in 
the case of sepsis, as the relative contributions of pro-inflammatory mediators that cause tissue damage 
versus anti-inflammatory mediators that may allow for pathogen replication in causing mortality 
remains controversial2.  The capacity of miR-222 to selectively regulate inflammation in response to 
multiple stimuli, while still allowing for some immunity in the form of antiviral and antimicrobial 
responses, suggests that it may be a promising target to address this issue in disease treatment.  Means 
for in vivo miRNA delivery have already been developed (see Chapter 5 introduction), and both a miRNA 
antagonist and a miRNA mimic have entered clinical trial (for the treatment of Hepatitis C and 
metastatic liver cancer, respectively)238,269.  Identification of miRNAs which selectively modulate immune 
responses may therefore be beneficial for the design of future therapeutic regiments. 
Unfortunately, miR-222 in particular seems to have many potential targets in other cell types, some of 
which may promote tumorigenesis (Table 4).  This would, of course, be problematic if a miR-222 mimic 
were systemically delivered in the clinic, especially in the case of chronic inflammatory disease, in which 
long-term treatments might be required.  However, the use of miR-222 mimics may be suitable for 
treatment of sepsis, for which only a short-term treatment is needed. 
In general, it is worth noting that tolerance seems to affect some genes very strongly and very rapidly, 
whereas others are affected more slowly or with lower overall effect.  For instance, it appears that there 
is sometimes a difference in the kinetics of suppression of IL-6 and IL-12p40 (Figure 4).  These 
differences seem to reflect the fact that many inflammatory genes have differing transcriptional 
requirements, and tolerance may affect some of these processes more than others.  This is particularly 
true of TNF-α, which seems to be suppressed in both transcriptional and post-transcriptional ways 
during tolerance.  This suggests that the single phenomenon of “tolerance” may involve multiple 
mechanisms of action.  Identification of further miRNA and other tolerogenic regulators may therefore 
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allow for the independent modulation of each of these processes, allowing for very precise control of 
inflammatory gene expression, and treatment of chronic inflammatory diseases with fewer side-effects. 
 
Conclusions 
Many positive and negative regulators of NF-κB and LPS stimulation are required to fine-tune an 
inflammatory response that balances proper containment of infection against the potential for 
damaging secondary effects. Tolerization may represent an important coordinated mechanism to 
address this predicament, dampening the initial pro-inflammatory response to prevent overwhelming 
septic shock, while at the same time increasing production of anti-microbial peptides to prevent 
susceptibility to secondary infection afterward. Chromatin modifications likely play a key role in this 
response, working in concert with signaling changes to differentially recruit NF-κB subunits and 
transcriptional machinery to gene promoters prior to and during secondary challenge. 
The potential therapeutic benefits of understanding this system are demonstrated by a recent study 
which found that synthetic histone mimetics can inhibit bromodomain protein recruitment to late 
response promoters during the LPS response, selectively abolishing expression of those genes. 
Intriguingly, this greatly improved septic shock survival of mice even if the inhibitor was introduced after 
LPS administration270, whereas other potential treatments such as IL-10 administration lose efficacy 
within a few hours of shock initiation44. This advantage makes treatments based on the concept of 
modulating histone modification far more practical for clinical use. 
Therefore, while our understanding of tolerance and its potential benefits remains limited, future 
studies seem warranted.  The characterization of miR-222 and other miRNAs as mediators of tolerance 
opens several new avenues of research, providing testable models of tolerogenesis as well as a target 
for studies of potential therapeutics and broader tolerogenic regulation.  The creation of the miR-222 
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knockout should provide a genetic model that at least partially abolishes the tolerant state.  This should 
allow for an improved ability to understand this complex process. 
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Chapter 7: Materials and methods 
Cell culture 
293FT cells (Invitrogen R7007) and L-929 cells (ATCC CCL-1) were cultured in DMEM (Invitrogen 11965-
084) supplemented with 10% fetal bovine serum (FBS; Invitrogen 10437-028) by volume.  Cells were 
passaged by rinsing with sterile 1x phosphate buffered saline (PBS; Invitrogen 10010-023) and 
trypsinization (Invitrogen 25300-054) 
To generate L-cell conditioned medium (LCM), L-929 cells were plated at roughly 20% confluency in 35 
ml medium in 15 cm tissue culture dishes (BD Falcon 353025).  Cells were allowed to grow for one week, 
at which point medium was collected, passed through 0.22 um bottle-top filters (Corning 431118), and 
stored at -80 C until use. 
For the isolation and culture of primary BMDMs, RPMI 1640 (Invitrogen 11875-085) was supplemented 
with 30% FBS by volume, sodium pyruvate (Invitrogen 11360-070) to a final concentration of 1mM, L-
Glutamine (Invitrogen 25030-081) to 2 mM, MEM non-essential amino acids (Invitrogen 11140-050), 
HEPES (Invitrogen 15630-080) to 10 mM, Pen Strep (Invitrogen 15140-122) to 100 U/ml and 100 μg/ml 
respectively, and β-mercaptoethanol (Invitrogen 21985) to 55 μM to generate “complete” medium.  
Femur and tibia bones were isolated.  Bones were ground in a mortar and pestle, and freed marrow was 
resuspended in 5 ml complete RPMI and passed through a 70 um cell strainer (BD Falcon 352350).  
Process was repeated one time, and cell strainer was subsequently rinsed with 5 ml medium.  Cells were 
spun down at 1.5x1000 rpm for 5 minutes, and resuspended in red blood cell lysis buffer (Sigma R7757) 
for 3-5 minutes.  Suspension was diluted in 20 ml complete medium, passed through a 70 um cell 
strainer, and spun down as previously.  Cells were resuspended in complete medium supplemented with 
20-30% LCM and plated on 15 cm petri dish, approximately 10x106 cells per dish, and allowed to 
 
105 
 
differentiate.  BMDMs were generally collected after day 5 of differentiation by rinsing dishes and 
scraping attached cells.  All experiments were concluded by day 12 of differentiation. 
For cell stimulations, stock solutions of LPS, recombinant human TNF-α (R&D Systems 210-TA), 
recombinant mouse IL-1β (R&D Systems 401-ML-005), recombinant mouse IFNg (BD Pharmingen 
554587), recombinant mouse IL-10 (eBioScience 88-7104-ST), dexamethasone (Sigma D402), and 
estrogen (Sigma E2758) were brought up in sterile PBS or DMSO and passed through a 0.22 low-protein 
binding syringe filter (Pall 4192).  Unless otherwise indicated, a final concentration of 10 ng/ml was used 
for LPS, 10 ng/ml for TNF-α, 100 ng/ml for IL-1β, 100 ng/ml for IFNg, 10 pg/ml for IL-10, 10 μM for 
dexamethasone, and 0.01 μM for estrogen. 
 
Tolerization of BMDMs 
BMDMs were stimulated with 10 ng/ml LPS for 15 hours (or as indicated in figure), washed 5 times with 
1x PBS, then allowed to rest for 2 hours in LPS-free complete medium supplemented with 20% LCM.  
BMDMs were then stimulated with 1 μg/ml LPS for 4 hours (for qPCR) or 12 hours (for ELISA), or as 
indicated in figure. 
 
Immortalization of BMDMs 
BMDMs isolated as above were immortalized by inoculation with the J2 retrovirus, as has been 
previously described271-273.  In brief, a virus-producing cell line (iNac) was cultured in DMEM 
supplemented with 10% FBS by volume.  After 2-3 days, supernatant was collected and passed through 
a low-protein binding 0.45 um syringe filter (Pall 4184).  Filtered supernatant was applied to BMDMs to 
be immortalized twice, on day 4 and day 7 after isolation.  Cells were then passaged past day 12, until 
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resumption of cell division.  Cells were subsequently maintained in complete RPMI supplemented with 
5% LCM. 
 
miRNA microarray 
Samples were treated as described, rinsed with 1x PBS, lysed in TRIzol, and sent to a commercial 
microRNA array profiling service (Exiqon).  As part of the service, samples were labeled using the 
miRCURY Hy3/Hy5 Power labeling kit and hybridized on the miRCURY LNA Array (v.11.0 hsa, mmu and 
rno).  All capture probes for the control spike-in oligonucleotides produced signals in the expected 
range. The quantified signals (background corrected) were normalized using the global Lowess (LOcally 
WEighted Scatterplot Smoothing) regression algorithm, and a list of differentially expressed miRNAs was 
returned. 
 
miRNA qPCR 
At least 50,000 cells were used to generate each sample.  Following treatment, cells were rinsed with 1x 
PBS and lysed by addition of TRIzol reagent (Invitrogen 15596-018) to the tissue culture plate.  RNA was 
then purified according to manufacturer instructions.  RNA yield was quantified by measuring 
absorbance at 260 nm with the Bio-Tek Take3 plate on a Synergy2 plate reader system.  Reverse 
transcription was performed with the Universal cDNA Synthesis Kit (Exiqon 203301), using 125 ng of 
RNA per sample.  For each PCR reaction, cDNA was diluted 1:80 and combined with PerfeCTa SYBR 
Green Fast Mix (Quanta Biosciences 95072) and appropriate LNA primers (Exiqon; see Supplementary 
Table 2) in a 10 μl total volume.  Reactions were cycled in a Bio-Rad CFX96 or CFX384 Real-Time PCR 
Detection System as follows:  10 minutes at 95 C, 40 cycles of (10 seconds at 95 C, 1 minutes at 60 C).  
Fluorescence data were collected at the 60 degree step, and a ramp-rate of 1.6 C/second was used.  A 
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melt curve analysis followed; data from any reactions that failed to produce a single peak in this analysis 
(representing production of a single PCR product) were discarded.  Expression data for each sample was 
normalized to U6 or SNORD65 expression levels. 
 
miRNA mimic and antagonist oligonucleotides 
Pre-miR miRNA precursors (Ambion AM17100) and Anti-miR miRNA inhibitors (Ambion AM17000) were 
transfected into BMDMs to modulate miRNA function in short term experiments.  Part numbers for 
oligonucleotides are as follows:  For overexpression experiments, Pre-miR Negative Control #1 (Ambion 
AM17110), miR-222-3p (PM11376), miR-221-3p (PM10337), miR-146a-5p (PM10722); for 
antagonization experiments, Anti-miR miRNA Negative Control #1 (Ambion AM17010), miR-222-3p 
(AM11376), miR-221-3p (AM10337), miR-146a-5p (AM10722). 
To optimize transfection conditions, the FAM Dye-Labeled Pre-miR Negative Control #1 (Invitrogen 
AM17121) oligonucleotide was used.  Transfection of 50,000 BMDMs per well of a 12-well plate with 6 
μl Lipofectamine and 0.1 nmol oligonucleotide diluted in 200 μl of Opti-MEM (total) was found to 
provide transfection of >80% of cells (as measured by flow cytometry), and these conditions were used 
for all further experiments in BMDMs.  Transfections were performed in antibiotic-free RPMI 
supplemented with 10% FBS and 20% LCM.  Medium was replaced with complete RPMI containing 20% 
LCM after 4 hours to minimize cytotoxicity.  Cells were allowed to recover for 24-48 hours before 
stimulation. 
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Production of virus and BMDM transduction 
Plasmids for miRNA overexpression or antagonization were transfected into 293FT cells with the Lenti-
Pac HIV Expression Packaging Kit (GeneCopoeia HPK-LVTR-20) or Lenti-Pac FIV Expression Packaging Kit 
(GeneCopoeia FPK-LVTR-20), as appropriate (see Table 5) to generate viral particles.  For inoculation, 
BMDMs were plated in 6 well plates and allowed to adhere overnight.  Supernatant was then replaced 
with medium containing viral particles in the presence of 6 μg/ml polybrene (Sigma H9268), and plates 
were then spun at 2250 rpm for 90 minutes at 28 C in an Eppendorf 5810 R centrifuge.  Following spin 
inoculation, viral supernatant was immediately replaced with complete RPMI supplemented with 20% 
LCM.  Cells were allowed to recover overnight.  If necessary (based on visual observation of 
fluorescence), a second round of inoculation was performed the following day to ensure successful 
transduction of the population of cells. 
Vector Catalog Promoter Selection Marker Viral Type 
Overexpression 
control 
CmiR0001-
MR01 
(GeneCopoeia) 
H1 Neomycin eGFP (via 
IRES) 
FIV 
miR-222 
overexpression 
MmiR3289-
MR01 
(GeneCopoeia) 
H1 Neomycin eGFP (via 
IRES) 
FIV 
miR-146a 
overexpression 
MmiR3434-
MR01 
(GeneCopoeia) 
H1 Neomycin eGFP (via 
IRES) 
FIV 
Antagonization 
control 
CmiR-AN0001-
AM03 
(GeneCopoeia) 
H1 Hygromycin mCherry 
(via CMV 
promoter) 
HIV 
miR-222 
antagonization 
HmiR-AN0399-
AM03 
(GeneCopoeia) 
H1 Hygromycin mCherry 
(via CMV 
promoter) 
HIV 
Table 5.  miRNA expression and antagonization vectors. 
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For primary BMDMs, plating for inoculation was generally performed on day 5 of differentiation.  The 
first spin infection was performed on day 6, second spin infection (if necessary) was performed on day 7, 
and plating for experiments was performed on day 8. 
 
ELISA 
BMDMs were plated at 50,000 cells/well.  Supernatants were collected after stimulation, and generally 
diluted 1:10 for TNF-α, 1:200 for IL-6, or 1:400 for IL-12p40 in assay diluent to ensure measured values 
remained in range of standard curves.  Cytokine concentrations were then measured using the BD 
OptEIA Mouse IL-6 ELISA Set (BD 555240), BD OptEIA Mouse IL-12 (p40) ELISA Set (BD 555165), or BD 
OptEIA Mouse TNF (Mono/Mono) ELISA Set (BD 555268) according to manufacturer instructions. 
 
qPCR 
Each sample of RNA was quantified as described above (for miRNA qPCR analysis), and 100-1000 ng total 
RNA was combined with SuperScript III Reverse Transcriptase (Invitrogen 56575) and either Oligo dT12-18 
(Invitrogen 58862, for mRNA analysis) or Random Hexamers (Applied Biosystems N8080127, for 
quantification of primary RNA transcripts) for reverse transcription.  Resulting cDNA was diluted 1:10, 
and 1 μl of product was combined with PerfeCTa SYBR Green Fast Mix (Quanta Biosciences 95072) and 
appropriate primers (see Table 6) in a 10 μl total reaction volume.  Reactions were cycled in a Bio-Rad 
CFX96 or CFX384 Real-Time PCR Detection System as follows:  10 minutes at 95 C, 40 cycles of (10 
seconds at 95 C, 1 minute at 60 C, and 30 seconds at 72 C).  Fluorescence data were collected at the 60 
degree step.  A melt curve analysis followed; data from any reactions that failed to produce a single 
peak in this analysis (representing production of a single PCR product) were discarded.  Expression data 
for each sample was normalized to β-actin levels. 
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Gene Forward Primer Reverse Primer Source 
For quantification of mRNA levels 
Actb AGAGGGAAATCGTGCGTGAC CAATAGTGATGACCTGGCCGT 25 
Gapd TGGTGAAGGTCGGTGTGAAC CCATGTAGTTGAGGTCAATGAAGG 25 
Tubb5 CCCTCAGCTTTCTCCAACTG CACCATTTACCCCCAATGAG  
Camp (Cnlp) CCCAAGTCTGTGAGGTTCCG GTGCACCAGGCTCGTTACA  
Cd83 CATCCTCAGATGGCAACCTT TGCTCAAGACCCTGTGTCAG 25 
Cxcl1 TGTCAGTGCCTGCAGACCAT GTGGCTATGACTTCGGTTTGG 25 
Cxcl11 AGTAACGGCTGCGACAAAGT CTGCATTATGAGGCGAGCTT 25 
Fos GTGACAGCCATCTCCACCA GTGGGGAGTCCGTAAGGATG 25 
Fosl1 (Fra1) GACTTCCTGCAGGCGGAGA CCACCTGGGTCCTTCTTGTC  
Fpr1 AAACAGCCTGTACTTTCGACTTC CTGAACCCAATGATGAACCTGAT Medzhitov lab 
Gbp2 CTCTACCGCACAGGCAAATC GATGCCCTTGGTGTGAGACT 25 
Il6 GTTCTCTGGGAAATCGTGGA TTTCTGCAAGTGCATCATCG 25 
Il10 AAGGACCAGCTGGACAACAT TCATTTCCGATAAGGCTTGG 25 
Il12b AGCCACTCACATCTGCTGCT AACCGTCCGGAGTAATTTGG 25 
Il23a GGTGCTTATAAAAAGCCAGACC AATAATGTGCCCCGTATCCA 25 
Ifnb1 AGCTCCAAGAAAGGACGAACAT GCCCTGTAGGTGAGGTTGATCT 25 
Irf1 TCCAAGTCCAGCCGAGACA TGCTGAGTCCATCAGAGAAAGTGT 25 
Lcn2 TTCCGGAGCGATCAGTTCC TGACCAGGATGGAGGTGACA 25 
Mmp13 GTTCAAGGAATTCAGTTTCTTTATGGT GGTAATGGCATCAAGGGATAGG 25 
Nfkbia CCTGGCCAGTGTAGCAGTCT AGAGGCTAGGTGCAGACACG 25 
Pten GAGTCACAATTCCCAGTCAGAGGCG GGAGGAATATATCTTCACCTTTAG Parsons lab 
Saa3 CCTTCCATTGCCATCATTCT AGTAGGCTCGCCACATGTCT 25 
Slfn1 CAAAAGCCGAGAGCAACCAC TCCTCACCTAAGCTGCTCTAC  
Smarca4 
(Brg1) 
GAGGAGGGCACGCTGGAGGA ACGTCCACTGCTGCTGTCTTTGT  
Tnf CCCCAAAGGGATGAGAAGTT TGGGCTACAGGCTTGTCACT 25 
Tnfaip3 GGCAGCTGGAATCTCTGAAA CTGCAGGTGTGTCTGCTGAT 25 
Tnfsf9 GCCCCAACACTACACAACAG GCTGTGCCAGTTCAGAGTTG 25 
For quantification of primary transcript levels 
Actb GAGGGGAGAGGGGGTAAAA TCGAGCCATAAAAGGCAACT Smale lab 
Il6 GCCCTCTAGTGGTGCTTGTT TTTCTGCAAGTGCATCATCG 25 
Il12b AGCCACTCACATCTGCTGCT ACTGTCAAGGGGGATGGAAT 25 
Saa3 CAGGATGAAGCCTTCCATTG TCATGAACTGGACCCATCTTT 25 
Tnf GGGAAGCCTAAAAGGCTCAT TGGGCTACAGGCTTGTCACT 25 
For detection of gene promoters (ChIP) 
Actb GAGGGGAGAGGGGGTAAAA TCGAGCCATAAAAGGCAACT 25 
Gapd GGTCCAAAGAGAGGGAGGAG GCCCTGCTTATCCAGTCCTA 25 
Ccl5 CTGCTACCCTGGCTCCCTAT TGGGAGATGCATGTGCTGT 25 
Ifnb1 GCCAGGAGCTTGAATAAAATG GATGGTCCTTTCTGCCTCAG 25 
Il6 AATGTGGGATTTTCCCATGA GCTCCAGAGCAGAATGAGCTA 25 
Il23a GCCTCTAGCCACAACAACCTC ATTCCCCTCCCTACATCATCTC 25 
Nos2 CCCTTTGGGAACAGTTATGC GGGGCCAGAGTCTCAGTCTT 25 
Saa3 CGCAATCTGGGGAAAGAAG AATGGAGCAATCCCTGTTTG 25 
 
111 
 
Tnf GATTCCTTGATGCCTGGGTGTC GAGCTTCTGCTGGCTGGCTGT 25 
For Fra1 (Fosl1) conditional knockout mouse genotyping 
P1 GAAATGGCTCCGTGGGTAAAGGTA 179 
P2 GACAGGGTTCATCTTCATAGTTCT 179 
P3 TGTACCGGACGCTTGTCATCTCAT 179 
For miR-222 targeting vector screening 
5-arm-F70 CCCTGCTAGGCTCTTCTGTG  
5-arm-
R6105 
GGAAAGGGTTCGAAGTTCCT  
3-arm-F-
14778 
CGCGGTACCATAACTTCGTA  
3-arm-R-
19267 
GTTGGTGAACAGGGGAAGTG  
Table 6.  Primer sequences. 
 
 
Construction of reporter vectors and luciferase reporter assays 
The Brg1 UTR was amplified from IMAGE clone 30533489 (Open Biosystems MMM1013-9498346) and 
cloned into the pMIR-Report (Ambion AM5795) multiple cloning site using HindIII and SpeI restriction 
sites.  The Tnf UTR amplified from cDNA generated from BMDMs stimulated with LPS for 1 hour, and 
inserted into the pMIR-Report vector as performed for the Brg1 UTR.   
Reporter plasmids were transfected into 293FT cells along with a Renilla luciferase reporter (used to 
normalize for transfection efficiency).  After 24 hours, Firefly and Renilla luciferase activity was 
quantified using the Dual-Luciferase Reporter Assay (Promega E1980). 
 
Intracellular staining for flow cytometry 
Cells were rinsed in cold 1x PBS, then scraped into cold 1X PBS and spun down for 5-10 minutes at 5,000 
rpm, 4 C.  Cells were fixed for 15-30 minutes at room temperature in 100 μl of 4% paraformaldehyde.  
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Cells were rinsed, then spun down for 10 minutes at 5,500 rpm at 4 C.  Cells were resuspended in 50 μl 
saponin (1% BSA, 5% saponin in PBS) for permeabilization and incubated for 10-20 minutes at room 
temperature.  1.5 μl of either anti-IκBα (L35A5, Cell Signaling 4814), anti-Brg1 antibody (H88, Santa Cruz 
sc-10768), or Rabbit mAb IgG Isotype Control (Cell Signaling 3900) was added, and cells were incubated 
for an additional 20 minutes at room temperature.  Cells were then rinsed and spun down as previously.  
Cells were resuspended in 50 μl saponin with 1:300 conjugated secondary anti-mouse (IκBα) or anti-
rabbit (Brg1) antibody (Alexa Fluor 488 Donkey Anti-Rabbit IgG, Invitrogen A21206, or Alexa Fluor 546 
Goat Anti-Rabbit IgG, Invitrogen A11010, or Alexa Fluor 546 Donkey Anti-Mouse IgG, Invitrogen 
A10036).  Incubated at room temperature for 20 minutes.  Cells were rinsed and spun down as 
previously.  Finally, cells were resuspended in 300 μl PBS and analyzed on a BD LSRII flow cytometer. 
 
Western blot 
Cells were lysed for 10 minutes on ice in RIPA buffer (150 mM sodium chloride, 1.0% NP-40 substitute, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM Tris, pH 8.0) supplemented with 
protease inhibitors (Roche 04693159001) and benzonase to remove viscosity resulting from genomic 
DNA.  Samples were spun down for 15 minutes at 16,100 rcf at 4 C.  Protein content of cleared samples 
was quantified using a Micro BCA Protein Assay Kit (Thermo 23235). 
30 μg of each protein sample was run out on a 10% acrylamide gel and transferred to a PVDF membrane 
(Millipore IPVH00010) by wet transfer at 100 V for 1.5 hours in a chilled system.  Membranes were 
blocked with 5% non-fat milk in TTBS (0.1% Tween 20, 100 mM Tris-HCI, pH7.5, 150 mM sodium 
chloride) for at least one hour, then incubated overnight at 4 C with primary antibody diluted in 5% non-
fat milk.  Brg1 antibody was used at a 1:1000 dilution, while Gapdh (Fitzgerald 10R-G109a) was used at a 
1:5000 dilution.  After at least 3 washes with TTBS, membrane was incubated with appropriate 
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secondary antibody diluted 1:10,000 in 5% non-fat milk for one hour at room temperature.  Membranes 
were then washed 3 times and visualized using ECL Western Blotting Detection Reagents (GE Healthcare 
RPN2106) and X-ray film (Medlink EBA45).  Film was developed in a Kodak X-Omat 2000 Film Processor. 
 
Chromatin immunoprecipitation 
To prepare chromatin samples, immortalized macrophages transduced with control or miR-222 
overexpression constructs were allowed to reach ~90% confluency in 15 cm petri dishes, then treated 
with LPS in 18 ml of medium for the given lengths of time.  Cells were fixed by addition of 500 μl of 37% 
formaldehyde directly to the culture medium and incubation at room temperature for 5 minutes.  Plates 
were rinsed twice with 10 ml cold 1x PBS, then scraped into 10 ml cold PBS and transferred to conical 
tubes and spun down at 1500 rpm for 5 minutes.  Cells were resuspended in buffer L1 (50 mM Tris at pH 
9, 2 mM EDTA, 0.1% NP-40, 10% glycerol, with protease inhibitors) and incubated for 5 minutes on ice.  
Nuclei were spun down for 5 minutes at 3500 rpm in an Eppendorf mini-centrifuge at 4 C.  Supernatant 
discarded.  Nuclei were resuspended in 500 ml buffer L2 (50 mM Tris at pH 8, 0.1% sodium dodecyl 
sulfate, and 5 mM EDTA).  Sonication was performed in a Bioruptor, using 10 cycles of 30 seconds each.  
15 μl from each sample was tested to ensure sonication was successful (i.e. DNA would run at 150-500 
bp after reversal of cross-linking and proteinase treatment). 
To perform immunoprecipitation, magnetic protein A beads (Millipore 16-661) were washed 3X with 
dilution buffer (50 mM Tris at pH 8, 0.5% NP-40, 0.2 M NaCl and 0.5 mM EDTA).  50 μl chromatin, 450 μl 
dilution buffer + protease inhibitors, 20 μl magnetic beads, and 2-10 μg antibody were mixed in an 
eppendorf tube.  5 μg anti-acetyl-histone H4 (Lys5; Millipore 07-327), 2 μg Brg1 (H-88; Santa Cruz sc-
10768), and 5 μg acetyl-histone H3 (Millipore 06-599) were used.  Tubes were rotated overnight at 4 C.  
The following day, supernatant (unbound fraction) was transferred to a new tube.  Beads were washed 
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3X in high salt buffer (20 mM Tris at pH 8.0, 0.1% SDS, 1% NP-40, 2 mM EDTA, and 0.5 M NaCl) followed 
by 3X in TE.  DNA was eluted from beads by resuspending beads in 100 μl elution buffer with fresh 
protease K added, and shaking for 2 hours at 60 degrees.  DNA was recovered from unbound fraction by 
adding 20 μl of 5 M NaCl, 50 μl of 10% SDS, and 5 μl of protease K, and shaking for 2 hours at 60 
degrees.  At end of elution, tubes were heated to 95 C for 10 minutes.  After cooling to room 
temperature, eluted DNA was transferred to new tube (to remove beads).  Eluted DNA (or 100 μl of 
unbound DNA) was purified using Qiagen PCR purification kit.  DNA stored at -20.  To check for promoter 
binding, qPCR was performed using DNA from the bound and unbound fractions.  5 μl of DNA was 
diluted in 40 μl of H2O, and 4.5 μl of diluted DNA used per 10 μl PCR reaction (see Supplementary Table 
2 for primer sequences).  Bound/unbound ratios were normalized to alpha-crystallin ratios, as this gene 
is expressed only in retinal cells and should represent a silent gene. 
 
Mice 
Female C57Bl/6J mice (Jackson 000664), 7-10 weeks of age, were used for all experiments unless 
otherwise noted.  Mice were maintained under specific pathogen-free conditions in animal facilities at 
Columbia University Medical Center.  All animal experiments were carried out according to guidelines 
set forth by the Institutional Animal Care and Use Committee. 
 
In vivo oligonucleotide delivery 
For each injection, 31.25 μg of control or anti-miR-222 oligonucleotide was combined with 121 μg of 
chimeric rabies virus glycoprotein fragment (RVG-9R; AnaSpec 62565) in a 200 μl volume of 5% glucose, 
and incubated at room temperature for 15 minutes to allow complex to form. 
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Mice were retro-orbitally injected with two doses of anti-miR:peptide complex, approximately 24 hours 
and 3 hours prior to induction of septic shock. 
 
Septic shock 
Mice were intraperitoneally injected with 10 mg/kg LPS (E. coli O55:B5; Sigma L2880) in a 200 μl volume 
of sterile PBS, and monitored for survival over the course of 72 hours.  All injections were performed in 
the afternoon, at approximately the same time. 
 
Fra-1 Genotyping 
The deletion strategy and genotyping of cells from Fra-1 mutant mice have been previously described179.  
In brief, genotyping to confirm targeting and deletion was performed by PCR using three primers, Fra1-
P1, Fra1-P2, and Fra1-P3 (see Supplementary Table 2 or reference for sequences).  PCR products were 
run out on a 2% agarose gel.  A 308 bp band indicated presence of a wildtype allele, while a 354 bp band 
indicated presence of a loxP-containing allele.  A 408 bp band indicated a loxP-containing allele that had 
undergone recombination.  
 
116 
 
References 
1. D. C. Angus, T. van der Poll, Severe sepsis and septic shock. The New England journal of medicine 
369, 840-851 (2013); published online Aug 29 (10.1056/NEJMra1208623). 
 
2. O. Huet, J. P. Chin-Dusting, Septic shock: desperately seeking treatment. Clinical science 126, 31-
39 (2014); published online Jan 1 (10.1042/CS20120668). 
 
3. J. Soong, N. Soni, Sepsis: recognition and treatment. Clinical medicine 12, 276-280 (2012); 
published online Jun (http://www.ncbi.nlm.nih.gov/pubmed/22783783). 
 
4. D. C. Angus, W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, M. R. Pinsky, Epidemiology 
of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of 
care. Critical care medicine 29, 1303-1310 (2001); published online Jul 
(http://www.ncbi.nlm.nih.gov/pubmed/11445675). 
 
5. M. J. Hall, S. N. Williams, C. J. DeFrances, A. Golosinskiy, Inpatient care for septicemia or sepsis: a 
challenge for patients and hospitals. NCHS data brief, 1-8 (2011); published online Jun 
(http://www.ncbi.nlm.nih.gov/pubmed/22142805). 
 
6. K. J. Tracey, B. Beutler, S. F. Lowry, J. Merryweather, S. Wolpe, I. W. Milsark, R. J. Hariri, T. J. 
Fahey, 3rd, A. Zentella, J. D. Albert, et al., Shock and tissue injury induced by recombinant 
human cachectin. Science 234, 470-474 (1986); published online Oct 24 
(http://www.ncbi.nlm.nih.gov/pubmed/3764421). 
 
7. J. Rothe, W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. 
Steinmetz, H. Bluethmann, Mice lacking the tumour necrosis factor receptor 1 are resistant to 
TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 
364, 798-802 (1993); published online Aug 26 (10.1038/364798a0). 
 
8. P. Li, H. Allen, S. Banerjee, S. Franklin, L. Herzog, C. Johnston, J. McDowell, M. Paskind, L. 
Rodman, J. Salfeld, et al., Mice deficient in IL-1 beta-converting enzyme are defective in 
production of mature IL-1 beta and resistant to endotoxic shock. Cell 80, 401-411 (1995); 
published online Feb 10 (http://www.ncbi.nlm.nih.gov/pubmed/7859282). 
 
9. Z. Chai, S. Gatti, C. Toniatti, V. Poli, T. Bartfai, Interleukin (IL)-6 gene expression in the central 
nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-
6-deficient mice. The Journal of experimental medicine 183, 311-316 (1996); published online 
Jan 1 (http://www.ncbi.nlm.nih.gov/pubmed/8551238). 
 
 
117 
 
10. M. A. Freudenberg, D. Keppler, C. Galanos, Requirement for lipopolysaccharide-responsive 
macrophages in galactosamine-induced sensitization to endotoxin. Infection and immunity 51, 
891-895 (1986); published online Mar (http://www.ncbi.nlm.nih.gov/pubmed/3949385). 
 
11. R. S. Munford, J. Pugin, Normal responses to injury prevent systemic inflammation and can be 
immunosuppressive. American journal of respiratory and critical care medicine 163, 316-321 
(2001); published online Feb (10.1164/ajrccm.163.2.2007102). 
 
12. F. J. Carey, A. I. Braude, M. Zalesky, Studies with radioactive endotoxin. III. The effect of 
tolerance on the distribution of radioactivity after intravenous injection of Escherichia coli 
endotoxin labeled with Cr51. The Journal of clinical investigation 37, 441-457 (1958); published 
online Mar (10.1172/JCI103624). 
 
13. D. S. Wheeler, P. M. Lahni, A. G. Denenberg, S. E. Poynter, H. R. Wong, J. A. Cook, B. Zingarelli, 
Induction of endotoxin tolerance enhances bacterial clearance and survival in murine 
polymicrobial sepsis. Shock 30, 267-273 (2008); published online Sep 
(10.1097/shk.0b013e318162c190). 
 
14. N. Rayhane, C. Fitting, O. Lortholary, F. Dromer, J. M. Cavaillon, Administration of endotoxin 
associated with lipopolysaccharide tolerance protects mice against fungal infection. Infection 
and immunity 68, 3748-3753 (2000); published online Jun 
(http://www.ncbi.nlm.nih.gov/pubmed/10816541). 
 
15. M. D. Lehner, J. Ittner, D. S. Bundschuh, N. van Rooijen, A. Wendel, T. Hartung, Improved innate 
immunity of endotoxin-tolerant mice increases resistance to Salmonella enterica serovar 
typhimurium infection despite attenuated cytokine response. Infection and immunity 69, 463-
471 (2001); published online Jan (10.1128/IAI.69.1.463-471.2001). 
 
16. S. L. Foster, D. C. Hargreaves, R. Medzhitov, Gene-specific control of inflammation by TLR-
induced chromatin modifications. Nature 447, 972-978 (2007); published online Jun 21 
(10.1038/nature05836). 
 
17. A. S. Yoo, B. T. Staahl, L. Chen, G. R. Crabtree, MicroRNA-mediated switching of chromatin-
remodelling complexes in neural development. Nature 460, 642-646 (2009); published online Jul 
30 (10.1038/nature08139). 
 
18. R. Garzon, S. Liu, M. Fabbri, Z. Liu, C. E. Heaphy, E. Callegari, S. Schwind, J. Pang, J. Yu, N. 
Muthusamy, V. Havelange, S. Volinia, W. Blum, L. J. Rush, D. Perrotti, M. Andreeff, C. D. 
Bloomfield, J. C. Byrd, K. Chan, L. C. Wu, C. M. Croce, G. Marcucci, MicroRNA-29b induces global 
DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by 
targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113, 6411-6418 (2009); 
published online Jun 18 (10.1182/blood-2008-07-170589). 
 
118 
 
 
19. Z. Jiang, P. Georgel, X. Du, L. Shamel, S. Sovath, S. Mudd, M. Huber, C. Kalis, S. Keck, C. Galanos, 
M. Freudenberg, B. Beutler, CD14 is required for MyD88-independent LPS signaling. Nature 
immunology 6, 565-570 (2005); published online Jun (10.1038/ni1207). 
 
20. M. S. Hayden, S. Ghosh, NF-kappaB, the first quarter-century: remarkable progress and 
outstanding questions. Genes & development 26, 203-234 (2012); published online Feb 1 
(10.1101/gad.183434.111). 
 
21. K. E. Welty-Wolf, M. S. Carraway, Y. C. Huang, S. G. Simonson, S. P. Kantrow, C. A. Piantadosi, 
Bacterial priming increases lung injury in gram-negative sepsis. American journal of respiratory 
and critical care medicine 158, 610-619 (1998); published online Aug 
(10.1164/ajrccm.158.2.9704064). 
 
22. A. Hoffmann, G. Natoli, G. Ghosh, Transcriptional regulation via the NF-kappaB signaling 
module. Oncogene 25, 6706-6716 (2006); published online Oct 30 (10.1038/sj.onc.1209933). 
 
23. A. S. Weinmann, S. E. Plevy, S. T. Smale, Rapid and selective remodeling of a positioned 
nucleosome during the induction of IL-12 p40 transcription. Immunity 11, 665-675 (1999); 
published online Dec (http://www.ncbi.nlm.nih.gov/pubmed/10626889). 
 
24. S. Saccani, S. Pantano, G. Natoli, Two waves of nuclear factor kappaB recruitment to target 
promoters. The Journal of experimental medicine 193, 1351-1359 (2001); published online Jun 
18 (http://www.ncbi.nlm.nih.gov/pubmed/11413190). 
 
25. V. R. Ramirez-Carrozzi, D. Braas, D. M. Bhatt, C. S. Cheng, C. Hong, K. R. Doty, J. C. Black, A. 
Hoffmann, M. Carey, S. T. Smale, A unifying model for the selective regulation of inducible 
transcription by CpG islands and nucleosome remodeling. Cell 138, 114-128 (2009); published 
online Jul 10 (10.1016/j.cell.2009.04.020). 
 
26. V. R. Ramirez-Carrozzi, A. A. Nazarian, C. C. Li, S. L. Gore, R. Sridharan, A. N. Imbalzano, S. T. 
Smale, Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling 
complexes during an inflammatory response. Genes & development 20, 282-296 (2006); 
published online Feb 1 (10.1101/gad.1383206). 
 
27. H. Kayama, V. R. Ramirez-Carrozzi, M. Yamamoto, T. Mizutani, H. Kuwata, H. Iba, M. Matsumoto, 
K. Honda, S. T. Smale, K. Takeda, Class-specific regulation of pro-inflammatory genes by MyD88 
pathways and IkappaBzeta. The Journal of biological chemistry 283, 12468-12477 (2008); 
published online May 2 (10.1074/jbc.M709965200). 
 
 
119 
 
28. D. C. Hargreaves, T. Horng, R. Medzhitov, Control of inducible gene expression by signal-
dependent transcriptional elongation. Cell 138, 129-145 (2009); published online Jul 10 
(10.1016/j.cell.2009.05.047). 
 
29. M. Yamamoto, S. Yamazaki, S. Uematsu, S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Kuwata, O. 
Takeuchi, K. Takeshige, T. Saitoh, S. Yamaoka, N. Yamamoto, S. Yamamoto, T. Muta, K. Takeda, 
S. Akira, Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear 
protein IkappaBzeta. Nature 430, 218-222 (2004); published online Jul 8 (10.1038/nature02738). 
 
30. A. S. Weinmann, D. M. Mitchell, S. Sanjabi, M. N. Bradley, A. Hoffmann, H. C. Liou, S. T. Smale, 
Nucleosome remodeling at the IL-12 p40 promoter is a TLR-dependent, Rel-independent event. 
Nature immunology 2, 51-57 (2001); published online Jan (10.1038/83168). 
 
31. T. Agalioti, G. Chen, D. Thanos, Deciphering the transcriptional histone acetylation code for a 
human gene. Cell 111, 381-392 (2002); published online Nov 1 
(http://www.ncbi.nlm.nih.gov/pubmed/12419248). 
 
32. G. Natoli, S. Ghisletti, I. Barozzi, The genomic landscapes of inflammation. Genes & development 
25, 101-106 (2011); published online Jan 15 (10.1101/gad.2018811). 
 
33. P. B. Beeson, R. Technical Assistance of Elizabeth, Tolerance to Bacterial Pyrogens : I. Factors 
Influencing Its Development. The Journal of experimental medicine 86, 29-38 (1947); published 
online Jun 30 (http://www.ncbi.nlm.nih.gov/pubmed/19871652). 
 
34. G. O. Favorite, H. R. Morgan, Effects Produced by the Intravenous Injection in Man of a Toxic 
Antigenic Material Derived from Eberthella Typhosa: Clinical, Hematological, Chemical and 
Serological Studies. The Journal of clinical investigation 21, 589-599 (1942); published online Sep 
(10.1172/JCI101337). 
 
35. H. R. Morgan, Immunologic Properties of an Antigenic Material Isolated from Eberthella 
Typhosa. J Immunol 41, 161-180 (1941). 
 
36. C. H. Lang, J. A. Spitzer, Glucose kinetics and development of endotoxin tolerance during long-
term continuous endotoxin infusion. Metabolism: clinical and experimental 36, 469-474 (1987); 
published online May (http://www.ncbi.nlm.nih.gov/pubmed/3574135). 
 
37. C. Munoz, J. Carlet, C. Fitting, B. Misset, J. P. Bleriot, J. M. Cavaillon, Dysregulation of in vitro 
cytokine production by monocytes during sepsis. The Journal of clinical investigation 88, 1747-
1754 (1991); published online Nov (10.1172/JCI115493). 
 
 
120 
 
38. D. L. Fraker, M. C. Stovroff, M. J. Merino, J. A. Norton, Tolerance to tumor necrosis factor in rats 
and the relationship to endotoxin tolerance and toxicity. The Journal of experimental medicine 
168, 95-105 (1988); published online Jul 1 (http://www.ncbi.nlm.nih.gov/pubmed/3294337). 
 
39. J. Roth, J. L. McClellan, M. J. Kluger, E. Zeisberger, Attenuation of fever and release of cytokines 
after repeated injections of lipopolysaccharide in guinea-pigs. The Journal of physiology 477 ( Pt 
1), 177-185 (1994); published online May 15 (http://www.ncbi.nlm.nih.gov/pubmed/8071885). 
 
40. R. D. Myers, T. A. Rudy, T. L. Yaksh, Fever produced by endotoxin injected into the hypothalamus 
of the monkey and its antagonism by salicylate. The Journal of physiology 243, 167-193 (1974); 
published online Nov (http://www.ncbi.nlm.nih.gov/pubmed/4615138). 
 
41. F. Randow, U. Syrbe, C. Meisel, D. Krausch, H. Zuckermann, C. Platzer, H. D. Volk, Mechanism of 
endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. 
The Journal of experimental medicine 181, 1887-1892 (1995); published online May 1 
(http://www.ncbi.nlm.nih.gov/pubmed/7722463). 
 
42. M. A. Freudenberg, C. Galanos, Induction of tolerance to lipopolysaccharide (LPS)-D-
galactosamine lethality by pretreatment with LPS is mediated by macrophages. Infection and 
immunity 56, 1352-1357 (1988); published online May 
(http://www.ncbi.nlm.nih.gov/pubmed/3356468). 
 
43. M. D. Lehner, S. Morath, K. S. Michelsen, R. R. Schumann, T. Hartung, Induction of cross-
tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like 
receptors independent of paracrine mediators. J Immunol 166, 5161-5167 (2001); published 
online Apr 15 (http://www.ncbi.nlm.nih.gov/pubmed/11290799). 
 
44. D. J. Berg, R. Kuhn, K. Rajewsky, W. Muller, S. Menon, N. Davidson, G. Grunig, D. Rennick, 
Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock 
and the Shwartzman reaction but not endotoxin tolerance. The Journal of clinical investigation 
96, 2339-2347 (1995); published online Nov (10.1172/JCI118290). 
 
45. M. Wysocka, S. Robertson, H. Riemann, J. Caamano, C. Hunter, A. Mackiewicz, L. J. Montaner, G. 
Trinchieri, C. L. Karp, IL-12 suppression during experimental endotoxin tolerance: dendritic cell 
loss and macrophage hyporesponsiveness. J Immunol 166, 7504-7513 (2001); published online 
Jun 15 (http://www.ncbi.nlm.nih.gov/pubmed/11390504). 
 
46. S. H. Zuckerman, G. F. Evans, Y. M. Snyder, W. D. Roeder, Endotoxin-macrophage interaction: 
post-translational regulation of tumor necrosis factor expression. J Immunol 143, 1223-1227 
(1989); published online Aug 15 (http://www.ncbi.nlm.nih.gov/pubmed/2501392). 
 
 
121 
 
47. K. E. LaRue, C. E. McCall, A labile transcriptional repressor modulates endotoxin tolerance. The 
Journal of experimental medicine 180, 2269-2275 (1994); published online Dec 1 
(http://www.ncbi.nlm.nih.gov/pubmed/7964499). 
 
48. G. D. Virca, S. Y. Kim, K. B. Glaser, R. J. Ulevitch, Lipopolysaccharide induces hyporesponsiveness 
to its own action in RAW 264.7 cells. The Journal of biological chemistry 264, 21951-21956 
(1989); published online Dec 25 (http://www.ncbi.nlm.nih.gov/pubmed/2480960). 
 
49. B. E. Henricson, C. L. Manthey, P. Y. Perera, T. A. Hamilton, S. N. Vogel, Dissociation of 
lipopolysaccharide (LPS)-inducible gene expression in murine macrophages pretreated with 
smooth LPS versus monophosphoryl lipid A. Infection and immunity 61, 2325-2333 (1993); 
published online Jun (http://www.ncbi.nlm.nih.gov/pubmed/8388859). 
 
50. A. E. Medvedev, A. Lentschat, L. M. Wahl, D. T. Golenbock, S. N. Vogel, Dysregulation of LPS-
induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 
activation in endotoxin-tolerant cells. J Immunol 169, 5209-5216 (2002); published online Nov 1 
(http://www.ncbi.nlm.nih.gov/pubmed/12391239). 
 
51. F. Nomura, S. Akashi, Y. Sakao, S. Sato, T. Kawai, M. Matsumoto, K. Nakanishi, M. Kimoto, K. 
Miyake, K. Takeda, S. Akira, Cutting edge: endotoxin tolerance in mouse peritoneal 
macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J 
Immunol 164, 3476-3479 (2000); published online Apr 1 
(http://www.ncbi.nlm.nih.gov/pubmed/10725699). 
 
52. A. E. Medvedev, K. M. Kopydlowski, S. N. Vogel, Inhibition of lipopolysaccharide-induced signal 
transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, 
and toll-like receptor 2 and 4 gene expression. J Immunol 164, 5564-5574 (2000); published 
online Jun 1 (http://www.ncbi.nlm.nih.gov/pubmed/10820230). 
 
53. A. E. Medvedev, P. Henneke, A. Schromm, E. Lien, R. Ingalls, M. J. Fenton, D. T. Golenbock, S. N. 
Vogel, Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese 
hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4. J 
Immunol 167, 2257-2267 (2001); published online Aug 15 
(http://www.ncbi.nlm.nih.gov/pubmed/11490013). 
 
54. S. Sato, F. Nomura, T. Kawai, O. Takeuchi, P. F. Muhlradt, K. Takeda, S. Akira, Synergy and cross-
tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol 
165, 7096-7101 (2000); published online Dec 15 
(http://www.ncbi.nlm.nih.gov/pubmed/11120839). 
 
55. D. Bosisio, N. Polentarutti, M. Sironi, S. Bernasconi, K. Miyake, G. R. Webb, M. U. Martin, A. 
Mantovani, M. Muzio, Stimulation of toll-like receptor 4 expression in human mononuclear 
 
122 
 
phagocytes by interferon-gamma: a molecular basis for priming and synergism with bacterial 
lipopolysaccharide. Blood 99, 3427-3431 (2002); published online May 1 
(http://www.ncbi.nlm.nih.gov/pubmed/11964313). 
 
56. Y. Xiong, F. Qiu, W. Piao, C. Song, L. M. Wahl, A. E. Medvedev, Endotoxin tolerance impairs IL-1 
receptor-associated kinase (IRAK) 4 and TGF-beta-activated kinase 1 activation, K63-linked 
polyubiquitination and assembly of IRAK1, TNF receptor-associated factor 6, and IkappaB kinase 
gamma and increases A20 expression. The Journal of biological chemistry 286, 7905-7916 
(2011); published online Mar 11 (10.1074/jbc.M110.182873). 
 
57. Y. Xiong, A. E. Medvedev, Induction of endotoxin tolerance in vivo inhibits activation of IRAK4 
and increases negative regulators IRAK-M, SHIP-1, and A20. Journal of leukocyte biology 90, 
1141-1148 (2011); published online Dec (10.1189/jlb.0611273). 
 
58. K. Kobayashi, L. D. Hernandez, J. E. Galan, C. A. Janeway, Jr., R. Medzhitov, R. A. Flavell, IRAK-M 
is a negative regulator of Toll-like receptor signaling. Cell 110, 191-202 (2002); published online 
Jul 26 (http://www.ncbi.nlm.nih.gov/pubmed/12150927). 
 
59. D. L. Boone, E. E. Turer, E. G. Lee, R. C. Ahmad, M. T. Wheeler, C. Tsui, P. Hurley, M. Chien, S. 
Chai, O. Hitotsumatsu, E. McNally, C. Pickart, A. Ma, The ubiquitin-modifying enzyme A20 is 
required for termination of Toll-like receptor responses. Nature immunology 5, 1052-1060 
(2004); published online Oct (10.1038/ni1110). 
 
60. H. W. Ziegler-Heitbrock, A. Wedel, W. Schraut, M. Strobel, P. Wendelgass, T. Sternsdorf, P. A. 
Bauerle, J. G. Haas, G. Riethmuller, Tolerance to lipopolysaccharide involves mobilization of 
nuclear factor kappa B with predominance of p50 homodimers. The Journal of biological 
chemistry 269, 17001-17004 (1994); published online Jun 24 
(http://www.ncbi.nlm.nih.gov/pubmed/7516328). 
 
61. J. G. Haas, P. A. Baeuerle, G. Riethmuller, H. W. Ziegler-Heitbrock, Molecular mechanisms in 
down-regulation of tumor necrosis factor expression. Proceedings of the National Academy of 
Sciences of the United States of America 87, 9563-9567 (1990); published online Dec 
(http://www.ncbi.nlm.nih.gov/pubmed/2263611). 
 
62. B. K. Yoza, J. Y. Hu, S. L. Cousart, C. E. McCall, Endotoxin inducible transcription is repressed in 
endotoxin tolerant cells. Shock 13, 236-243 (2000); published online Mar 
(http://www.ncbi.nlm.nih.gov/pubmed/10718382). 
 
63. C. Porta, M. Rimoldi, G. Raes, L. Brys, P. Ghezzi, D. Di Liberto, F. Dieli, S. Ghisletti, G. Natoli, P. De 
Baetselier, A. Mantovani, A. Sica, Tolerance and M2 (alternative) macrophage polarization are 
related processes orchestrated by p50 nuclear factor kappaB. Proceedings of the National 
 
123 
 
Academy of Sciences of the United States of America 106, 14978-14983 (2009); published online 
Sep 1 (10.1073/pnas.0809784106). 
 
64. K. Wahlstrom, J. Bellingham, J. L. Rodriguez, M. A. West, Inhibitory kappaBalpha control of 
nuclear factor-kappaB is dysregulated in endotoxin tolerant macrophages. Shock 11, 242-247 
(1999); published online Apr (http://www.ncbi.nlm.nih.gov/pubmed/10220299). 
 
65. J.-M. Cavaillon, Pitton, C., Fitting, C., Endotoxin tolerance is not a LPS-specific phenomenon:  
partial mimicry with IL-1, IL-10 and TGFβ. Journal of Endotoxin Research, 21-29 (1994). 
 
66. A. Erroi, G. Fantuzzi, M. Mengozzi, M. Sironi, S. F. Orencole, B. D. Clark, C. A. Dinarello, A. Isetta, 
P. Gnocchi, M. Giovarelli, et al., Differential regulation of cytokine production in 
lipopolysaccharide tolerance in mice. Infection and immunity 61, 4356-4359 (1993); published 
online Oct (http://www.ncbi.nlm.nih.gov/pubmed/8406825). 
 
67. H. P. Knopf, F. Otto, R. Engelhardt, M. A. Freudenberg, C. Galanos, F. Herrmann, R. R. Schumann, 
Discordant adaptation of human peritoneal macrophages to stimulation by lipopolysaccharide 
and the synthetic lipid A analogue SDZ MRL 953. Down-regulation of TNF-alpha and IL-6 is 
paralleled by an up-regulation of IL-1 beta and granulocyte colony-stimulating factor expression. 
J Immunol 153, 287-299 (1994); published online Jul 1 
(http://www.ncbi.nlm.nih.gov/pubmed/7515924). 
 
68. S. Flohe, E. Dominguez Fernandez, M. Ackermann, T. Hirsch, J. Borgermann, F. U. Schade, 
Endotoxin tolerance in rats: expression of TNF-alpha, IL-6, IL-10, VCAM-1 AND HSP 70 in lung 
and liver during endotoxin shock. Cytokine 11, 796-804 (1999); published online Oct 
(10.1006/cyto.1998.0490). 
 
69. M. Frankenberger, H. Pechumer, H. W. Ziegler-Heitbrock, Interleukin-10 is upregulated in LPS 
tolerance. Journal of inflammation 45, 56-63 
(1995)http://www.ncbi.nlm.nih.gov/pubmed/7583353). 
 
70. R. Flach, Flohe, S., Laschinski, M., Hofmann, K., Kreuzfelder, E., Schade, F.U., Interleukin-10 is 
downregulated in mononuclear cells from endotoxin tolerant humans. Journal of Endotoxin 
Research 4, 189-195 (1997). 
 
71. M. El Gazzar, B. K. Yoza, J. Y. Hu, S. L. Cousart, C. E. McCall, Epigenetic silencing of tumor necrosis 
factor alpha during endotoxin tolerance. The Journal of biological chemistry 282, 26857-26864 
(2007); published online Sep 14 (10.1074/jbc.M704584200). 
 
72. X. Chen, M. El Gazzar, B. K. Yoza, C. E. McCall, The NF-kappaB factor RelB and histone H3 lysine 
methyltransferase G9a directly interact to generate epigenetic silencing in endotoxin tolerance. 
 
124 
 
The Journal of biological chemistry 284, 27857-27865 (2009); published online Oct 9 
(10.1074/jbc.M109.000950). 
 
73. C. Chan, L. Li, C. E. McCall, B. K. Yoza, Endotoxin tolerance disrupts chromatin remodeling and 
NF-kappaB transactivation at the IL-1beta promoter. J Immunol 175, 461-468 (2005); published 
online Jul 1 (http://www.ncbi.nlm.nih.gov/pubmed/15972680). 
 
74. T. F. Liu, B. K. Yoza, M. El Gazzar, V. T. Vachharajani, C. E. McCall, NAD+-dependent SIRT1 
deacetylase participates in epigenetic reprogramming during endotoxin tolerance. The Journal 
of biological chemistry 286, 9856-9864 (2011); published online Mar 18 
(10.1074/jbc.M110.196790). 
 
75. B. K. Yoza, J. Y. Hu, S. L. Cousart, L. M. Forrest, C. E. McCall, Induction of RelB participates in 
endotoxin tolerance. J Immunol 177, 4080-4085 (2006); published online Sep 15 
(http://www.ncbi.nlm.nih.gov/pubmed/16951372). 
 
76. J. Bohuslav, V. V. Kravchenko, G. C. Parry, J. H. Erlich, S. Gerondakis, N. Mackman, R. J. Ulevitch, 
Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. The 
Journal of clinical investigation 102, 1645-1652 (1998); published online Nov 1 
(10.1172/JCI3877). 
 
77. J. Chen, L. B. Ivashkiv, IFN-gamma abrogates endotoxin tolerance by facilitating Toll-like 
receptor-induced chromatin remodeling. Proceedings of the National Academy of Sciences of the 
United States of America 107, 19438-19443 (2010); published online Nov 9 
(10.1073/pnas.1007816107). 
 
78. X. Zhang, D. C. Morrison, Lipopolysaccharide-induced selective priming effects on tumor 
necrosis factor alpha and nitric oxide production in mouse peritoneal macrophages. The Journal 
of experimental medicine 177, 511-516 (1993); published online Feb 1 
(http://www.ncbi.nlm.nih.gov/pubmed/8426119). 
 
79. M. R. Fabian, N. Sonenberg, The mechanics of miRNA-mediated gene silencing: a look under the 
hood of miRISC. Nature structural & molecular biology 19, 586-593 (2012); published online Jun 
(10.1038/nsmb.2296). 
 
80. A. E. Pasquinelli, MicroRNAs and their targets: recognition, regulation and an emerging 
reciprocal relationship. Nature reviews. Genetics 13, 271-282 (2012); published online Apr 
(10.1038/nrg3162). 
 
81. D. P. Bartel, MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009); 
published online Jan 23 (10.1016/j.cell.2009.01.002). 
 
125 
 
 
82. K. D. Taganov, M. P. Boldin, K. J. Chang, D. Baltimore, NF-kappaB-dependent induction of 
microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. 
Proceedings of the National Academy of Sciences of the United States of America 103, 12481-
12486 (2006); published online Aug 15 (10.1073/pnas.0605298103). 
 
83. M. El Gazzar, A. Church, T. Liu, C. E. McCall, MicroRNA-146a regulates both transcription 
silencing and translation disruption of TNF-alpha during TLR4-induced gene reprogramming. 
Journal of leukocyte biology 90, 509-519 (2011); published online Sep (10.1189/jlb.0211074). 
 
84. M. A. Nahid, K. M. Pauley, M. Satoh, E. K. Chan, miR-146a is critical for endotoxin-induced 
tolerance: IMPLICATION IN INNATE IMMUNITY. The Journal of biological chemistry 284, 34590-
34599 (2009); published online Dec 11 (10.1074/jbc.M109.056317). 
 
85. M. P. Boldin, K. D. Taganov, D. S. Rao, L. Yang, J. L. Zhao, M. Kalwani, Y. Garcia-Flores, M. Luong, 
A. Devrekanli, J. Xu, G. Sun, J. Tay, P. S. Linsley, D. Baltimore, miR-146a is a significant brake on 
autoimmunity, myeloproliferation, and cancer in mice. The Journal of experimental medicine 
208, 1189-1201 (2011); published online Jun 6 (10.1084/jem.20101823). 
 
86. F. Bazzoni, M. Rossato, M. Fabbri, D. Gaudiosi, M. Mirolo, L. Mori, N. Tamassia, A. Mantovani, M. 
A. Cassatella, M. Locati, Induction and regulatory function of miR-9 in human monocytes and 
neutrophils exposed to proinflammatory signals. Proceedings of the National Academy of 
Sciences of the United States of America 106, 5282-5287 (2009); published online Mar 31 
(10.1073/pnas.0810909106). 
 
87. A. Androulidaki, D. Iliopoulos, A. Arranz, C. Doxaki, S. Schworer, V. Zacharioudaki, A. N. 
Margioris, P. N. Tsichlis, C. Tsatsanis, The kinase Akt1 controls macrophage response to 
lipopolysaccharide by regulating microRNAs. Immunity 31, 220-231 (2009); published online Aug 
21 (10.1016/j.immuni.2009.06.024). 
 
88. X. M. Chen, P. L. Splinter, S. P. O'Hara, N. F. LaRusso, A cellular micro-RNA, let-7i, regulates Toll-
like receptor 4 expression and contributes to cholangiocyte immune responses against 
Cryptosporidium parvum infection. The Journal of biological chemistry 282, 28929-28938 (2007); 
published online Sep 28 (10.1074/jbc.M702633200). 
 
89. D. Iliopoulos, H. A. Hirsch, K. Struhl, An epigenetic switch involving NF-kappaB, Lin28, Let-7 
MicroRNA, and IL6 links inflammation to cell transformation. Cell 139, 693-706 (2009); published 
online Nov 13 (10.1016/j.cell.2009.10.014). 
 
90. F. Gao, Z. L. Zhao, W. T. Zhao, Q. R. Fan, S. C. Wang, J. Li, Y. Q. Zhang, J. W. Shi, X. L. Lin, S. Yang, 
R. Y. Xie, W. Liu, T. T. Zhang, Y. L. Sun, K. Xu, K. T. Yao, D. Xiao, miR-9 modulates the expression 
of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma 
 
126 
 
cells. Biochemical and biophysical research communications 431, 610-616 (2013); published 
online Feb 15 (10.1016/j.bbrc.2012.12.097). 
 
91. S. W. Jones, G. Watkins, N. Le Good, S. Roberts, C. L. Murphy, S. M. Brockbank, M. R. Needham, 
S. J. Read, P. Newham, The identification of differentially expressed microRNA in osteoarthritic 
tissue that modulate the production of TNF-alpha and MMP13. Osteoarthritis and cartilage / 
OARS, Osteoarthritis Research Society 17, 464-472 (2009); published online Apr 
(10.1016/j.joca.2008.09.012). 
 
92. F. J. Sheedy, E. Palsson-McDermott, E. J. Hennessy, C. Martin, J. J. O'Leary, Q. Ruan, D. S. 
Johnson, Y. Chen, L. A. O'Neill, Negative regulation of TLR4 via targeting of the proinflammatory 
tumor suppressor PDCD4 by the microRNA miR-21. Nature immunology 11, 141-147 (2010); 
published online Feb (10.1038/ni.1828). 
 
93. Y. Liu, Q. Chen, Y. Song, L. Lai, J. Wang, H. Yu, X. Cao, Q. Wang, MicroRNA-98 negatively 
regulates IL-10 production and endotoxin tolerance in macrophages after LPS stimulation. FEBS 
letters 585, 1963-1968 (2011); published online Jun 23 (10.1016/j.febslet.2011.05.029). 
 
94. Y. Singh, V. Kaul, A. Mehra, S. Chatterjee, S. Tousif, V. P. Dwivedi, M. Suar, L. Van Kaer, W. R. 
Bishai, G. Das, Mycobacterium tuberculosis controls microRNA-99b (miR-99b) expression in 
infected murine dendritic cells to modulate host immunity. The Journal of biological chemistry 
288, 5056-5061 (2013); published online Feb 15 (10.1074/jbc.C112.439778). 
 
95. S. W. Kim, K. Ramasamy, H. Bouamar, A. P. Lin, D. Jiang, R. C. Aguiar, MicroRNAs miR-125a and 
miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor 
alpha-induced protein 3 (TNFAIP3, A20). Proceedings of the National Academy of Sciences of the 
United States of America 109, 7865-7870 (2012); published online May 15 
(10.1073/pnas.1200081109). 
 
96. M. El Gazzar, C. E. McCall, MicroRNAs distinguish translational from transcriptional silencing 
during endotoxin tolerance. The Journal of biological chemistry 285, 20940-20951 (2010); 
published online Jul 2 (10.1074/jbc.M110.115063). 
 
97. E. Tili, J. J. Michaille, A. Cimino, S. Costinean, C. D. Dumitru, B. Adair, M. Fabbri, H. Alder, C. G. 
Liu, G. A. Calin, C. M. Croce, Modulation of miR-155 and miR-125b levels following 
lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to 
endotoxin shock. J Immunol 179, 5082-5089 (2007); published online Oct 15 
(http://www.ncbi.nlm.nih.gov/pubmed/17911593). 
 
98. A. A. Chaudhuri, A. Y. So, N. Sinha, W. S. Gibson, K. D. Taganov, R. M. O'Connell, D. Baltimore, 
MicroRNA-125b potentiates macrophage activation. J Immunol 187, 5062-5068 (2011); 
published online Nov 15 (10.4049/jimmunol.1102001). 
 
127 
 
 
99. G. Liu, A. Friggeri, Y. Yang, Y. J. Park, Y. Tsuruta, E. Abraham, miR-147, a microRNA that is 
induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory 
responses. Proceedings of the National Academy of Sciences of the United States of America 
106, 15819-15824 (2009); published online Sep 15 (10.1073/pnas.0901216106). 
 
100. R. M. O'Connell, K. D. Taganov, M. P. Boldin, G. Cheng, D. Baltimore, MicroRNA-155 is induced 
during the macrophage inflammatory response. Proceedings of the National Academy of 
Sciences of the United States of America 104, 1604-1609 (2007); published online Jan 30 
(10.1073/pnas.0610731104). 
 
101. Y. Chen, W. Liu, T. Sun, Y. Huang, Y. Wang, D. K. Deb, D. Yoon, J. Kong, R. Thadhani, Y. C. Li, 1,25-
Dihydroxyvitamin D promotes negative feedback regulation of TLR signaling via targeting 
microRNA-155-SOCS1 in macrophages. J Immunol 190, 3687-3695 (2013); published online Apr 1 
(10.4049/jimmunol.1203273). 
 
102. R. M. O'Connell, A. A. Chaudhuri, D. S. Rao, D. Baltimore, Inositol phosphatase SHIP1 is a primary 
target of miR-155. Proceedings of the National Academy of Sciences of the United States of 
America 106, 7113-7118 (2009); published online Apr 28 (10.1073/pnas.0902636106). 
 
103. M. Rossato, G. Curtale, N. Tamassia, M. Castellucci, L. Mori, S. Gasperini, B. Mariotti, M. De Luca, 
M. Mirolo, M. A. Cassatella, M. Locati, F. Bazzoni, IL-10-induced microRNA-187 negatively 
regulates TNF-alpha, IL-6, and IL-12p40 production in TLR4-stimulated monocytes. Proceedings 
of the National Academy of Sciences of the United States of America 109, E3101-3110 (2012); 
published online Nov 6 (10.1073/pnas.1209100109). 
 
104. Q. Chen, H. Wang, Y. Liu, Y. Song, L. Lai, Q. Han, X. Cao, Q. Wang, Inducible microRNA-223 down-
regulation promotes TLR-triggered IL-6 and IL-1beta production in macrophages by targeting 
STAT3. PloS one 7, e42971 (2012)10.1371/journal.pone.0042971). 
 
105. D. Lagos, G. Pollara, S. Henderson, F. Gratrix, M. Fabani, R. S. Milne, F. Gotch, C. Boshoff, miR-
132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-
activator. Nature cell biology 12, 513-519 (2010); published online May (10.1038/ncb2054). 
 
106. S. J. Bultman, J. I. Herschkowitz, V. Godfrey, T. C. Gebuhr, M. Yaniv, C. M. Perou, T. Magnuson, 
Characterization of mammary tumors from Brg1 heterozygous mice. Oncogene 27, 460-468 
(2008); published online Jan 17 (10.1038/sj.onc.1210664). 
 
107. S. Bultman, T. Gebuhr, D. Yee, C. La Mantia, J. Nicholson, A. Gilliam, F. Randazzo, D. Metzger, P. 
Chambon, G. Crabtree, T. Magnuson, A Brg1 null mutation in the mouse reveals functional 
differences among mammalian SWI/SNF complexes. Molecular cell 6, 1287-1295 (2000); 
published online Dec (http://www.ncbi.nlm.nih.gov/pubmed/11163203). 
 
128 
 
 
108. J. K. Takeuchi, X. Lou, J. M. Alexander, H. Sugizaki, P. Delgado-Olguin, A. K. Holloway, A. D. Mori, 
J. N. Wylie, C. Munson, Y. Zhu, Y. Q. Zhou, R. F. Yeh, R. M. Henkelman, R. P. Harvey, D. Metzger, 
P. Chambon, D. Y. Stainier, K. S. Pollard, I. C. Scott, B. G. Bruneau, Chromatin remodelling 
complex dosage modulates transcription factor function in heart development. Nature 
communications 2, 187 (2011)10.1038/ncomms1187). 
 
109. C. J. Fryer, T. K. Archer, Chromatin remodelling by the glucocorticoid receptor requires the BRG1 
complex. Nature 393, 88-91 (1998); published online May 7 (10.1038/30032). 
 
110. W. Shen, C. Xu, W. Huang, J. Zhang, J. E. Carlson, X. Tu, J. Wu, Y. Shi, Solution structure of human 
Brg1 bromodomain and its specific binding to acetylated histone tails. Biochemistry 46, 2100-
2110 (2007); published online Feb 27 (10.1021/bi0611208). 
 
111. S. Guil, M. Esteller, DNA methylomes, histone codes and miRNAs: tying it all together. The 
international journal of biochemistry & cell biology 41, 87-95 (2009); published online Jan 
(10.1016/j.biocel.2008.09.005). 
 
112. S. Huang, S. Wang, C. Bian, Z. Yang, H. Zhou, Y. Zeng, H. Li, Q. Han, R. C. Zhao, Upregulation of 
miR-22 promotes osteogenic differentiation and inhibits adipogenic differentiation of human 
adipose tissue-derived mesenchymal stem cells by repressing HDAC6 protein expression. Stem 
cells and development 21, 2531-2540 (2012); published online Sep 1 (10.1089/scd.2012.0014). 
 
113. A. Jovicic, J. F. Zaldivar Jolissaint, R. Moser, F. Silva Santos Mde, R. Luthi-Carter, MicroRNA-22 
(miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also 
target specific Huntington's disease-related mechanisms. PloS one 8, e54222 
(2013)10.1371/journal.pone.0054222). 
 
114. A. Takata, M. Otsuka, K. Kojima, T. Yoshikawa, T. Kishikawa, H. Yoshida, K. Koike, MicroRNA-22 
and microRNA-140 suppress NF-kappaB activity by regulating the expression of NF-kappaB 
coactivators. Biochemical and biophysical research communications 411, 826-831 (2011); 
published online Aug 12 (10.1016/j.bbrc.2011.07.048). 
 
115. M. Yaseen Balkhi, O. H. Iwenofu, N. Bakkar, K. J. Ladner, D. S. Chandler, P. J. Houghton, C. A. 
London, W. Kraybill, D. Perrotti, C. M. Croce, C. Keller, D. C. Guttridge, miR-29 Acts as a Decoy in 
Sarcomas to Protect the Tumor Suppressor A20 mRNA from Degradation by HuR. Science 
signaling 6, ra63 (2013)10.1126/scisignal.2004177). 
 
116. J. L. Zhao, D. S. Rao, M. P. Boldin, K. D. Taganov, R. M. O'Connell, D. Baltimore, NF-kappaB 
dysregulation in microRNA-146a-deficient mice drives the development of myeloid 
malignancies. Proceedings of the National Academy of Sciences of the United States of America 
108, 9184-9189 (2011); published online May 31 (10.1073/pnas.1105398108). 
 
129 
 
 
117. R. M. O'Connell, D. S. Rao, A. A. Chaudhuri, M. P. Boldin, K. D. Taganov, J. Nicoll, R. L. Paquette, 
D. Baltimore, Sustained expression of microRNA-155 in hematopoietic stem cells causes a 
myeloproliferative disorder. The Journal of experimental medicine 205, 585-594 (2008); 
published online Mar 17 (10.1084/jem.20072108). 
 
118. J. B. Johnnidis, M. H. Harris, R. T. Wheeler, S. Stehling-Sun, M. H. Lam, O. Kirak, T. R. 
Brummelkamp, M. D. Fleming, F. D. Camargo, Regulation of progenitor cell proliferation and 
granulocyte function by microRNA-223. Nature 451, 1125-1129 (2008); published online Feb 28 
(10.1038/nature06607). 
 
119. M. S. Hayden, S. Ghosh, Shared principles in NF-kappaB signaling. Cell 132, 344-362 (2008); 
published online Feb 8 (10.1016/j.cell.2008.01.020). 
 
120. P. Wang, J. Hou, L. Lin, C. Wang, X. Liu, D. Li, F. Ma, Z. Wang, X. Cao, Inducible microRNA-155 
feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of 
cytokine signaling 1. J Immunol 185, 6226-6233 (2010); published online Nov 15 
(10.4049/jimmunol.1000491). 
 
121. S. Jiang, H. W. Zhang, M. H. Lu, X. H. He, Y. Li, H. Gu, M. F. Liu, E. D. Wang, MicroRNA-155 
functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 
gene. Cancer research 70, 3119-3127 (2010); published online Apr 15 (10.1158/0008-5472.CAN-
09-4250). 
 
122. J. Winter, S. Jung, S. Keller, R. I. Gregory, S. Diederichs, Many roads to maturity: microRNA 
biogenesis pathways and their regulation. Nature cell biology 11, 228-234 (2009); published 
online Mar (10.1038/ncb0309-228). 
 
123. J. Han, Y. Lee, K. H. Yeom, Y. K. Kim, H. Jin, V. N. Kim, The Drosha-DGCR8 complex in primary 
microRNA processing. Genes & development 18, 3016-3027 (2004); published online Dec 15 
(10.1101/gad.1262504). 
 
124. R. I. Gregory, K. P. Yan, G. Amuthan, T. Chendrimada, B. Doratotaj, N. Cooch, R. Shiekhattar, The 
Microprocessor complex mediates the genesis of microRNAs. Nature 432, 235-240 (2004); 
published online Nov 11 (10.1038/nature03120). 
 
125. A. M. Denli, B. B. Tops, R. H. Plasterk, R. F. Ketting, G. J. Hannon, Processing of primary 
microRNAs by the Microprocessor complex. Nature 432, 231-235 (2004); published online Nov 
11 (10.1038/nature03049). 
 
 
130 
 
126. Y. Lee, C. Ahn, J. Han, H. Choi, J. Kim, J. Yim, J. Lee, P. Provost, O. Radmark, S. Kim, V. N. Kim, The 
nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415-419 (2003); published 
online Sep 25 (10.1038/nature01957). 
 
127. R. Duan, C. Pak, P. Jin, Single nucleotide polymorphism associated with mature miR-125a alters 
the processing of pri-miRNA. Human molecular genetics 16, 1124-1131 (2007); published online 
May 1 (10.1093/hmg/ddm062). 
 
128. T. Fukuda, K. Yamagata, S. Fujiyama, T. Matsumoto, I. Koshida, K. Yoshimura, M. Mihara, M. 
Naitou, H. Endoh, T. Nakamura, C. Akimoto, Y. Yamamoto, T. Katagiri, C. Foulds, S. Takezawa, H. 
Kitagawa, K. Takeyama, B. W. O'Malley, S. Kato, DEAD-box RNA helicase subunits of the Drosha 
complex are required for processing of rRNA and a subset of microRNAs. Nature cell biology 9, 
604-611 (2007); published online May (10.1038/ncb1577). 
 
129. S. Guil, J. F. Caceres, The multifunctional RNA-binding protein hnRNP A1 is required for 
processing of miR-18a. Nature structural & molecular biology 14, 591-596 (2007); published 
online Jul (10.1038/nsmb1250). 
 
130. S. R. Viswanathan, G. Q. Daley, R. I. Gregory, Selective blockade of microRNA processing by 
Lin28. Science 320, 97-100 (2008); published online Apr 4 (10.1126/science.1154040). 
 
131. T. J. Marquart, R. M. Allen, D. S. Ory, A. Baldan, miR-33 links SREBP-2 induction to repression of 
sterol transporters. Proceedings of the National Academy of Sciences of the United States of 
America 107, 12228-12232 (2010); published online Jul 6 (10.1073/pnas.1005191107). 
 
132. K. J. Rayner, Y. Suarez, A. Davalos, S. Parathath, M. L. Fitzgerald, N. Tamehiro, E. A. Fisher, K. J. 
Moore, C. Fernandez-Hernando, MiR-33 contributes to the regulation of cholesterol 
homeostasis. Science 328, 1570-1573 (2010); published online Jun 18 
(10.1126/science.1189862). 
 
133. G. Cao, B. Huang, Z. Liu, J. Zhang, H. Xu, W. Xia, J. Li, S. Li, L. Chen, H. Ding, Q. Zhao, M. Fan, B. 
Shen, N. Shao, Intronic miR-301 feedback regulates its host gene, ska2, in A549 cells by targeting 
MEOX2 to affect ERK/CREB pathways. Biochemical and biophysical research communications 
396, 978-982 (2010); published online Jun 11 (10.1016/j.bbrc.2010.05.037). 
 
134. K. Okamura, J. W. Hagen, H. Duan, D. M. Tyler, E. C. Lai, The mirtron pathway generates 
microRNA-class regulatory RNAs in Drosophila. Cell 130, 89-100 (2007); published online Jul 13 
(10.1016/j.cell.2007.06.028). 
 
135. J. G. Ruby, C. H. Jan, D. P. Bartel, Intronic microRNA precursors that bypass Drosha processing. 
Nature 448, 83-86 (2007); published online Jul 5 (10.1038/nature05983). 
 
131 
 
 
136. M. M. Chong, G. Zhang, S. Cheloufi, T. A. Neubert, G. J. Hannon, D. R. Littman, Canonical and 
alternate functions of the microRNA biogenesis machinery. Genes & development 24, 1951-1960 
(2010); published online Sep 1 (10.1101/gad.1953310). 
 
137. R. Yi, Y. Qin, I. G. Macara, B. R. Cullen, Exportin-5 mediates the nuclear export of pre-microRNAs 
and short hairpin RNAs. Genes & development 17, 3011-3016 (2003); published online Dec 15 
(10.1101/gad.1158803). 
 
138. I. J. MacRae, E. Ma, M. Zhou, C. V. Robinson, J. A. Doudna, In vitro reconstitution of the human 
RISC-loading complex. Proceedings of the National Academy of Sciences of the United States of 
America 105, 512-517 (2008); published online Jan 15 (10.1073/pnas.0710869105). 
 
139. Y. Lee, I. Hur, S. Y. Park, Y. K. Kim, M. R. Suh, V. N. Kim, The role of PACT in the RNA silencing 
pathway. The EMBO journal 25, 522-532 (2006); published online Feb 8 
(10.1038/sj.emboj.7600942). 
 
140. A. D. Haase, L. Jaskiewicz, H. Zhang, S. Laine, R. Sack, A. Gatignol, W. Filipowicz, TRBP, a 
regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA 
silencing. EMBO reports 6, 961-967 (2005); published online Oct (10.1038/sj.embor.7400509). 
 
141. R. I. Gregory, T. P. Chendrimada, N. Cooch, R. Shiekhattar, Human RISC couples microRNA 
biogenesis and posttranscriptional gene silencing. Cell 123, 631-640 (2005); published online 
Nov 18 (10.1016/j.cell.2005.10.022). 
 
142. R. Fukunaga, B. W. Han, J. H. Hung, J. Xu, Z. Weng, P. D. Zamore, Dicer partner proteins tune the 
length of mature miRNAs in flies and mammals. Cell 151, 533-546 (2012); published online Oct 
26 (10.1016/j.cell.2012.09.027). 
 
143. D. Cifuentes, H. Xue, D. W. Taylor, H. Patnode, Y. Mishima, S. Cheloufi, E. Ma, S. Mane, G. J. 
Hannon, N. D. Lawson, S. A. Wolfe, A. J. Giraldez, A novel miRNA processing pathway 
independent of Dicer requires Argonaute2 catalytic activity. Science 328, 1694-1698 (2010); 
published online Jun 25 (10.1126/science.1190809). 
 
144. A. Khvorova, A. Reynolds, S. D. Jayasena, Functional siRNAs and miRNAs exhibit strand bias. Cell 
115, 209-216 (2003); published online Oct 17 
(http://www.ncbi.nlm.nih.gov/pubmed/14567918). 
 
145. D. S. Schwarz, G. Hutvagner, T. Du, Z. Xu, N. Aronin, P. D. Zamore, Asymmetry in the assembly of 
the RNAi enzyme complex. Cell 115, 199-208 (2003); published online Oct 17 
(http://www.ncbi.nlm.nih.gov/pubmed/14567917). 
 
132 
 
 
146. L. Rice, C. E. Waters, J. Eccles, H. Garside, P. Sommer, P. Kay, F. H. Blackhall, L. Zeef, B. Telfer, I. 
Stratford, R. Clarke, D. Singh, A. Stevens, A. White, D. W. Ray, Identification and functional 
analysis of SKA2 interaction with the glucocorticoid receptor. The Journal of endocrinology 198, 
499-509 (2008); published online Sep (10.1677/JOE-08-0019). 
 
147. M. Shibanuma, F. Ishikawa, M. Kobayashi, K. Katayama, H. Miyoshi, M. Wakamatsu, K. Mori, K. 
Nose, Critical roles of the cAMP-responsive element-binding protein-mediated pathway in 
disorganized epithelial phenotypes caused by mitochondrial dysfunction. Cancer science 103, 
1803-1810 (2012); published online Oct (10.1111/j.1349-7006.2012.02369.x). 
 
148. M. R. Copley, S. Babovic, C. Benz, D. J. Knapp, P. A. Beer, D. G. Kent, S. Wohrer, D. Q. Treloar, C. 
Day, K. Rowe, H. Mader, F. Kuchenbauer, R. K. Humphries, C. J. Eaves, The Lin28b-let-7-Hmga2 
axis determines the higher self-renewal potential of fetal haematopoietic stem cells. Nature cell 
biology 15, 916-925 (2013); published online Aug (10.1038/ncb2783). 
 
149. M. D. Kaeser, A. Aslanian, M. Q. Dong, J. R. Yates, 3rd, B. M. Emerson, BRD7, a novel PBAF-
specific SWI/SNF subunit, is required for target gene activation and repression in embryonic 
stem cells. The Journal of biological chemistry 283, 32254-32263 (2008); published online Nov 21 
(10.1074/jbc.M806061200). 
 
150. A. Nystrom, D. Velati, V. R. Mittapalli, A. Fritsch, J. S. Kern, L. Bruckner-Tuderman, Collagen VII 
plays a dual role in wound healing. The Journal of clinical investigation 123, 3498-3509 (2013); 
published online Aug 1 (10.1172/JCI68127). 
 
151. C. Feng, W. Xu, Z. Zuo, Knockout of the regulatory factor X1 gene leads to early embryonic 
lethality. Biochemical and biophysical research communications 386, 715-717 (2009); published 
online Sep 4 (10.1016/j.bbrc.2009.06.111). 
 
152. Q. Seguin-Estevez, R. De Palma, M. Krawczyk, E. Leimgruber, J. Villard, C. Picard, A. Tagliamacco, 
G. Abbate, J. Gorski, A. Nocera, W. Reith, The transcription factor RFX protects MHC class II 
genes against epigenetic silencing by DNA methylation. J Immunol 183, 2545-2553 (2009); 
published online Aug 15 (10.4049/jimmunol.0900376). 
 
153. T. Zama, R. Aoki, T. Kamimoto, K. Inoue, Y. Ikeda, M. Hagiwara, A novel dual specificity 
phosphatase SKRP1 interacts with the MAPK kinase MKK7 and inactivates the JNK MAPK 
pathway. Implication for the precise regulation of the particular MAPK pathway. The Journal of 
biological chemistry 277, 23909-23918 (2002); published online Jun 28 
(10.1074/jbc.M200837200). 
 
154. M. Barzik, T. I. Kotova, H. N. Higgs, L. Hazelwood, D. Hanein, F. B. Gertler, D. A. Schafer, 
Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping 
 
133 
 
proteins. The Journal of biological chemistry 280, 28653-28662 (2005); published online Aug 5 
(10.1074/jbc.M503957200). 
 
155. K. L. Goh, L. Cai, C. L. Cepko, F. B. Gertler, Ena/VASP proteins regulate cortical neuronal 
positioning. Current biology : CB 12, 565-569 (2002); published online Apr 2 
(http://www.ncbi.nlm.nih.gov/pubmed/11937025). 
 
156. V. Laurent, T. P. Loisel, B. Harbeck, A. Wehman, L. Grobe, B. M. Jockusch, J. Wehland, F. B. 
Gertler, M. F. Carlier, Role of proteins of the Ena/VASP family in actin-based motility of Listeria 
monocytogenes. The Journal of cell biology 144, 1245-1258 (1999); published online Mar 22 
(http://www.ncbi.nlm.nih.gov/pubmed/10087267). 
 
157. W. M. Grady, R. K. Parkin, P. S. Mitchell, J. H. Lee, Y. H. Kim, K. D. Tsuchiya, M. K. Washington, C. 
Paraskeva, J. K. Willson, A. M. Kaz, E. M. Kroh, A. Allen, B. R. Fritz, S. D. Markowitz, M. Tewari, 
Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal 
cancer. Oncogene 27, 3880-3888 (2008); published online Jun 19 (10.1038/onc.2008.10). 
 
158. S. Griffiths-Jones, The microRNA Registry. Nucleic acids research 32, D109-111 (2004); published 
online Jan 1 (10.1093/nar/gkh023). 
 
159. S. Griffiths-Jones, R. J. Grocock, S. van Dongen, A. Bateman, A. J. Enright, miRBase: microRNA 
sequences, targets and gene nomenclature. Nucleic acids research 34, D140-144 (2006); 
published online Jan 1 (10.1093/nar/gkj112). 
 
160. S. Griffiths-Jones, H. K. Saini, S. van Dongen, A. J. Enright, miRBase: tools for microRNA 
genomics. Nucleic acids research 36, D154-158 (2008); published online Jan 
(10.1093/nar/gkm952). 
 
161. A. Kozomara, S. Griffiths-Jones, miRBase: integrating microRNA annotation and deep-
sequencing data. Nucleic acids research 39, D152-157 (2011); published online Jan 
(10.1093/nar/gkq1027). 
 
162. A. Kozomara, S. Griffiths-Jones, miRBase: annotating high confidence microRNAs using deep 
sequencing data. Nucleic acids research 42, D68-73 (2014); published online Jan 
(10.1093/nar/gkt1181). 
 
163. W. Yang, T. P. Chendrimada, Q. Wang, M. Higuchi, P. H. Seeburg, R. Shiekhattar, K. Nishikura, 
Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. 
Nature structural & molecular biology 13, 13-21 (2006); published online Jan 
(10.1038/nsmb1041). 
 
134 
 
 
164. Y. Kawahara, M. Megraw, E. Kreider, H. Iizasa, L. Valente, A. G. Hatzigeorgiou, K. Nishikura, 
Frequency and fate of microRNA editing in human brain. Nucleic acids research 36, 5270-5280 
(2008); published online Sep (10.1093/nar/gkn479). 
 
165. Y. Kawahara, B. Zinshteyn, P. Sethupathy, H. Iizasa, A. G. Hatzigeorgiou, K. Nishikura, Redirection 
of silencing targets by adenosine-to-inosine editing of miRNAs. Science 315, 1137-1140 (2007); 
published online Feb 23 (10.1126/science.1138050). 
 
166. D. J. Luciano, H. Mirsky, N. J. Vendetti, S. Maas, RNA editing of a miRNA precursor. Rna 10, 1174-
1177 (2004); published online Aug (10.1261/rna.7350304). 
 
167. M. J. Blow, R. J. Grocock, S. van Dongen, A. J. Enright, E. Dicks, P. A. Futreal, R. Wooster, M. R. 
Stratton, RNA editing of human microRNAs. Genome biology 7, R27 (2006)10.1186/gb-2006-7-4-
r27). 
 
168. M. R. Jones, L. J. Quinton, M. T. Blahna, J. R. Neilson, S. Fu, A. R. Ivanov, D. A. Wolf, J. P. Mizgerd, 
Zcchc11-dependent uridylation of microRNA directs cytokine expression. Nature cell biology 11, 
1157-1163 (2009); published online Sep (10.1038/ncb1931). 
 
169. H. W. Hwang, E. A. Wentzel, J. T. Mendell, A hexanucleotide element directs microRNA nuclear 
import. Science 315, 97-100 (2007); published online Jan 5 (10.1126/science.1136235). 
 
170. S. Galardi, N. Mercatelli, M. G. Farace, S. A. Ciafre, NF-kB and c-Jun induce the expression of the 
oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic acids 
research 39, 3892-3902 (2011); published online May (10.1093/nar/gkr006). 
 
171. Y. Liang, D. Ridzon, L. Wong, C. Chen, Characterization of microRNA expression profiles in 
normal human tissues. BMC genomics 8, 166 (2007)10.1186/1471-2164-8-166). 
 
172. D. H. Mathews, M. D. Disney, J. L. Childs, S. J. Schroeder, M. Zuker, D. H. Turner, Incorporating 
chemical modification constraints into a dynamic programming algorithm for prediction of RNA 
secondary structure. Proceedings of the National Academy of Sciences of the United States of 
America 101, 7287-7292 (2004); published online May 11 (10.1073/pnas.0401799101). 
 
173. A. R. Gruber, R. Lorenz, S. H. Bernhart, R. Neubock, I. L. Hofacker, The Vienna RNA websuite. 
Nucleic acids research 36, W70-74 (2008); published online Jul 1 (10.1093/nar/gkn188). 
 
 
135 
 
174. R. Lorenz, S. H. Bernhart, C. Honer Zu Siederdissen, H. Tafer, C. Flamm, P. F. Stadler, I. L. 
Hofacker, ViennaRNA Package 2.0. Algorithms for molecular biology : AMB 6, 26 
(2011)10.1186/1748-7188-6-26). 
 
175. P. Cavaillon J-M, C., Fitting, C., Endotoxin tolerance is not a LPS-specific phenomenon:  partial 
mimicry with IL-1, IL-10 and TGFβ. Journal of Endotoxin Research, 21-29 (1994). 
 
176. S. Stinson, M. R. Lackner, A. T. Adai, N. Yu, H. J. Kim, C. O'Brien, J. Spoerke, S. Jhunjhunwala, Z. 
Boyd, T. Januario, R. J. Newman, P. Yue, R. Bourgon, Z. Modrusan, H. M. Stern, S. Warming, F. J. 
de Sauvage, L. Amler, R. F. Yeh, D. Dornan, TRPS1 targeting by miR-221/222 promotes the 
epithelial-to-mesenchymal transition in breast cancer. Science signaling 4, ra41 
(2011)10.1126/scisignal.2001538). 
 
177. T. Curran, B. R. Franza, Jr., Fos and Jun: the AP-1 connection. Cell 55, 395-397 (1988); published 
online Nov 4 (http://www.ncbi.nlm.nih.gov/pubmed/3141060). 
 
178. H. Morishita, F. Saito, H. Kayama, K. Atarashi, H. Kuwata, M. Yamamoto, K. Takeda, Fra-1 
negatively regulates lipopolysaccharide-mediated inflammatory responses. International 
immunology 21, 457-465 (2009); published online Apr (10.1093/intimm/dxp015). 
 
179. R. Eferl, A. Hoebertz, A. F. Schilling, M. Rath, F. Karreth, L. Kenner, M. Amling, E. F. Wagner, The 
Fos-related antigen Fra-1 is an activator of bone matrix formation. The EMBO journal 23, 2789-
2799 (2004); published online Jul 21 (10.1038/sj.emboj.7600282). 
 
180. Z. Paroo, X. Ye, S. Chen, Q. Liu, Phosphorylation of the human microRNA-generating complex 
mediates MAPK/Erk signaling. Cell 139, 112-122 (2009); published online Oct 2 
(10.1016/j.cell.2009.06.044). 
 
181. M. Vaz, N. M. Reddy, S. Rajasekaran, S. P. Reddy, Genetic disruption of Fra-1 decreases 
susceptibility to endotoxin-induced acute lung injury and mortality in mice. American journal of 
respiratory cell and molecular biology 46, 55-62 (2012); published online Jan 
(10.1165/rcmb.2011-0169OC). 
 
182. S. L. Ameres, P. D. Zamore, Diversifying microRNA sequence and function. Nature reviews. 
Molecular cell biology 14, 475-488 (2013); published online Aug (10.1038/nrm3611). 
 
183. L. Wu, J. Fan, J. G. Belasco, MicroRNAs direct rapid deadenylation of mRNA. Proceedings of the 
National Academy of Sciences of the United States of America 103, 4034-4039 (2006); published 
online Mar 14 (10.1073/pnas.0510928103). 
 
 
136 
 
184. A. A. Bazzini, M. T. Lee, A. J. Giraldez, Ribosome profiling shows that miR-430 reduces translation 
before causing mRNA decay in zebrafish. Science 336, 233-237 (2012); published online Apr 13 
(10.1126/science.1215704). 
 
185. D. G. Hendrickson, D. J. Hogan, H. L. McCullough, J. W. Myers, D. Herschlag, J. E. Ferrell, P. O. 
Brown, Concordant regulation of translation and mRNA abundance for hundreds of targets of a 
human microRNA. PLoS biology 7, e1000238 (2009); published online Nov 
(10.1371/journal.pbio.1000238). 
 
186. H. Guo, N. T. Ingolia, J. S. Weissman, D. P. Bartel, Mammalian microRNAs predominantly act to 
decrease target mRNA levels. Nature 466, 835-840 (2010); published online Aug 12 
(10.1038/nature09267). 
 
187. D. Baek, J. Villen, C. Shin, F. D. Camargo, S. P. Gygi, D. P. Bartel, The impact of microRNAs on 
protein output. Nature 455, 64-71 (2008); published online Sep 4 (10.1038/nature07242). 
 
188. M. Selbach, B. Schwanhausser, N. Thierfelder, Z. Fang, R. Khanin, N. Rajewsky, Widespread 
changes in protein synthesis induced by microRNAs. Nature 455, 58-63 (2008); published online 
Sep 4 (10.1038/nature07228). 
 
189. L. P. Lim, N. C. Lau, P. Garrett-Engele, A. Grimson, J. M. Schelter, J. Castle, D. P. Bartel, P. S. 
Linsley, J. M. Johnson, Microarray analysis shows that some microRNAs downregulate large 
numbers of target mRNAs. Nature 433, 769-773 (2005); published online Feb 17 
(10.1038/nature03315). 
 
190. T. M. Witkos, E. Koscianska, W. J. Krzyzosiak, Practical Aspects of microRNA Target Prediction. 
Current molecular medicine 11, 93-109 (2011); published online Mar 
(http://www.ncbi.nlm.nih.gov/pubmed/21342132). 
 
191. Y. Tay, L. Kats, L. Salmena, D. Weiss, S. M. Tan, U. Ala, F. Karreth, L. Poliseno, P. Provero, F. Di 
Cunto, J. Lieberman, I. Rigoutsos, P. P. Pandolfi, Coding-independent regulation of the tumor 
suppressor PTEN by competing endogenous mRNAs. Cell 147, 344-357 (2011); published online 
Oct 14 (10.1016/j.cell.2011.09.029). 
 
192. L. Poliseno, L. Salmena, J. Zhang, B. Carver, W. J. Haveman, P. P. Pandolfi, A coding-independent 
function of gene and pseudogene mRNAs regulates tumour biology. Nature 465, 1033-1038 
(2010); published online Jun 24 (10.1038/nature09144). 
 
193. F. A. Karreth, Y. Tay, D. Perna, U. Ala, S. M. Tan, A. G. Rust, G. DeNicola, K. A. Webster, D. Weiss, 
P. A. Perez-Mancera, M. Krauthammer, R. Halaban, P. Provero, D. J. Adams, D. A. Tuveson, P. P. 
Pandolfi, In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-
 
137 
 
induced mouse model of melanoma. Cell 147, 382-395 (2011); published online Oct 14 
(10.1016/j.cell.2011.09.032). 
 
194. M. Cesana, D. Cacchiarelli, I. Legnini, T. Santini, O. Sthandier, M. Chinappi, A. Tramontano, I. 
Bozzoni, A long noncoding RNA controls muscle differentiation by functioning as a competing 
endogenous RNA. Cell 147, 358-369 (2011); published online Oct 14 
(10.1016/j.cell.2011.09.028). 
 
195. P. Sumazin, X. Yang, H. S. Chiu, W. J. Chung, A. Iyer, D. Llobet-Navas, P. Rajbhandari, M. Bansal, 
P. Guarnieri, J. Silva, A. Califano, An extensive microRNA-mediated network of RNA-RNA 
interactions regulates established oncogenic pathways in glioblastoma. Cell 147, 370-381 (2011); 
published online Oct 14 (10.1016/j.cell.2011.09.041). 
 
196. T. B. Hansen, T. I. Jensen, B. H. Clausen, J. B. Bramsen, B. Finsen, C. K. Damgaard, J. Kjems, 
Natural RNA circles function as efficient microRNA sponges. Nature 495, 384-388 (2013); 
published online Mar 21 (10.1038/nature11993). 
 
197. N. Li, B. Tang, E. D. Zhu, B. S. Li, Y. Zhuang, S. Yu, D. S. Lu, Q. M. Zou, B. Xiao, X. H. Mao, 
Increased miR-222 in H. pylori-associated gastric cancer correlated with tumor progression by 
promoting cancer cell proliferation and targeting RECK. FEBS letters 586, 722-728 (2012); 
published online Mar 23 (10.1016/j.febslet.2012.01.025). 
 
198. C. Z. Zhang, J. X. Zhang, A. L. Zhang, Z. D. Shi, L. Han, Z. F. Jia, W. D. Yang, G. X. Wang, T. Jiang, Y. 
P. You, P. Y. Pu, J. Q. Cheng, C. S. Kang, MiR-221 and miR-222 target PUMA to induce cell survival 
in glioblastoma. Molecular cancer 9, 229 (2010)10.1186/1476-4598-9-229). 
 
199. P. Dentelli, A. Rosso, F. Orso, C. Olgasi, D. Taverna, M. F. Brizzi, microRNA-222 controls 
neovascularization by regulating signal transducer and activator of transcription 5A expression. 
Arteriosclerosis, thrombosis, and vascular biology 30, 1562-1568 (2010); published online Aug 
(10.1161/ATVBAHA.110.206201). 
 
200. R. Ueda, G. Kohanbash, K. Sasaki, M. Fujita, X. Zhu, E. R. Kastenhuber, H. A. McDonald, D. M. 
Potter, R. L. Hamilton, M. T. Lotze, S. A. Khan, R. W. Sobol, H. Okada, Dicer-regulated microRNAs 
222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation 
of ICAM-1. Proceedings of the National Academy of Sciences of the United States of America 
106, 10746-10751 (2009); published online Jun 30 (10.1073/pnas.0811817106). 
 
201. A. M. Evangelista, A. M. Deschamps, D. Liu, N. Raghavachari, E. Murphy, miR-222 contributes to 
sex-dimorphic cardiac eNOS expression via ets-1. Physiological genomics 45, 493-498 (2013); 
published online Jun 17 (10.1152/physiolgenomics.00008.2013). 
 
 
138 
 
202. C. Quintavalle, D. Mangani, G. Roscigno, G. Romano, A. Diaz-Lagares, M. Iaboni, E. 
Donnarumma, D. Fiore, P. De Marinis, Y. Soini, M. Esteller, G. Condorelli, MiR-221/222 target the 
DNA methyltransferase MGMT in glioma cells. PloS one 8, e74466 
(2013)10.1371/journal.pone.0074466). 
 
203. T. E. Miller, K. Ghoshal, B. Ramaswamy, S. Roy, J. Datta, C. L. Shapiro, S. Jacob, S. Majumder, 
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. The 
Journal of biological chemistry 283, 29897-29903 (2008); published online Oct 31 
(10.1074/jbc.M804612200). 
 
204. Z. Chun-Zhi, H. Lei, Z. An-Ling, F. Yan-Chao, Y. Xiao, W. Guang-Xiu, J. Zhi-Fan, P. Pei-Yu, Z. Qing-
Yu, K. Chun-Sheng, MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell 
proliferation and radioresistance by targeting PTEN. BMC cancer 10, 367 (2010)10.1186/1471-
2407-10-367). 
 
205. J. J. Zhao, J. Lin, H. Yang, W. Kong, L. He, X. Ma, D. Coppola, J. Q. Cheng, MicroRNA-221/222 
negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in 
breast cancer. The Journal of biological chemistry 283, 31079-31086 (2008); published online 
Nov 7 (10.1074/jbc.M806041200). 
 
206. M. Koelz, J. Lense, F. Wrba, M. Scheffler, H. P. Dienes, M. Odenthal, Down-regulation of miR-221 
and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors. 
International journal of oncology 38, 503-511 (2011); published online Feb 
(10.3892/ijo.2010.857). 
 
207. C. le Sage, R. Nagel, D. A. Egan, M. Schrier, E. Mesman, A. Mangiola, C. Anile, G. Maira, N. 
Mercatelli, S. A. Ciafre, M. G. Farace, R. Agami, Regulation of the p27(Kip1) tumor suppressor by 
miR-221 and miR-222 promotes cancer cell proliferation. The EMBO journal 26, 3699-3708 
(2007); published online Aug 8 (10.1038/sj.emboj.7601790). 
 
208. S. Galardi, N. Mercatelli, E. Giorda, S. Massalini, G. V. Frajese, S. A. Ciafre, M. G. Farace, miR-221 
and miR-222 expression affects the proliferation potential of human prostate carcinoma cell 
lines by targeting p27Kip1. The Journal of biological chemistry 282, 23716-23724 (2007); 
published online Aug 10 (10.1074/jbc.M701805200). 
 
209. M. Kedde, M. van Kouwenhove, W. Zwart, J. A. Oude Vrielink, R. Elkon, R. Agami, A Pumilio-
induced RNA structure switch in p27-3' UTR controls miR-221 and miR-222 accessibility. Nature 
cell biology 12, 1014-1020 (2010); published online Oct (10.1038/ncb2105). 
 
210. C. Quintavalle, M. Garofalo, C. Zanca, G. Romano, M. Iaboni, M. del Basso De Caro, J. C. 
Martinez-Montero, M. Incoronato, G. Nuovo, C. M. Croce, G. Condorelli, miR-221/222 
 
139 
 
overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate 
PTPmu. Oncogene 31, 858-868 (2012); published online Feb 16 (10.1038/onc.2011.280). 
 
211. C. Zhang, J. Zhang, A. Zhang, Y. Wang, L. Han, Y. You, P. Pu, C. Kang, PUMA is a novel target of 
miR-221/222 in human epithelial cancers. International journal of oncology 37, 1621-1626 
(2010); published online Dec (http://www.ncbi.nlm.nih.gov/pubmed/21042732). 
 
212. S. Stinson, M. R. Lackner, A. T. Adai, N. Yu, H. J. Kim, C. O'Brien, J. Spoerke, S. Jhunjhunwala, Z. 
Boyd, T. Januario, R. J. Newman, P. Yue, R. Bourgon, Z. Modrusan, H. M. Stern, S. Warming, F. J. 
de Sauvage, L. Amler, R. F. Yeh, D. Dornan, miR-221/222 targeting of trichorhinophalangeal 1 
(TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Science signaling 4, pt5 
(2011); published online Aug 16 (10.1126/scisignal.2002258). 
 
213. M. W. Marino, A. Dunn, D. Grail, M. Inglese, Y. Noguchi, E. Richards, A. Jungbluth, H. Wada, M. 
Moore, B. Williamson, S. Basu, L. J. Old, Characterization of tumor necrosis factor-deficient mice. 
Proceedings of the National Academy of Sciences of the United States of America 94, 8093-8098 
(1997); published online Jul 22 (http://www.ncbi.nlm.nih.gov/pubmed/9223320). 
 
214. G. Stoecklin, M. Lu, B. Rattenbacher, C. Moroni, A constitutive decay element promotes tumor 
necrosis factor alpha mRNA degradation via an AU-rich element-independent pathway. 
Molecular and cellular biology 23, 3506-3515 (2003); published online May 
(http://www.ncbi.nlm.nih.gov/pubmed/12724409). 
 
215. E. Carballo, W. S. Lai, P. J. Blackshear, Feedback inhibition of macrophage tumor necrosis factor-
alpha production by tristetraprolin. Science 281, 1001-1005 (1998); published online Aug 14 
(http://www.ncbi.nlm.nih.gov/pubmed/9703499). 
 
216. G. A. Taylor, E. Carballo, D. M. Lee, W. S. Lai, M. J. Thompson, D. D. Patel, D. I. Schenkman, G. S. 
Gilkeson, H. E. Broxmeyer, B. F. Haynes, P. J. Blackshear, A pathogenetic role for TNF alpha in the 
syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) 
deficiency. Immunity 4, 445-454 (1996); published online May 
(http://www.ncbi.nlm.nih.gov/pubmed/8630730). 
 
217. J. Y. Lu, N. Sadri, R. J. Schneider, Endotoxic shock in AUF1 knockout mice mediated by failure to 
degrade proinflammatory cytokine mRNAs. Genes & development 20, 3174-3184 (2006); 
published online Nov 15 (10.1101/gad.1467606). 
 
218. T. H. Thai, D. P. Calado, S. Casola, K. M. Ansel, C. Xiao, Y. Xue, A. Murphy, D. Frendewey, D. 
Valenzuela, J. L. Kutok, M. Schmidt-Supprian, N. Rajewsky, G. Yancopoulos, A. Rao, K. Rajewsky, 
Regulation of the germinal center response by microRNA-155. Science 316, 604-608 (2007); 
published online Apr 27 (10.1126/science.1141229). 
 
140 
 
 
219. J. L. Zhao, D. S. Rao, R. M. O'Connell, Y. Garcia-Flores, D. Baltimore, MicroRNA-146a acts as a 
guardian of the quality and longevity of hematopoietic stem cells in mice. eLife 2, e00537 
(2013)10.7554/eLife.00537). 
 
220. U. Klein, M. Lia, M. Crespo, R. Siegel, Q. Shen, T. Mo, A. Ambesi-Impiombato, A. Califano, A. 
Migliazza, G. Bhagat, R. Dalla-Favera, The DLEU2/miR-15a/16-1 cluster controls B cell 
proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer cell 17, 28-40 
(2010); published online Jan 19 (10.1016/j.ccr.2009.11.019). 
 
221. C. Y. Park, L. T. Jeker, K. Carver-Moore, A. Oh, H. J. Liu, R. Cameron, H. Richards, Z. Li, D. Adler, Y. 
Yoshinaga, M. Martinez, M. Nefadov, A. K. Abbas, A. Weiss, L. L. Lanier, P. J. de Jong, J. A. 
Bluestone, D. Srivastava, M. T. McManus, A resource for the conditional ablation of microRNAs 
in the mouse. Cell reports 1, 385-391 (2012); published online Apr 19 
(10.1016/j.celrep.2012.02.008). 
 
222. H. M. Prosser, H. Koike-Yusa, J. D. Cooper, F. C. Law, A. Bradley, A resource of vectors and ES 
cells for targeted deletion of microRNAs in mice. Nature biotechnology 29, 840-845 (2011); 
published online Sep (10.1038/nbt.1929). 
 
223. B. Gentner, G. Schira, A. Giustacchini, M. Amendola, B. D. Brown, M. Ponzoni, L. Naldini, Stable 
knockdown of microRNA in vivo by lentiviral vectors. Nature methods 6, 63-66 (2009); published 
online Jan (10.1038/nmeth.1277). 
 
224. J. Xie, S. L. Ameres, R. Friedline, J. H. Hung, Y. Zhang, Q. Xie, L. Zhong, Q. Su, R. He, M. Li, H. Li, X. 
Mu, H. Zhang, J. A. Broderick, J. K. Kim, Z. Weng, T. R. Flotte, P. D. Zamore, G. Gao, Long-term, 
efficient inhibition of microRNA function in mice using rAAV vectors. Nature methods 9, 403-409 
(2012); published online Apr (10.1038/nmeth.1903). 
 
225. J. Kota, R. R. Chivukula, K. A. O'Donnell, E. A. Wentzel, C. L. Montgomery, H. W. Hwang, T. C. 
Chang, P. Vivekanandan, M. Torbenson, K. R. Clark, J. R. Mendell, J. T. Mendell, Therapeutic 
microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005-
1017 (2009); published online Jun 12 (10.1016/j.cell.2009.04.021). 
 
226. J. Krutzfeldt, N. Rajewsky, R. Braich, K. G. Rajeev, T. Tuschl, M. Manoharan, M. Stoffel, Silencing 
of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689 (2005); published online Dec 1 
(10.1038/nature04303). 
 
227. J. Elmen, M. Lindow, S. Schutz, M. Lawrence, A. Petri, S. Obad, M. Lindholm, M. Hedtjarn, H. F. 
Hansen, U. Berger, S. Gullans, P. Kearney, P. Sarnow, E. M. Straarup, S. Kauppinen, LNA-
mediated microRNA silencing in non-human primates. Nature 452, 896-899 (2008); published 
online Apr 17 (10.1038/nature06783). 
 
141 
 
 
228. K. J. Rayner, C. C. Esau, F. N. Hussain, A. L. McDaniel, S. M. Marshall, J. M. van Gils, T. D. Ray, F. J. 
Sheedy, L. Goedeke, X. Liu, O. G. Khatsenko, V. Kaimal, C. J. Lees, C. Fernandez-Hernando, E. A. 
Fisher, R. E. Temel, K. J. Moore, Inhibition of miR-33a/b in non-human primates raises plasma 
HDL and lowers VLDL triglycerides. Nature 478, 404-407 (2011); published online Oct 20 
(10.1038/nature10486). 
 
229. S. H. Najafi-Shoushtari, F. Kristo, Y. Li, T. Shioda, D. E. Cohen, R. E. Gerszten, A. M. Naar, 
MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 
328, 1566-1569 (2010); published online Jun 18 (10.1126/science.1189123). 
 
230. R. L. Montgomery, T. G. Hullinger, H. M. Semus, B. A. Dickinson, A. G. Seto, J. M. Lynch, C. Stack, 
P. A. Latimer, E. N. Olson, E. van Rooij, Therapeutic inhibition of miR-208a improves cardiac 
function and survival during heart failure. Circulation 124, 1537-1547 (2011); published online 
Oct 4 (10.1161/CIRCULATIONAHA.111.030932). 
 
231. J. Worm, J. Stenvang, A. Petri, K. S. Frederiksen, S. Obad, J. Elmen, M. Hedtjarn, E. M. Straarup, J. 
B. Hansen, S. Kauppinen, Silencing of microRNA-155 in mice during acute inflammatory response 
leads to derepression of c/ebp Beta and down-regulation of G-CSF. Nucleic acids research 37, 
5784-5792 (2009); published online Sep (10.1093/nar/gkp577). 
 
232. T. Thum, C. Gross, J. Fiedler, T. Fischer, S. Kissler, M. Bussen, P. Galuppo, S. Just, W. Rottbauer, S. 
Frantz, M. Castoldi, J. Soutschek, V. Koteliansky, A. Rosenwald, M. A. Basson, J. D. Licht, J. T. 
Pena, S. H. Rouhanifard, M. U. Muckenthaler, T. Tuschl, G. R. Martin, J. Bauersachs, S. 
Engelhardt, MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling 
in fibroblasts. Nature 456, 980-984 (2008); published online Dec 18 (10.1038/nature07511). 
 
233. A. Bonauer, G. Carmona, M. Iwasaki, M. Mione, M. Koyanagi, A. Fischer, J. Burchfield, H. Fox, C. 
Doebele, K. Ohtani, E. Chavakis, M. Potente, M. Tjwa, C. Urbich, A. M. Zeiher, S. Dimmeler, 
MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 
324, 1710-1713 (2009); published online Jun 26 (10.1126/science.1174381). 
 
234. Y. Wu, M. Crawford, Y. Mao, R. J. Lee, I. C. Davis, T. S. Elton, L. J. Lee, S. P. Nana-Sinkam, 
Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer. Molecular 
therapy. Nucleic acids 2, e84 (2013)10.1038/mtna.2013.14). 
 
235. I. A. Babar, C. J. Cheng, C. J. Booth, X. Liang, J. B. Weidhaas, W. M. Saltzman, F. J. Slack, 
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of 
lymphoma. Proceedings of the National Academy of Sciences of the United States of America 
109, E1695-1704 (2012); published online Jun 26 (10.1073/pnas.1201516109). 
 
 
142 
 
236. J. Elmen, M. Lindow, A. Silahtaroglu, M. Bak, M. Christensen, A. Lind-Thomsen, M. Hedtjarn, J. B. 
Hansen, H. F. Hansen, E. M. Straarup, K. McCullagh, P. Kearney, S. Kauppinen, Antagonism of 
microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a 
large set of predicted target mRNAs in the liver. Nucleic acids research 36, 1153-1162 (2008); 
published online Mar (10.1093/nar/gkm1113). 
 
237. R. E. Lanford, E. S. Hildebrandt-Eriksen, A. Petri, R. Persson, M. Lindow, M. E. Munk, S. 
Kauppinen, H. Orum, Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C 
virus infection. Science 327, 198-201 (2010); published online Jan 8 (10.1126/science.1178178). 
 
238. E. van Rooij, A. L. Purcell, A. A. Levin, Developing microRNA therapeutics. Circulation research 
110, 496-507 (2012); published online Feb 3 (10.1161/CIRCRESAHA.111.247916). 
 
239. N. S. Maloney, L. B. Thackray, G. Goel, S. Hwang, E. Duan, P. Vachharajani, R. Xavier, H. W. 
Virgin, Essential cell-autonomous role for interferon (IFN) regulatory factor 1 in IFN-gamma-
mediated inhibition of norovirus replication in macrophages. Journal of virology 86, 12655-
12664 (2012); published online Dec (10.1128/JVI.01564-12). 
 
240. M. Chromek, I. Arvidsson, D. Karpman, The antimicrobial peptide cathelicidin protects mice from 
Escherichia coli O157:H7-mediated disease. PloS one 7, e46476 
(2012)10.1371/journal.pone.0046476). 
 
241. L. Zhang, J. Yu, C. C. Wong, T. K. Ling, Z. J. Li, K. M. Chan, S. X. Ren, J. Shen, R. L. Chan, C. C. Lee, 
M. S. Li, A. S. Cheng, K. F. To, R. L. Gallo, J. J. Sung, W. K. Wu, C. H. Cho, Cathelicidin protects 
against Helicobacter pylori colonization and the associated gastritis in mice. Gene therapy 20, 
751-760 (2013); published online Jul (10.1038/gt.2012.92). 
 
242. C. C. Carter, V. Y. Gorbacheva, D. J. Vestal, Inhibition of VSV and EMCV replication by the 
interferon-induced GTPase, mGBP-2: differential requirement for wild-type GTP binding domain. 
Archives of virology 150, 1213-1220 (2005); published online Jun (10.1007/s00705-004-0489-2). 
 
243. D. Degrandi, E. Kravets, C. Konermann, C. Beuter-Gunia, V. Klumpers, S. Lahme, E. Wischmann, 
A. K. Mausberg, S. Beer-Hammer, K. Pfeffer, Murine guanylate binding protein 2 (mGBP2) 
controls Toxoplasma gondii replication. Proceedings of the National Academy of Sciences of the 
United States of America 110, 294-299 (2013); published online Jan 2 
(10.1073/pnas.1205635110). 
 
244. B. Marsh, S. L. Stevens, A. E. Packard, B. Gopalan, B. Hunter, P. Y. Leung, C. A. Harrington, M. P. 
Stenzel-Poore, Systemic lipopolysaccharide protects the brain from ischemic injury by 
reprogramming the response of the brain to stroke: a critical role for IRF3. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 29, 9839-9849 (2009); 
published online Aug 5 (10.1523/JNEUROSCI.2496-09.2009). 
 
143 
 
 
245. C. Ye, J. G. Choi, S. Abraham, H. Wu, D. Diaz, D. Terreros, P. Shankar, N. Manjunath, Human 
macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates 
sepsis in a humanized mouse model. Proceedings of the National Academy of Sciences of the 
United States of America 109, 21052-21057 (2012); published online Dec 18 
(10.1073/pnas.1216195109). 
 
246. S. J. Cullen, S. Ponnappan, U. Ponnappan, Catalytic activity of the proteasome fine-tunes Brg1-
mediated chromatin remodeling to regulate the expression of inflammatory genes. Molecular 
immunology 47, 600-605 (2009); published online Dec (10.1016/j.molimm.2009.09.008). 
 
247. M. H. Sung, N. Li, Q. Lao, R. A. Gottschalk, G. L. Hager, I. D. Fraser, Switching of the relative 
dominance between feedback mechanisms in lipopolysaccharide-induced NF-kappaB signaling. 
Science signaling 7, ra6 (2014); published online Jan 14 (10.1126/scisignal.2004764). 
 
248. D. M. Mosser, J. P. Edwards, Exploring the full spectrum of macrophage activation. Nature 
reviews. Immunology 8, 958-969 (2008); published online Dec (10.1038/nri2448). 
 
249. B. J. Reinhart, F. J. Slack, M. Basson, A. E. Pasquinelli, J. C. Bettinger, A. E. Rougvie, H. R. Horvitz, 
G. Ruvkun, The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis 
elegans. Nature 403, 901-906 (2000); published online Feb 24 (10.1038/35002607). 
 
250. A. E. Pasquinelli, B. J. Reinhart, F. Slack, M. Q. Martindale, M. I. Kuroda, B. Maller, D. C. Hayward, 
E. E. Ball, B. Degnan, P. Muller, J. Spring, A. Srinivasan, M. Fishman, J. Finnerty, J. Corbo, M. 
Levine, P. Leahy, E. Davidson, G. Ruvkun, Conservation of the sequence and temporal expression 
of let-7 heterochronic regulatory RNA. Nature 408, 86-89 (2000); published online Nov 2 
(10.1038/35040556). 
 
251. R. C. Lee, R. L. Feinbaum, V. Ambros, The C. elegans heterochronic gene lin-4 encodes small 
RNAs with antisense complementarity to lin-14. Cell 75, 843-854 (1993); published online Dec 3 
(http://www.ncbi.nlm.nih.gov/pubmed/8252621). 
 
252. T. Li, M. J. Morgan, S. Choksi, Y. Zhang, Y. S. Kim, Z. G. Liu, MicroRNAs modulate the 
noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase 
IKKalpha during macrophage differentiation. Nature immunology 11, 799-805 (2010); published 
online Sep (10.1038/ni.1918). 
 
253. S. Y. Na, S. K. Lee, S. J. Han, H. S. Choi, S. Y. Im, J. W. Lee, Steroid receptor coactivator-1 interacts 
with the p50 subunit and coactivates nuclear factor kappaB-mediated transactivations. The 
Journal of biological chemistry 273, 10831-10834 (1998); published online May 1 
(http://www.ncbi.nlm.nih.gov/pubmed/9556555). 
 
144 
 
 
254. E. G. Lee, D. L. Boone, S. Chai, S. L. Libby, M. Chien, J. P. Lodolce, A. Ma, Failure to regulate TNF-
induced NF-kappaB and cell death responses in A20-deficient mice. Science 289, 2350-2354 
(2000); published online Sep 29 (http://www.ncbi.nlm.nih.gov/pubmed/11009421). 
 
255. M. Fabbri, R. Garzon, A. Cimmino, Z. Liu, N. Zanesi, E. Callegari, S. Liu, H. Alder, S. Costinean, C. 
Fernandez-Cymering, S. Volinia, G. Guler, C. D. Morrison, K. K. Chan, G. Marcucci, G. A. Calin, K. 
Huebner, C. M. Croce, MicroRNA-29 family reverts aberrant methylation in lung cancer by 
targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences 
of the United States of America 104, 15805-15810 (2007); published online Oct 2 
(10.1073/pnas.0707628104). 
 
256. J. Fang, Q. Hao, L. Liu, Y. Li, J. Wu, X. Huo, Y. Zhu, Epigenetic changes mediated by microRNA 
miR29 activate cyclooxygenase 2 and lambda-1 interferon production during viral infection. 
Journal of virology 86, 1010-1020 (2012); published online Jan (10.1128/JVI.06169-11). 
 
257. S. Monticelli, G. Natoli, Short-term memory of danger signals and environmental stimuli in 
immune cells. Nature immunology 14, 777-784 (2013); published online Aug (10.1038/ni.2636). 
 
258. T. W. Hurd, A. A. Culbert, K. J. Webster, J. M. Tavare, Dual role for mitogen-activated protein 
kinase (Erk) in insulin-dependent regulation of Fra-1 (fos-related antigen-1) transcription and 
phosphorylation. The Biochemical journal 368, 573-580 (2002); published online Dec 1 
(10.1042/BJ20020579). 
 
259. L. F. Poli-de-Figueiredo, A. G. Garrido, N. Nakagawa, P. Sannomiya, Experimental models of 
sepsis and their clinical relevance. Shock 30 Suppl 1, 53-59 (2008); published online Oct 
(10.1097/SHK.0b013e318181a343). 
 
260. M. Schreiber, Z. Q. Wang, W. Jochum, I. Fetka, C. Elliott, E. F. Wagner, Placental vascularisation 
requires the AP-1 component fra1. Development 127, 4937-4948 (2000); published online Nov 
(http://www.ncbi.nlm.nih.gov/pubmed/11044407). 
 
261. L. Poliseno, A. Tuccoli, L. Mariani, M. Evangelista, L. Citti, K. Woods, A. Mercatanti, S. Hammond, 
G. Rainaldi, MicroRNAs modulate the angiogenic properties of HUVECs. Blood 108, 3068-3071 
(2006); published online Nov 1 (10.1182/blood-2006-01-012369). 
 
262. C. T. Hang, J. Yang, P. Han, H. L. Cheng, C. Shang, E. Ashley, B. Zhou, C. P. Chang, Chromatin 
regulation by Brg1 underlies heart muscle development and disease. Nature 466, 62-67 (2010); 
published online Jul 1 (10.1038/nature09130). 
 
 
145 
 
263. S. Glaros, G. M. Cirrincione, A. Palanca, D. Metzger, D. Reisman, Targeted knockout of BRG1 
potentiates lung cancer development. Cancer research 68, 3689-3696 (2008); published online 
May 15 (10.1158/0008-5472.CAN-07-6652). 
 
264. I. M. Pedersen, D. Otero, E. Kao, A. V. Miletic, C. Hother, E. Ralfkiaer, R. C. Rickert, K. Gronbaek, 
M. David, Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell 
lymphomas. EMBO molecular medicine 1, 288-295 (2009); published online Aug 
(10.1002/emmm.200900028). 
 
265. K. C. Vickers, B. T. Palmisano, B. M. Shoucri, R. D. Shamburek, A. T. Remaley, MicroRNAs are 
transported in plasma and delivered to recipient cells by high-density lipoproteins. Nature cell 
biology 13, 423-433 (2011); published online Apr (10.1038/ncb2210). 
 
266. S. A. Bellingham, B. M. Coleman, A. F. Hill, Small RNA deep sequencing reveals a distinct miRNA 
signature released in exosomes from prion-infected neuronal cells. Nucleic acids research 40, 
10937-10949 (2012); published online Nov 1 (10.1093/nar/gks832). 
 
267. A. Chawla, K. D. Nguyen, Y. P. Goh, Macrophage-mediated inflammation in metabolic disease. 
Nature reviews. Immunology 11, 738-749 (2011); published online Nov (10.1038/nri3071). 
 
268. D. V. Chartoumpekis, A. Zaravinos, P. G. Ziros, R. P. Iskrenova, A. I. Psyrogiannis, V. E. 
Kyriazopoulou, I. G. Habeos, Differential expression of microRNAs in adipose tissue after long-
term high-fat diet-induced obesity in mice. PloS one 7, e34872 
(2012)10.1371/journal.pone.0034872). 
 
269. F. M. Ling H, Calin GA., MicroRNAs and other non-coding RNAs as targets for anticancer drug 
development. Nat Rev Drug Discov 12, 847–865 (2013)10.1038/nrd4140). 
 
270. E. Nicodeme, K. L. Jeffrey, U. Schaefer, S. Beinke, S. Dewell, C. W. Chung, R. Chandwani, I. 
Marazzi, P. Wilson, H. Coste, J. White, J. Kirilovsky, C. M. Rice, J. M. Lora, R. K. Prinjha, K. Lee, A. 
Tarakhovsky, Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119-1123 
(2010); published online Dec 23 (10.1038/nature09589). 
 
271. S. M. Roberson, W. S. Walker, Immortalization of cloned mouse splenic macrophages with a 
retrovirus containing the v-raf/mil and v-myc oncogenes. Cellular immunology 116, 341-351 
(1988); published online Oct 15 (http://www.ncbi.nlm.nih.gov/pubmed/2460250). 
 
272. G. W. Cox, B. J. Mathieson, L. Gandino, E. Blasi, D. Radzioch, L. Varesio, Heterogeneity of 
hematopoietic cells immortalized by v-myc/v-raf recombinant retrovirus infection of bone 
marrow or fetal liver. Journal of the National Cancer Institute 81, 1492-1496 (1989); published 
online Oct 4 (http://www.ncbi.nlm.nih.gov/pubmed/2778838). 
 
146 
 
 
273. V. Hornung, F. Bauernfeind, A. Halle, E. O. Samstad, H. Kono, K. L. Rock, K. A. Fitzgerald, E. Latz, 
Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal 
destabilization. Nature immunology 9, 847-856 (2008); published online Aug (10.1038/ni.1631). 
 
 
